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behorende bij het proefschrit 
The role of Lipocalin 2 in 
Alzheimer's disease and depression 
Petrus Johan Wichardt N aude 
1. A healthy functional immune system and optimal brain functioning goes hand in 
hand. 
2. Depression is an immunological disease. 
3. Lipocalin 2 is a pathophysiological element in Alzheimer's disease. 
4. Increased circulating Lipocalin 2 levels are closely associated with symptoms of 
depression. 
5. Lipocalin 2 is a marker of frailty for cardiovascular disease and compromised 
neuronal health. 
6. There is no thing such as permanent in the brain. 
7. The brain is in charge of cognition and mood, according to the brain. However, the 
immune system takes the reins when illness strikes. 
8. Most if not all diseases can be cured via specific modulation of the immune system. 
9. Doing a PhD will cause a significant increase in circulating Lipocalin 2 levels, some 
time or another (see stelling 4). 
10. "Serendipidy" is a researchers' ally and "Murphy's law" a researchers' enemy. 
11. Afrikaans speaking South Africans are referred to as "Dutchman" by the English 
speaking South Africans. As an Afrikaans speaking person, I can assure you that 
these people have no idea what they are talking about. 
The research reported in this thesis was carried out at the Department of Molecular 
Neurobiology of the University of Groningen, the Netherlands and was financially 
supported by the Jan Kornelis de Cock Stich ting project number 635155, the EU­
grand FP6 NeuroprMiSe LSHM-CT-2005-018637. 
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Ageing is a biological process characterized by time-dependent functional declines, influenced 
by numerous environmental and physiological factors. 
"Healthy ageing", "successful ageing" or "active ageing" in humans has been defined by 
Rowe J .W. and Kahn R.L as a multidimensional process that is dependent on the following 
basic factors: 
• the avoidance of disease and disability 
• the maintenance of high physical and cognitive function 
• sustained engagement in social and productive activities (Rowe and Kahn, 1997). 
Advanced human age is indisputably accompanied by characteristic medical conditions 
(Vaillancourt and Newell, 2002). The increase in the number of older adults is a concern 
given the likelihood that it will entail increasing age-related health problems, including chronic 
disease, physical and mental impairment, and disability, thus leading to a significant social and 
economic burden. The notion of healthy ageing has attracted a considerable amount of 
attention from various research fields in order to improve the quality of life due to an 
increasing global aged population. 
Mortality rates due to major age-associated diseases e.g. heart disease, stroke and some types 
of cancer decreased significantly since the start of the millennium, indicating advancements of 
improved medical care (Alzheimer's disease facts and figures (2011; 2012)). On the contrary, 
Alzheimer's disease (AD) is increasingly becoming a contributor to mortality rates 
(Alzheimer's disease facts and figures (2011; 2012)). AD not only affects the individual but 
also causes a severe social burden, especially on the care takers. Research showed that the 
average cost per patient with AD exceeds other major chronic conditions due to the extended 
period of this disease (Berto et al., 2000). At this moment no effective treatments or concrete 
attributes of the etiology of AD exist. Urgent scientific advancements in AD are therefore of 
utmost importance to implement positive future perspectives for effective treatments for this 
disease. This necessity is further incited by the fact that the number of very old individuals are 
increasing rapidly in coming decades. 
Epidemiology of Alzheimer's disease 
Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of 
dementia. In the western world, the prevalence of dementia is below 1 % in individuals aged 
60-64 years, but increases exponentially with age, so that the prevalence in people aged 85 
years or older is between 24% and 33% (Ferri et al., 2005) and may exceed 50% in a 
population of 95 years of age (Katzman, 2002). The estimated global occurrence of AD was 
26.6 million in the year 2006 and have been forecasted to reach 106.2 million by the year 2050 
(Brookmeyer et al., 2007) due to an increasing population of aged individuals . These 
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estimations raise concerns that AD will become an imminent global epidemic in the near 
future if necessary preventative processes are not undertaken in time. 
AD can be classified into 2 subtypes based on the age of onset; early-onset AD (AD 
diagnosed before the age of 65) and late-onset AD. Early-onset AD due to familial AD is rare 
and accounts for less that 1 % of all cases and affected age ranges roughly from 30 years to 60 
years (Harvey et al., 2003). The genes implicated in familial types of AD are the genes 
encoding for amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 
(PSEN2) (Ertekin-Taner, 2007). The etiology of late onset AD, also referred to as sporadic 
AD, is still largely unknown. Age is the first and foremost risk factor for late onset AD. The 
apolipoprotein E (APOE) E 4 allele is the main known genetic risk factor for the 
development of late-onset AD (Corder et al., 1993) but as a susceptibility gene it is neither 
necessary nor sufficient to cause late-onset AD (Patterson et al., 2008). Presently, genetic risk 
factors as a causative element for the development of late-onset AD seems to be trivial. 
However, genetic factors can influence the age of onset of AD (Hutton et al., 1998; Maimone 
et al., 2001; Selkoe, 2001). An up-to-date overview on the status of potential AD candidate 
genes can be found at the Alzheimer's Research Forum genetic database, "AlzGene" 
http://www.alzgene.org). Interestingly, people with Down Syndrome have an extra copy of 
chromosome 21 that harbors several genes implicated in AD such as APP and /J-site APP 
cleaving enzyme, BACE2. Most people with Down Syndrome develop AD-like pathology by 
the fourth decade of life (Webb and Murphy, 2012). 
Psychological indicators of early AD 
The classical clinical characteristics associated with development of AD can be characterized 
into the following three main phases. (1) A presymptomatic phase in which subjects are 
cognitively normal but have AD pathology. (2) A prodromal phase termed mild cognitive 
impairment (MCI). (3) Dementia with impairments in multiple domains and loss of function 
in activities of daily living (Petersen et al., 1999; Petersen, 2004; Savva et al., 2009). 
N europsychological assessment is the gold standard method used at this moment to identify 
AD. Characterization of Mild cognitive impairment (MCI) made it possible to define a group 
of patients at a high risk of developing dementia, particularly Alzheimer-type dementia. MCI 
can be defined as a transitional phase between normal ageing and dementia disorders and is 
associated with a highly increased risk for dementia due to Alzheimer's disease (Petersen et 
al., 1999; Ritchie and Touchon, 2000). MCI is a stage in which early neuropathology of AD 
can occur, but do not meet the clinical criteria (Grundman et al., 2002). 
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The following main subtypes of MCI have been classified in relation to the likelihood of AD 
progression: 
• Amnestic MCI (aMCI), characterized mainly by memory impairments, progress 
preferentially to Alzheimer's disease. 
• MCI characterized by a slight impairment of multiple cognitive domains incl1:_ding 
memory, which may progress to Alzheimer's disease and also to vascular dementia, or 
may even represent a cognitive ageing process qualified as normal. 
• Non-amnestic MCI corresponding to isolated impairment of a cognitive domain other 
than of memory, which may progress to non-Alzheimer-type dementia. 
Occurrence of aMCI as main risk factor for developing AD was validated 1t1 a 3-year 
multicenter randomized clinical trial showing a progression rate of 16% per year rate 
(Petersen et al., 2005). 
Neuropsychiatric disturbances are common in MCI, with prevalence between 35% and 75% 
and the same symptoms frequently occur even in the early phases of Alzheimer's disease, 
particularly depression (Palmer et al., 2007; Apostolova and Cummings, 2008). Mood-related 
depressive symptoms among MCI individuals greatly increased the probability of Alzheimer's 
disease symptoms measured in a 3 year follow-up study (Palmer et al., 2007). A meta-analysis 
indicated that depression on its own may also be a significant risk factor for Alzheimer's 
disease (Ownby et al., 2006). This fmding was further supported by a longitudinal study 
showing that the risk for developing Alzheimer's disease nearly doubled with the presence of 
mood-related depressive symptoms in cognitively intact subjects at baseline (Palmer et al., 
2007). Late onset depression was recently identified by numerous studies to be characterized 
with reduced volumes of brain regions associated with early pathology of AD (Ballmaier et 
al., 2008; Dotson et al., 2009; Lim et al., 2012). Investigation of post mortem brain tissue of 
elderly humans revealed that a history of depressive symptoms was associated with the 
presence of AD pathology in the hippocampus, (Rapp et al., 2006) which was also found in a 
later study measured with positron emission tomography (Kumar et al., 2011). The data of 
these studies indicates early AD pathology as a possible underlying mechanism between late­
life depression and AD, especially when early cognitive impairments are present. These 
insights into late-life depression revealed exciting new research prospects regarding its 
association with pathological changes of early AD. 
Pathology of AD 
Macroscopically, brains of AD patients are characterized by an overall decreased brain 
volume, increased ventricular system, decreased hippocampal volume, shrinkage of the gyri 
and widening of the sulci. More than 100 years ago (1907) Alois Alzheimer described in a 
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short paper, the combined presence of plaques and tangles in the brain from a patient who 
suffered from presenile dementia (Alzheimer, 1907; Moller and Graeber, 1998). A 
clinicopathological description of AD and the first description of the senile plaque was 
described by Oskar Fischer in the same year (Fischer, 1907; Goedert, 2009). Advances in 
research have led to the identification of these two phenomena as Amyloid beta (A�) in senile 
plaques and phosphorylated tau in neurofibrillary tangles (NFTs) (Holtzman et al., 2011). 
There seems to be a close correlation between the progress of AD neuropathology with 
cognitive impairment, although this relationship is complex (Nelson et al., 2010). Cross­
sectional autopsy studies indicate that accumulation of misfolded proteins in AD follows 
distinctive and predictable patterns. A� plaques first appear in the neocortex, followed by the 
allocortex and finally subcortical regions (fhal et al., 2002). Neurofibrillary tangles initially 
appear in the locus coeruleus and transentorhinal area and then spread to the amygdala and 
interconnected neocortical brain regions (Braak and Del Tredici, 201 la). 
Amyloid fJ 
A� is a metabolite of the amyloid precursor protein (APP), a transmembrane protein that can 
be cleaved by C<-, �- and y-secretases. The cleavage of APP by C<-secretases results in 
production of excreted soluble C<-cleaved APP (APPsC<) and membrane bound C-terminal 
fragment-Cl (CTFC<), which is further cleaved at the transmembrane domain by y-secretase to 
release p3. Cleavage by �-secretases on the other hand results in the production of excreted 
APPs� and membrane bound CTF�. Cleavage of the latter by y-secretase results in the 
production of A� (fhinakaran and Koo, 2008). y-Secretase can cleave CTF� at multiple sites 
within the transmembrane domain, thus generating A� peptides with different lengths, 
ranging from 38 to 43 residues (Selkoe and Wolfe, 2007). Increased A�42 is believed to play a 
major role in AD pathology, as A�42 is more fibrillogenic Qan et al., 2008). See reviews 
(Larson and Lesne, 2012; Rajendran and Annaert, 2012; Zhang et al., 2012) for a detailed 
description of A� regulation and trafficking. Interestingly some researchers introduced the 
concept that A� in AD relates to prion disease (Kim and Holtzman, 201 O; J ucker and Walker, 
2011; Nussbaum et al., 2012). 
N eurofibri//ary tangles 
NFTs consist of aggregations of hyperphosphorylated tau protein. Under normal conditions, 
tau is important for the assembly and maintenance of the cell's microtubule network, which 
forms the cell's cytoskeleton and for axonal transport along microtubules. 
Hyperphosphorylation of tau and assembly into NFTs thus results in disruption of the 
microtubule network and axonal transport leading to impaired communication between 
neurons and eventually to neuronal degradation (Hernandez and Avila, 2007). NFTs are not 
AD specific and may develop in different brain regions dependent on the associated trauma 
or pathology (Hof et al., 1996; McKee et al., 2009; Nelson et al., 20096; Nelson et al., 2009a; 
Min et al., 2010; von Gunten et al., 2010; Braak and Del Tredici, 2011 b ). Data presented in 
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the thesis of Ate S. Boerema (electronic ISBN: 978-90-367-5328-9) illustrated that 
hyperphosphorylated Tau occurs in brains of certain animals during torpor, illustrating it to 
be a natural phenomenon of energy regulation. 
Our knowledge is still very limited whether abnormal accumulation of A� plaques precedes 
hyperphosphorylated tau or vice versa, since this can only be positively validated by 
examination of post mortem brain tissue. This topic still remains largely under debate in the 
scientific community. 
A� as pathological agent of AD 
A�42 is a naturally occurring peptide, essential for normal neuronal functioning at 
physiological concentrations (Pearson and Peers, 2006) especially as modulator of synaptic 
plasticity in its monomeric form (Parihar and Brewer, 2010). However, during AD, abnormal 
accumulation of A�42 in the brain occurs. The "A� hypothesis" is accepted as the central 
explanation for AD pathology. A�, especially A�42, has been studied substantially due to its 
association with plaques in AD brains, interference with synaptic function and pathogenesis 
of AD (Walsh et al., 2002). A�42 is actively transported from the brain at interfaces separating 
the CNS from the periphery. However, AD is associated with increased brain A�42 load and 
significantly reduced CSP A�42 concentrations (Blennow et al., 2010). It has been shown that 
the accumulating brain A�42 in sporadic AD patients is due to reduced clearance of A�42 from 
brain tissue (Bateman et al., 2006; Mawuenyega et al., 2010). Mechanistically, the ineffective 
removal of A�42 may be explained by ineffective plaque clearance through dysfunctional 
microglia (DeWitt et al., 1998) and reduced transporters of A�42 that actively transport A�42 
from the brain to the CSP (Pascale et al., 2011), resulting in the reduced CSP A�42 as observed 
in human studies. The A� hypothesis led to the development of novel compounds, aimed to 
reduce A�42, decrease A�42 aggregation and facilitate A�42 clearance (Herrmann et al., 2011). 
Unfortunately none of these compounds so far showed clinical success in human studies 
(Herrmann et al., 2011). Interestingly, a long term follow-up study in patients immunized with 
the AN-1792 A� vaccination showed that cognitive decline continued despite effective 
removal of A�42 plaques verified by autopsy of post mortem brain tissue (Holmes et al., 
2008). However, results from clinical studies performed with a promising new monoclonal 
antibody, Bapineuzumab that targets A�42 plaques, will be disclosed later in 2012*. (* 011 6 
A 11,g11sl 2012 ii was a111101mced that ji,rther testi11g rf 13api11euzah 111as di.m111ti1111ed. I 4/e-slctge trails sho]lled that Hapineuzah was 110/ 11mre efji:cti1•c them placebo in patients who had 111ild lo 111oderate AD.) 
Ever increasing knowledge of the pathology of AD created caveats on our current 
understanding of A�42 as the principal pathological agent in AD. This was in part instigated 
by the renowned Nun study of ageing and Alzheimer's disease. A remarkable observation was 
made in this study whereby a 101 year old woman had normal cognitive functioning, despite 
having abundant neurofibrillary tangles and senile plaques, associated with the classic lesions 
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of AD (Snowdon, 1997). A study in a community based sample of volunteers using amyloid 
imaging further validated this finding by uncovering that approximately 21 % of cognitively 
normal elderly people have substantial amyloid deposition in the brain comparable to the 
levels observed in AD patients (Aizenstein et al., 2008). Studies using imaging to detect A� 
further confirmed that amyloid deposition begins before clinically observable cognitive 
symptoms occur (Sojkova et al., 2011; Villemagne et al., 2011). Information obtained from 
these studies suggests that the brain can tolerate a high A� burden without occurrence of 
cognitive dysfunction. The damaging effects of A�42 may not be due to the A�42 load itself, 
but might rather be dependent on the specific A�42 species present in the brain. A�42 goes 
through a course of progressive aggregation from monomers to oligomers through 
fibrillization to plaque formation (Ashe and Zahs, 2010). Newly acquired insights show that 
oligomers are the toxic species of A�42 Gin et al., 20116; Kayed and Lasagna-Reeves, 2012). In 
summary, data suggest that even though A�42 is used as a measurement to identify AD 
pathology, its relationship to cell dysfunction and cognitive decline is still uncertain and it 
may not be the sole target aimed to prevent neurodegeneration due to AD. 
Neuroinflammation hypothesis of AD 
Neuroinflammation has become an active area of investigation in Alzheimer's and other 
neurodegenerative diseases. Microglia, the predominant cells of the innate immune system of 
the central nervous system are key cellular mediators of neuroinflammatory processes. In the 
context of AD, association of activated microglia with plaques and NFfs has been observed 
since the 1980's (Rozemuller et al., 1986; Rogers et al., 1988; Griffin et al., 1989; Dennis J, 
1991). Other neuronal cells such as astrocytes and neurons have also been found to 
contribute to the chronic neuroinflammatory processes in AD (Del Bo et al., 1995; Li et al., 
2011). These findings changed the view of the brain as previously believed immune-privileged 
organ. In the 1990's additional findings of cytokines, chemokines and their associated 
receptors (Streit and Kincaid-Colton, 1995; Arvin et al., 1996; Mattson et al., 1997; 
Mennicken et al., 1999) undeniably revealed the involvement of innate immunity in the 
reaction to the AD-related stimuli. This led to the acknowledged neuroinflammation 
hypothesis in AD, which was also recognized as a therapeutic target. An essential matter that 
still needs to be resolved is whether inflammation precedes AD pathology or vice versa (the 
classic "chicken and egg" question). The orthodox believe is that neuroinflammation to be a 
downstream result of AD pathology (Kalaria, 1999; Eikelenboom et al., 2006; Hoozemans et 
al., 2006). However, Herrup et al. recently presented an alternative model, suggesting that 
neuroinflammation precedes AD pathology (Herrup, 2010). In this review Herrup explains 
that earlier CNS injury, e.g. microstroke or head trauma, can induce a chronic inflammatory 
response that subsequently lead to irreversible neuronal cellular changes and damage. Herrup 
further describes that extracellularly A�42 naturally accumulates with age and that increased 
immune response can increase A�42 production and that increased A�42 further can lead to 
increased neuroinflammation. This model also demotes the significance of the A� hypothesis 
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as the key pathological causative factor for of AD. Albeit the sequence of events concerning 
neuroinflammation is still under scrutiny, the presence of systemic inflammation in cognitive 
decline and possible presymptomatic AD has been identified (fiemeier et al., 2003; Dik et al., 
2005; Kuo ct al., 2005; Milaneschi et al., 2009; Swardfager ct al., 2010; .Milancschi ct al., 2011). 
Despite the fact that peripheral circulating inflammatory proteins have been used to describe 
the association of inflammation with AD, compelling research showed a bi-directional 
interaction between the immune system of the periphery and the central nervous system 
(CNS) (Banks et al., 1995; Turnbull and Rivier, 1999; Banks et al., 2002; Dantzer et al., 2008). 
The association of neuroinflammation with AD pathology is widely regarded as a double­
edged sword: it can exert both neuroprotective and neurotoxic functions. The 
neuroinflammation can have beneficial characteristics in fighting AD via activated microglia 
cells that remove amyloid plaques (Rogers et al., 2002) or through molecular mechanism by 
activation of pro-survival cellular signaling mechanisms (Mattson and Meffert, 2006). On the 
other hand, It has been proposed that the inflammatory response can execute damaging 
effects, possibly via the formation of free radicals that might contribute to neuronal 
degeneration (McGeer and McGeer, 2004; Streit, 2004; Lee et al., 2010a). Inflammatory 
reactions can increase A�42 production (Franciosi et al., 2005) and also directly alter A�42 
structures, creating more toxic A�42 species (Kummer et al., 2011). Recent findings illustrated 
that the ageing process causes aberrant immune regulation by shifting the immune system to 
a low grade pro-inflammatory state, resulting in a chronic increase of pro-inflammatory 
cytokines (Weinert and Timiras, 2003; Franceschi et al., 2007). This consequently can 
abrogate the neuroprotective properties of the immune system (Bodles and Barger, 2004), 
necessary for AD prevention. The cytokine, TNF-cx is one of the most studied cytokines in 
AD due to its interesting cellular signaling mechanisms. Detailed information regarding the 
cellular mechanisms of TNF-cx is reviewed in chapter 2 and also in chapter 3 and its 
involvement in AD is discussed in chapter 4 of this thesis. 
Lipocalin 2 
Lipocalins are a diverse family of over 20 small soluble and, often secreted, proteins. They are 
defined as lipocalins based on their tertiary structure "\vhich is comprised of a single eight­
stranded, continuously hydrogen-bonded anti-parallel �-barrel (Flower, 1994). The cavity in 
the �-barrel is thought to bind and transport a variety of lipophilic substances (Flower, 1994). 
Lipocalins can bind to specific cell-surface receptors and may deliver ligands, including iron, 
growth, or survival factors, to the cell by receptor-mediated endocytosis (Flower, 2000). The 
functions of the lipocalins are not well understood. Lipocalin 2 (Lcn2) is known by several 
names as neutrophil gelatinase-associated lipocalin (NGAL), siderocalin, 24p3 and uterocalin. 
Lcn2 was discovered nearly two decades ago as a protein associated with purified human 
neutrophil gelatinase (Kjeldsen et al., 1993). Lcn2 is an acute phase protein upregulated via 
different pro-inflammatory stimuli, including TNF-cx (Liu and Nilsen-Hamilton, 1995). 
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Research has shown that Lcn2 is involved in a variety of physiological functions including 
transport of iron (Richardson, 2005), regulation of red blood cell production (Miharada et al., 
2005), inflammation (Nielsen et al., 1996) and immunomodulation (Devireddy et al., 2001). 
Lcn2 knockout mice showed normal phenotype, but had a higher susceptibility to bacterial 
infections (Flo et al., 2004). Increased levels of Lcn2 has been associated with the diseases 
conditions such as cancer (Bolignano et al., 2010c) kidney disease (Devarajan, 2010; Urbschat 
et al., 2011), insulin resistance (Wang et al., 20076; Cakal et al., 2010) and cerebrovascular 
disease (Elneihoum et al., 1996). On the cellular level, Lcn2 can act as a pro-apoptotic or pro­
survival factor, depending on the cell type and cellular environment (Devireddy et al., 2001; 
Devireddy et al., 2005; Hanai et al., 2005; Lee et al., 2007; Miharada et al., 2008; Lee et al., 
2009). The function of Lcn2 within the CNS has only recently begun to be elucidated. In 
vitro studies showed that Lcn2 can activate and sensitize astrocytes and microglia to 
apoptosis (Lee et al., 2007; Lee et al., 2009). Recent in vivo studies showed increased CNS 
Lcn2 production after intraperitoneal injection of lipopolysaccharide (Ip et al., 2011). Lcn2 
plays a detrimental role in the CNS following spinal cord injury in mice (Rathore et al., 2011) 
and Lcn2 inhibits hippocampal neuronal maturation in a mouse model of stress (Mucha et al., 
2011). These findings will further be elaborated in chapters 5 to 7 of this thesis. 
Targeting inflammation as therapeutic approach 
Several epidemiological studies identified the associated use of Non-Steroidal Anti­
Inflammatory (NSAID) with reduced prevalence of AD. A systematic review of 11 cross­
sectional, retrospective or prospective observational studies found that NSAID exposure was 
associated with decreased risk of AD (Szekely et al., 2004). This was further evaluated in 
different animal models of AD with great success (Imbimbo, 2009). However, various anti­
inflammatory drugs later tested in clinical trials designed to inhibit inflammation in AD, failed 
as treatments to inhibit AD progression (Imbimbo, 2009). To add further perplexity to this 
matter, a 4 year follow-up study done in MCI patients treated with the NSAID rofecoxib 
showed that rofecoxib significantly increased the conversion rate of MCI to AD (Thal et al., 
2005). 
Failure of current findings of NSAID as treatments might be explained by the choice of 
NSAIDs, the duration of treatment, or the advanced age or presymptomatic 
neurodegeneration in the subject population. Timing of treatment seems of utmost 
importance. It is quite evident from the epidemiological studies showing that NSAID reduced 
the prevalence of AD, were performed as follow-up studies in participants whom were all 
non-demented at baseline of the study and later developed AD (McGeer et al., 1996; in 't 
Veld et al., 2001). This indicates that NSAID might have to be administered during pre­
symptomatic AD. In addition, long term treatment duration of NSAID treatment also seems 
to be important (in 't Veld et al., 2001). These studies in essence show that possible future 




specific immunomodulation, aiming to inhibit the damaging effects of the immune system 
without dampening its protective effects. 
Better understandings of the cytokine; TNF-cx. and its corresponding signaling mechanisms 
made an indicative target with the intent to specifically modulate the immune system to treat 
neurodegenerative diseases. Human studies demonstrated the association of increased TNF-cx 
protein levels with AD pathology (Rao et al., 2011) and increased CSP concentrations with 
the progress from MCI to AD (Holmes et al., 2009) . Selective manipulation of TNF-cx 
signaling via its receptors have shown promising results in AD mouse models (He et al., 2007; 
Kim et al., 2008; Chakrabarty et al., 2011) . A preliminary clinical study illustrated that a 
perispinal injection of etanercept reduced the symptoms of AD (Tobinick and Gross, 2008), 
yet still seen as controversial in the scientific community. These data signify TNF-cx. as a 
promising immunomodulatory target. Better understandings of TNF-cx. and its signaling 
mechanisms during the ageing process and altered environments due to pathology are still 
necessary in order to be used as effective treatment in neurodegenerative diseases. 
Detecting presymptomatic- and prodromal- AD and its implications for 
successful therapeutic targets 
Biomarkers identifying early presymptomatic and prodromal AD have recently gained 
considerable attention in both the research field and industry due to the following possible 
applications: 
• They can serve as objective measurements that reflect the biological state of disease. 
Identifying markers uniquely characterized with the presence of AD pathology can 
greatly improve diagnostic efficiency and accuracy. In addition, the likelihood of AD 
development and disease severity might be determined. 
• Biomarkers can provide insight of the underlying etiology of AD and therefore serve as 
potential new targets for future drug developments and serve as indicators for correct 
therapy when treatments are available. 
• Biomarkers can also be used as an aid to determine the efficacy of therapies. 
Advancements of detection methods and new discoveries of the pathology of AD during the 
last 3 decades made it possible to track the sequence of certain biological alterations involved 
in the disease progression of AD (see table 1.1). 
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Table 1.1. Popular markers currently researched in order to identify pathological changes associated 
with AD (Albert et al., 201 1 ;  Cummings, 201 l ; Jack Jr et al., 201 1 ; Alves et al., 2012) .  
CSF markers Plasma Imaging 
-AD associated pathology -AD associated pathology -AD associated pathology 
•A�42 • A�42: A�40 ratios •PET 
•tau/ phosphorylated-tau -Inflammatory markers •SPECT 
-Inflammatory markers • cytokines -Metabolism 
•cytokines •PET 
-Oxidative stress •SPECT 
•isoprostanes -Measttrement of altered brain strHcture 
• Magnetic resonance imaging (MRI) 
•Computerized tomography (C1) 
- Ne11roinflan1mation 
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Imaging techniques, CSF markers and plasma markers have been useful to investigate 
markers that synchronically correspond to disease progression of AD. Numerous studies 
have shown that biomarkers can predict conversion from MCI to AD (Visser et al., 1999; 
Dickerson et al., 2001; Chetelat et al., 2003; Mattsson et al., 2009; Shaw et al., 2009; Craig­
Schapiro et al., 2010; Swardfager et al., 2010; Molinuevo et al., 2011; Ossenkoppele et al., 
2011; Villemagne et al., 2011). 
Due to these findings, scientists lately suggested that that the diagnostic criteria for early AD 
should be redefined by the presence of memory impairments plus biomarker evidence of AD 
(Dubois et al., 2007; Albert et al., 2011; Jack Jr et al., 2011; McKhann et al., 2011; Molinuevo 
et al., 2011; Sperling et al., 2011). This combination will undoubtedly aid clinicians in 
diagnostic accuracy and may have important implications for the design of future clinical 
trials aimed to find treatments for preclinical and prodromal AD in order to prevent progress 
to AD. 
What have we learnt from markers? 
The described events are illustrated in figure 1.1. Early clinical symptoms. Various 
psychiatric manifestations have been evaluated in order to identify possible associations with 
AD. This has led to the identification of late-life depression as a psychopathological marker 
as indicative risk factor for AD Oost and Grossberg, 1996; Alexopoulos, 2005; Brommelhoff 
et al., 2009). AD pathology. Neuroimaging techniques and analysis of CSP markers are 
currently used to assess A� related changes (Bloudek et al., 2011). CSP is in direct contact 
with the extracellular space of the brain, and its constituents reflect many biochemical 
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changes in the brain. CSP A�42, total tau and phosphorylated tau are the best established and 
validated markers shown to be altered during early forms of AD (Blennow et al., 2010). 
Recent findings have showed that CSP A�42 precedes phosphorylated tau measured as 
biomarkers in patients that conversed to AD, supporting the concept that A�42 precedes 
phosphorylated tau during the development of AD pathology (Holtzman et al., 201 1 ; 
Buchhave et al., 201 2; Desikan et al., 2012). Inflammation. Numerous findings indicates 
increased peripheral and CSP inflammatory markers in patients associated with the 
occurrence of early symptoms of AD (Swardfager et al., 2010). Recent findings further 
suggest that inflammatory markers may predict cognitive decline (Teunissen et al., 2003; Dik 
et al., 2005; Schram et al., 2007). A study by Schuitenmaker et al, suggested that increased 
CSP inflammatory markers e.g. IL-6 may even precede A�42 abnormalities in the disease 
process (Schuitemaker et al., 2009). Neuroinflammation interestingly decreases in late stages 
of AD (Hoozemans et al., 201 1 ). Atrophy. Structural MRI can provide measures of cerebral 
atrophy, which is caused by dendritic reduction and loss of synapses and neurons (Bobinski et 
al. , 2000). MRI measurements of brain atrophy shows a strong correlation between brain 
atrophy and cognitive dysfunction Qack et al., 1 992). MRI is the marker later affected in AD 
pathology, showing abnormality only in later stages of AD pathology in association with 
cognitive decline. This demonstrates that underlying pathological events of AD precedes 
brain atrophy years in advance. 
Of note, newer studies have found A� in brains of patients with late-life depression, 
signifying increased pathology of AD (Butters et al., 2008; Kumar et al., 201 1 ). Increased 
inflammatory markers found during early AD has also been found to be increased during 
late-life depression (Craddock and Thomas, 2006; Eikelenboom et al., 2006; Hoozemans et 
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Figure 1.1. Illustrated relationship between the time course of changes on indicated biomarkers in 
relation to the neuropathology and clinical changes of Alzheimer's disease (Eikelenboom et al., 2006; 
Hoozemans et al., 2006; Brommelhoff et al., 2009; Schuitemaker et al., 2009; Shaw et al., 2009; Dowlati 
et al., 2010a; Swardfager et al., 2010; Hoozemans et al., 201 1 ;  Sperling et al., 201 1 ;  Buchhave et al., 
2012). 
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Outline of this thesis 
Significance of altered immune functioning during ageing and its association with late-life 
depression and disease progression of AD opened exciting new opportunities in research. 
The aim of this thesis is to investigate the intricate functions of the immune system during 
the ageing process and development of AD with respect to TNF-cx functioning. This 
approach was undertaken to not only gain novel information of the underlying molecular 
etiology of AD development but also to identify novel targets for potential therapeutic 
intervention. TNF-cx signaling mechanisms are complex. Chapter 2 therefore provides a 
clarification of the signaling mechanisms induced by TNF-cx via its receptor 1 and receptor 2. 
Physiological functions of individual TNF-cx receptor signaling are briefly explained. This 
chapter furthermore provides a thorough description of the cross-talk that occurs between its 
two receptors. CNS functions of TNF-cx is also reviewed in the introduction of chapter 3. 
Research showed that TNF-cx and its receptor functioning are altered in the ageing process 
(Gupta and Gollapudi, 2005; Patel and Brewer, 2008a; Patel and Brewer, 2008b). In chapter 3 
we investigated the differential effects of TNF-cx receptor 1 and receptor 2 on cognitive -, 
behavior- and physical- functioning during ageing in mice. 
In chapter 4 we sought novel factors that are induced by TNF-cx contributing to its 
neuroprotective functions. In this chapter the discovery of Lcn2 was made, being the 
fundamental finding in this thesis. Chapter 4 forms the core of this thesis, describing novel 
mechanisms on how TNF-cx regulates Lcn2 production, Lcn2 as novel inflammatory marker 
in MCI and AD and the role of Lcn2 as novel immunopathogen in AD. This chapter also 
defines Lcn2 as product of TNF receptor 1 activation, which in turn regulates TNF receptor 
2 signaling. Findings of chapter 4 instigated curiosity whether Lcn2 is associated with the 
ageing process specifically late-life depression, being a risk factor for AD development. In 
chapter 5 plasma Lcn2 concentrations in participants from the Netherlands Study on 
Depression in Older Persons (NESDO) were analyzed. Its correlation to various 
psychopathological conditions of depression was investigated. In chapter 6, a detailed analysis 
of plasma Lcn2 from the NESDO cohort was done to identify the association of Lcn2 in a 
subgroup of people who possibly are at high risk of developing AD. Chapter 7 provides 
conclusions for the findings obtained in this thesis and their novelty to the research field. 
Implications for future research based on these findings are also reviewed. 
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Abstract 
Extensive research has been performed to unravel the mechanistic signaling pathways 
mediated by tumor necrosis factor receptor-1 (TNFR1) in contrast there is limited knowledge 
on cellular signaling upon activation of TNF receptor-2. Recently published data have 
revealed that these two receptors do not only function independently, but also can influence 
each other via cross-talk between the different signaling pathways initiated by TNFR1 and 
TNFR2 stimulation. Furthermore, the complexity of this cross-talk is also dependent on the 
different signaling kinetics between TNFR1 and TNFR2, by which a delicate balance between 
cell survival and apoptosis can be maintained. Some known signaling factors and the kinetics 
that are involved in the receptor cross-talk between TNFR1 and TNFR2 is the topic of the 
present review. 
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Introduction 
Tumor necrosis factor-alpha (fNF-cx) was discovered - 30 years ago as a product of immune 
activation. In the last three decades, an impressive amount of knowledge has been obtained 
regarding the biological functions of TNF-cx, as well as the signaling mechanisms engaged by 
its receptors. TNF-cx primarily occurs as a type II transmembrane protein of 26 kDa, which 
can be cleaved by the metalloprotease TNF-cx-converting enzyme to a 17 kDa TNF-cx protein 
that is biologically active in a soluble homo-trimeric molecule of 51 kDa (Grell, 1995; Wajant 
et al., 2003). 
TNF-cx exerts a broad range of biological effects via two known transmembrane receptors 
that were discovered - 30 years ago (Hohmann et al., 1989): the 55 kDa tumor necrosis 
factor receptor-1 (fNFR1) that is expressed ubiquitously on almost all cell types, and a larger 
75 kDa tumor necrosis factor receptor-2 (fNFR2), which is under normal physiological 
conditions expressed at low levels typically in cells of the immune system (Loetscher et al., 
1990; Schall et al., 1990; Smith et al., 1990; Fiers, 1991; Tartaglia and Goeddel, 1992). 
TNFR1 serves as the major mediator of TNF-cx induced signaling pathways. TNFR1 signaling 
has pleiotropic functions such as activation of nuclear factor-kappaB (NF-xB) and induction 
of apoptosis, both of which depend on the cellular environment. The expression of TNFR2, 
however, is much more limited to specific cell types compared with TNFR1. TNFR2 
expression is restricted to specific neuronal subtypes, and to oligodendrocytes, microglia and 
astrocytes in the brain, to endothelial cells, and certain T-cell subpopulations, including 
lymphocytes (CD4+ and CDS+ T-cells), cardiac myocytes, thymocytes and human 
mesenchymal stem cells (Choi et al., 2005; Faustman and Davis, 2010). A large body of 
research has shown that TNF-cx possesses the capacity to exert a great deal of highly different 
biological functions via its two receptors. Some aspects regarding cross-talk between TNF-cx 
receptors and signaling cascades have been discussed in review papers (MacEwan, 2002; 
Aggarwal, 2003; Gaut and Aggarwal, 2003). 
TNF Signaling in immunity 
The significant role of TNFR1 in immunity has been shown in several studies in vivo. Flynn, et 
al., (Flynn et al., 1995) illustrated that TNFR1 is essential to protect mice against tuberculosis 
infection, reactive nitrogen production by macrophages and also proper granuloma 
functioning. TNFR1- and TNF-cx-deficient mice die from a fulminant necrotizing encephalitis 
when orally infected with a low-virulent strain of Toxoplasma gondii, whereas TNFR2 deficient 
mice were unaffected (Deckert-Schluter et al., 1998). Furthermore it was shown that TNFR1 
is the TNF-cx receptor primarily responsible for initiating inflammatory responses (Loetscher 
et al., 1993; van der Poll et al., 1996). Kim et al., (2006) published evidence that CD4 + and 
CDS+ T-cells depend on TNFR2 for survival during clonal expansion in response to 
intracellular bacterial pathogens, thus allowing larger accumulation of effector cells and 
1 7  
Chapter 2 
thereby optimizing protection from apoptosis by inducing a substantial generation of the 
antigen-specific memory T-cell population memory pool (Kim et al., 2006). In an another 
study, it was found that TNFR2- and TNF-cx-knockout mice have delayed clearance of 
hepatic replication-deficient adenovirus and also decreased adenovirus-specific cytotoxic T­
lymphocyte activity of intrahepatic lymphocytes. TNFR1 knockout mice did not display such 
effects allowing the conclusion that TNFR2 facilitates the generation of antigen specific 
cytotoxic T-lymphocytes for antiviral immune responses (Kafrouni et al., 2003). Also, 
TNFR2 knockout mice had no CD8+ T-cell-mediated lung injury associated with clearance 
of experimental influenza virus, indicating that TNFR2 to be important for the occurrence of 
immunopathology in alveolar tissue (Liu et al., 2005). However, in another study it was 
shown that TNFR2 activation by insulin selectively killed autoreactive T-cells derived from 
blood of type 1 diabetes patients, which did not have an effect on other activated and 
memory T-cell populations (Ban et al., 2008). In summary, TNFR2 can play a vital role in the 
maintenance of the delicate and complex processes involved in functioning of the immune 
system. 
TNF Signaling in the Cellular survival 
TNF-cx in the nervous system exerts opposing effects via TNFR1 and TNFR2 with respect to 
cell survival in neuronal tissue exposed to traumatic insults. See review regarding TNFR1 
mediated cell death and survival signalling mechanisms (Yan Herreweghe et al., 2010). In a 
retinal ischemia mouse model, both TNFR1 and TNFR2 were upregulated in neuronal retinal 
cell layers a few hours after ischemia-reperfusion-induced retinal damage. Interestingly 
TNFR1 aggravated neuronal death while TNFR2 protected against ischemic tissue 
destruction (Fontaine et al., 2002). TNFR2 is also necessary for TNF-cx induced regeneration 
of myelin forming oligodendrocyte precursor cells (Arnett et al., 2001). Specific stimulation of 
TNFR1 in baboons caused a local skin necrosis, whereas TNFR2 specific stimulation had no 
effect on skin necrosis (:$/ elborn et al., 1996). Furthermore, in a large human clinical trial 
study it became clear that a TNF-cx neutralising antibody exacerbated the symptoms when 
administered to patients with multiple sclerosis (van Oosten et al., 1996; 1999). It has also 
been shown in an in vivo heart failure model in mice that TNFR1 has damaging effects to 
chamber remodeling, systolic dysfunction and hypertrophy while TNFR2 proved to be 
cardioprotective in this regard (Hamid et al., 2009). Although most of our knowledge with 
respect to TNF-cx signaling has been obtained in models using TNFR1- and TNFR2 
knockout mouse models as well as agonistic antibodies specifically stimulating either one of 
the receptors, the co-existence and co-stimulation of both receptors in an unaltered biological 
system should be taken into consideration. It can be possible that the genetic modification to 
the animals might have an influence on many different aspects regarding TNF-cx signaling. 
Deletion of the TNF-cx might lead to alterations in the balance of intricate signaling cascades, 
epigenetic modifications and decreased soluble TNF receptors, which also functions as TNF­
cx inhibitors. Recently, research has shown that cross-talk between TNFR1 and TNFR2 can 
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take place which is controlled or influenced by many factors, including cell type, intracellular 
or extracellular environment, age, response to injury, inflammation and occurrence of NF-xB 
activation (Faustman and Davis, 2010). 
TNFR1 signaling pathway 
TNFR1 is activated via both membrane bound TNF-cx as well as soluble TNF-cx (Grell et al., 
1995). The extracellular domain of TNFR1 contains three well-ordered cysteine-rich domains 
(CRD1, -2, and -3) that characterize the TNF-cx receptor superfamily and a fourth membrane­
proximal cysteine-rich division (Tuma et al., 1995). The N-terminal cysteine-rich domain, 
known as the preligand binding assembly domain, favors preassembly of TNFR1 into 
trimeric complexes. The preligand binding assembly domain functions to prevent 
spontaneous receptor autoactivation and is also a prerequisite for ligand binding (Chan et al., 
2000). The intracellular part of TNFR1 contains a protein-protein interaction region called 
the death domain (Tartaglia et al., 1993). After ligand binding to the TNFR1, silencer of death 
domain (SODD) dissociates from the intracellular death domain of TNFR1 upon which the 
adapter protein TNF-cx receptor-associated death domain (TRADD) is recruited that binds to 






Figure 2.1. TNF-induced signaling via TNFR1 . 
DD, death domain; cIAP cellular inhibitor of apoptosis; FADD, Fas-associated death domain protein; 
cFLIP, caspase-8 homologue FLICE-inhibitory protein; IKK, IxB kinase; IxBcx, inhibitor of kappa B; 
NF-xB, nuclear factor kappa B; RIP, receptor interacting protein; TRADD, TNF receptor-associated 
death domain; TRAF, TNF receptor associate factor; TNF, tumor necrosis factor; TNFR1 , tumor 
necrosis factor receptor-1 .  
TRADD subsequently recruits otl1er proteins that are involved in downstream signaling, e.g. 
TNF-oc receptor associate factor-2 (TRAF2) and it was also believed that tl1e death domain 
kinase, receptor interacting protein (RIP) can also interact with the death domain of TNFR1 
(Boldin et al., 1996; Hsu et al., 1996; Ting et al., 1996). However, recent research has shown 
that RIP can be recruited to TNFR1 independent of TRADD (Chen et al., 2008). This 
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membrane-bound TNFR1 signaling complex (complex 1) rapidly initiates signaling cascades 
leading to NF-xB and c-Jun N-terminal kinase GNK)/SAPK activation (Hsu et al., 1 996; 
Micheau and Tschopp, 2003). 
Upon NP-xB activation via TNFR1, TRAF2 or TRAPS, and cellular inhibitor of apoptosis-
1 /2 (c-IAPl /2), together with E2, ubiquitin conjugated protein Ubc13  is associated to 
TRADD and RIP1 (Figure 2. 1) .  c-IAPs and both TRAP2 and TRAPS contribute to the 
ubiquitination of RIP1 upon TNFR1 stimulation via ubiquitin chains linked through lysine 63 
(K63) (Lee et al., 2004; Mahoney et al., 2008; Varfolomeev et al., 2008), (for more details see 
Wajant and Scheurich, 201 1) .  Polyubiquitinated RIP1 can act through signaling of MEKK.3 
and the TAK1/TAB 2 complex to activate the catalytic IxB kinase (IKK) complex, which is 
composed of three proteins, IKI<a (IKK1) ,  IKK� (IKK2) and IKKy (NP-xB essential 
modulator), leading to phosphorylation of inhibitor of kappaB-alpha (IxBa), the NF-xB 
inhibitory protein. Phospho-IxBa is then degraded via the ubiquitin-proteasome pathway, 
allowing NF-xB to translocate to the nucleus and initiate transcription (Ea et al., 2006; Wu et 
al., 2006a) . Polyubiquitinated RIP1 can alternatively activate the IKK complex via interaction 
of  the TAKl complex, consisting of the TAK1 kinase and its associated proteins TAI<J­
binding protein 1 /2/3 (TAB1,  TAB2, and TAB3). TAB1 -3 serve as the regulatory ubiquitin­
binding subunits and trigger the allosteric activation of TAK1 (Blonska et al., 2005; Ea et al., 
2006), which in tum phosphorylates and activates IKK (Israel, 2006) . Activation of NF-xB 
allows it to translocate to the nucleus and initiate transcription of anti-apoptotic target genes, 
such as c-IAP1 ,  c-IAP2, caspase 8 homolog FLICE-inhibitory protein, TRAP1 and TRAF2 
(Wang et al., 1 998) (Figure 2. 1) .  Upon release from the TNFR1 signaling complex TRADD 
and RIP can also associate with Fas-associated death domain protein (F ADD) and caspase-8 
forming a cytoplasmic complex (complex II) which was believed not to be associated with 
TNFR1 but on the contrary it was demonstrated by (Schneider-Brachert et al., 2004) that 
TNR1 endocytosis and a death-inducing signaling complex (DISC) formation are inseparable 
events, which can then lead to caspase cascade activation, resulting in apoptosis (Hsu et al., 
1 996; Yeh et al., 1 998; Micheau and Tschopp, 2003) . Activation of the classical NF-xB 
pathway (see Wajant and Scheurich, (Wajant and Scheurich, 201 1) and RIP1 ubiquitination 
(see O'Donnell and Ting, (O'Donnell and Ting, 201 1) ,  which favorably occur during normal 
cellular functioning, prevent TNP-a-induced apoptosis (Liu et al., 1 996) .  However, during 
circumstances of deficient accessibility of c-IAP and PUCE-inhibitory protein, complex II 
triggers caspase-8 activation and apoptotic cell death (Muppidi et al., 2004) . 
TNFR2 signaling pathway 
Unlike TNFR1, TNFR2 does not possess a death domain and activation induces a long 
lasting NF-xB activation (Rothe et al., 1 995b) ,  (Figure 2.2) .  It has been shown that TNPR2 
activation of NP-xB occurs independent of the TNFR1 signaling pathway (Thommesen and 
Laegreid, 2005) . Indeed, it has been observed in several cell lines that TNFR2 stimulation via 
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membrane-integrated TNF-cx can activate the non-canonical NF-xB pathway (Rauert et al., 
2010) as well as the canonical NF-xB pathway (tv[archetti et al., 2004) . TNFR2 is 
preferentially activated by membrane-integrated TNF-cx while soluble TNF-cx binds TNFR2 
but fails to properly stimulate TNFR2 signaling (Grell et al., 1 995) .  Trimerization of TNFR2 
takes place upon binding of TNF-cx, which leads to the recruitment of TRAF2 to the 
intracellular TRAP binding motif and consequently also to indirect recruitment of tl1e 
TRAF2-associated proteins TRAF1 ,  clAP1 and cIAP2 which already interact with TRAF2 in 
unstimulated cells (Rothe et al., 1 994; Rothe et al., 1 9956) .  
clAPl/2 •• • •




Figure 2.2. TNFR2-mediated TNF signaling. 
cIAP cellular inhibitor of apoptosis; IKK, IxB kinase; IxBcx, inhibitor of kappa B; NIK, NF-xB­
Inducing Kinase; PBK/ Akt, protein kinase B / serine-threonine kinase; PI3K, phosphoinositide 3-
kinases; PTEN, phosphatase and tensin homolog deleted on chromosome ten; NF-xB, nuclear factor 




It has been shown that a dominant negative mutant of TRAF2 blocks 1NFR2-mediated NF­
xB activation, whereas overexpression of TRAF2 causes activation of NF-xB, suggesting that 
TRAF2 plays a pivotal function in 1NFR2-mediated NF-xB activation (Rothe et al., 1995a). 
In unstimulated cells, the TRAF2-c-IAP1/2 complex interacts with a complex of TRAF3 and 
NF-xB -Inducing Kinase (NIK) resulting in c-IAPl/2-mediated ubiquitination of NIK and 
the subsequent proteosomal degradation of NIK. Recently it was demonstrated in several cell 
lines including primary immune cells that only membrane-bound TNF-cx and not soluble 
TNF-cx trimers stimulates the noncanonical NF-xB pathway via TNFR2 stimulation by 
deviation of the NIK degradation-inducing TRAF2-c-IAP1/2 complex from the cytosol 
(Rauert et al., 2010). Thus, it was reported that TNFR2 activation results in an accumulation 
of NIK. NIK is then able to stimulate IKI<cx. The NIK-activated IKKcx in turn 
phosphorylates the NF-xB precursor protein p 100, thus triggers its limited proteasomal 
proteolysis to p52 which results in activation of p52-containing NF-xBs. The noncanonical 
NF-xB activation is independent of NF-xB essential modulator and IKK� (Sun and Ley, 
2008). TNFR2 can signal via activation of Akt (Al-Lamki et al., 2005). Upon exclusive 
stimulation of TNFR2 in neurons lacking the TNFR1, NF-xB was activated via the PI3K­
PKB/ Akt pathway, whereas selective stimulation of 1NFR1 in TNFR2 /- neurons had no 
influence on this pathway (Marchetti et al., 2004). It was also demonstrated that IKKcx is the 
prime target of this pathway, which then leads in IKK� activation and subsequent IxBcx 
phosphorylation (Gustin et al., 2004) and activation of cRel and p50/p65, indicating that NF­
xB is activated via the canonical NF-xB pathway (Marchetti et al., 2004). In addition, co­
incubation of TNF-cx with a PI3K inhibitor, LY294002, in wild type as well as in TNFR1-/­
neurons (selective TNFR2 activation) reduced IxBcx phosphorylation (Marchetti et al., 2004), 
thus indicating that the phosphatidylinositol 3-kinase-protein kinase B / serine-threonine 
kinase pathway may play a major role in TNFR2-mediated activation of NF-xB. Furthermore, 
NF-xB activation via TNF-cx leads to a downregulation of the phosphatase and tensin 
homolog deleted on chromosome ten (PTEN) protein, which is a strong inhibitor of the 
phosphatidylinositol 3-K/ Akt pathway. Thereby, this cascade may lead to an autoregulatory 
loop, which could lead to a persistent protein kinase B/serine-threonine kinase 
phosphorylation and sequentially NF-xB activation (Eisel et al., 2006). 
Involvement of TRAF1 and TRAF2 in the cross-talk of TNFR1 and TNFR2 
Contrary to the general belief that TNFR1 signaling can cause apoptosis and that TNFR2 
signaling pathway primarily induces pro-survival, there is convincing evidence that exclusive 
TNFR2 stimulation can trigger some cells to undergo apoptosis in spite of the fact that 
TNFR2 does not contain a death domain (Bigda et al., 1994; Medvedev et al., 1994). For this 
reason, it was speculated that some form of receptor cross-talk might take place between 
TNFR1 and TNFR2, especially via the involvement of TRAFs, which has been confirmed by 
more recent research. TRAFs are pivotal to TNF-cx signaling and are recruited to both 
TNFR1 and TNFR2 complexes to commence cellular signaling (Wajant et al., 2001). TRAF2 
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plays a crucial role in TNFR1-mediated activation of c-Jun as well as NF-xB which is essential 
for cellular survival. These pathways can be inhibited by TNFR2-mediated depletion of 
TRAF2 (Fotin-Mleczek et al., 2002). A few hours prestimulation of TNFR2 with a TNFR2 
agonist causes depletion of endogenous TRAF2 (Fotin-Mleczek et al., 2002). c-IAP1 and c­
IAP2, which have initially been identified as components of the TNFR2 signaling complex 
are also recruited via TRAF2 into the TNFR1 signaling complex. There is evidence that the 
TRAF2-c-IAP1/2 complex interferes with TNFR1-associated caspase-8 activation and 
apoptosis induction (Roy et al., 1997; Wang et al., 1998). Stimulation of TNFR2 leads to the 
recruitment of TRAF2 into a Triton X-100-insoluble compartment, and subsequent 
ubiquitination and proteasomal degradation via the TRAF2 associated c-IAP1 (Chan and 
Lenardo, 2000; Fotin-Mleczek et al., 2002; Li et al., 2002; Wu et al., 2005). However, an 
important finding in that respect was that TRAF1 interferes with this process and reduces 
TNFR2-induced TRAF2 depletion by preserving TRAF2 in the Triton X-100 soluble 
fraction. Furthermore, TRAF1 rescued TNFR1 induced NF-xB and JNK activation of 
TNFR2 prestimulated TRAF1 transfected cells (Wicovsky et al., 2009). The important role of 
TRAF1 to induce NF-xB activation is possibly due to preservation of cytoplasmic TRAF2. 
Contradictory results regarding the regulatory effects of TRAF1 on NF-xB signaling have 
been reported by in vitro studies, in which overexpression of TRAF1 caused an increase 
(Schwenzer et al., 1999) but also an inhibition of NF-xB activation (Carpentier and Beyaert, 
1999). In vivo, T-cells from TRAF1-deficient mice showed enhanced NF-xB activity and 
increased II<I<� activity (Tsitsikov et al., 2001), but dendritic cells from TRAF1-deficient 
mice showed attenuated NF-xB signaling (Arron et al., 2002). TRAF molecules form homo­
or heteromeric complexes. TRAF1 strongly interacts with TRAF2 and the resulting complex 
plays important roles in signaling function (Wajant et al., 2003). It has been shown that the 
interaction of TRAF1 with TRAF2 represses TNF-cx induced caspase 8 activation (Wang et 
al., 1998). Transgenic mice overexpressing TRAF1, for example, presented reduced antigen­
induced apoptosis of CDS+ T cells (Speiser et al., 1997). Conflicting results obtained related 
to TRAF1 might be at least to some extent be explained by the competence of this molecule 
to manipulate the interaction of TRAF2 with TRAF2-interacting receptors (Fotin-Mleczek et 
al., 2002). Interestingly, in a study wherein TRAF1-transfected cell lines were used, it was 
shown that TRAF1 is co-recruited together with TRAF2 to TNFR1 signaling complex 
without affecting RIP modification or II<I<.cx recruitment (Wicovsky et al., 2009). In these 
conditions, the amount of TRAF2 recruitment to the TNFR1 complex was relatively reduced. 
Thus, TRAF1 can act as a substitute for TRAF2 in TNFR1 signaling as long as it is part of a 
heteromeric complex with TRAF2 (Wicovsky et al., 2009). In addition, TRAF2 recruitment to 
TNFR2 was also partially reduced in these TRAF1 transfected cells. Moreover, it can be 
speculated that heteromeric TRAF1-TRAF2 complexes are more efficient to activate NF-xB 
than homomeric TRAF2 complexes in TNFR2 signaling (Rothe et al., 19956; Wicovsky et al., 
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2009). This suggests that TRAF1 can substitute for TRAF2 in 1NFR1 as well as 1NFR2 
signaling complex formation (Figure 2.3). 
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Figure 2.3. Cellular signaling crosstalk between TNFR1 and TNFR2. 
-
ASK1, Apoptosis signal-regulating kinase 1; cIAP cellular inhibitor of apoptosis; FADD, Fas­
associated death domain protein; IKK, IxB kinase; JNK, c-Jun N-terminal kinases; NFxB, nuclear 
factor-xB; RIP, receptor interacting protein; TACE, TNF-alpha converting enzyme; TRADD, TNF 
receptor-associated death domain; TRAF, TNF receptor associate factor; 1NF, tumor necrosis factor; 
TNFR1 , tumor necrosis factor receptor-1 ;  1NFR2, tumor necrosis factor receptor-2. 
Of note, TRAF1 is transcriptionally upregulated by NF-xB (Schwenzer et al., 1999; Wajant et 
al., 2001), and degradation of TRAF2 is triggered by 1NFR2 signaling (Bradley and Pober, 
2001;  Wajant et al., 2001). It can therefore be expected that the duration of NF-xB activation 
can shift the balance of the TRAF1/TRAF2 ratio. There might possibly be an alteration in 
the ratio of TRAF1 to TRAF2 that differs from normal cellular conditions to inflammatory 
conditions. Co-stimulation of 1NFR1 and 1NFR2 can occur in the presence of cells 
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expressing membrane TNF-a. In a study it was observed that although specific stimulation of 
either TNFR1 or TNFR2 initially increased NF-xB, only TNFR2 induced cell proliferation of 
murine fibroblasts (Kalb et al., 1996). This can be explained by the signaling kinetics in the 
activation of NF-xB differs considerably between TNFR1 and TNFR2 upon stimulation via 
TNF-oc. After stimulation via TNFR1, NF-xB is activated for - 1-3 h, whereas TNFR2-
mediated NF-xB activation lasts for up to 24 h after stimulation (Marchetti et al., 2004). Thus, 
in the initial phase of TNF-oc stimulation via its two receptors, NF-xB activation via TNFR1 
will take place before TNFR2-induced depletion of TRAF2 has occurred. TNFR1 is 
internalized rapidly into the cell and further TNFR1 signaling will primarily depend on the 
activation of new receptor molecules emerging on the plasma membrane. During stimulation 
of the newly formed TNFR1, an environment in which TRAF2 has already been degraded via 
TNFR2 stimulation will be present. TNFR1-TNFR2 co-signaling becomes even more 
complex since TNFR2-induced TRAF2 degradation occurs only momentarily, which is then 
hampered by the upregulation of TRAF1 via earlier TNFR1 activation, thus diminishing 
cytoplasmic TRAF2 downregulation. Moreover, induction of endogenous membrane TNF-oc 
might further promote TRAF1 to upregulate its own production by enhancing TNFR2-
induced NF-xB signaling. This regulatory mechanism during long term TNF-oc stimulation in 
TNFR1 and TNFR2 co-expressing cells might explain the interaction between these two 
receptors to prevent apoptosis by sustained NF-xB activation (Wicovsky et al., 2009) . 
Receptor cross-talk via regulation of ASK1 
Apoptosis signal-regulating kinase-1 (ASK.1), a member of the MAPK kinase kinase family, 
associates with TRAF2 to induce the p38 and JNK activation upon TNF-oc stimulation (Liu 
et al., 1996; Nishitoh et al., 1998). During TNFR2 stimulation, c-IAP1 and c-IAP2 are 
recruited to the receptor complex. The c-IAP1 protein, in particular, induces TRAF2 
degradation via ubiquitin protein ligase E3 activity (Li et al., 2002). This then can lead to an 
early termination of the TNF-induced JNK pathway upon TNFR2 stimulation. Interestingly 
Zhao et al., showed that ASK1 is ubiquitinated in TNFR2 expressing cell lines as well as in 
resting B cells via E3 activity of c-IAP1, and that c-IAP1-/- B cells did not succeed to hinder 
TNF-oc induced MAP kinase signaling (Zhao et al., 2007). In addition, it has also been 
suggested that TNFR2, which is upregulated during inflammatory conditions, may control 
TNFR1 activation via a feedback mechanism by reducing JNK activation. 
Conclusion 
The physiological and mechanistic involvement of TNFR2 in the functioning of TNF-oc has 
long been underestimated for several reasons. Soluble TNF-a has been used to study the 
effects of TNF-a, which predominantly stimulates TNFR1 and poorly activates TNFR2. In 
addition, it was shown that only soluble and not membrane-bound TNF-a triggers the 
expression of alveolar monocyte chemoattractant protein-1 via TNFR2 in alveolar epithelial 
26 
TNF-cx crosstalk 
cells, which append more complexity to the signaling of TNFR2 (Liu et al., 2005). TNFR2 
also has restricted expression in specific cell types. It is also sometimes difficult to measure 
detectable receptor expression under normal physiological conditions. Cross-talk between 
TNFR1 and TNFR2 occurs on multiple levels. First, signaling kinetics differ significantly 
between the two receptors. TNFR1-induced NF-xB activation can occur in a matter of 
minutes and normalize in a few hours, whereas TNFR2 can take a few hours to promote NF­
xB activation and then can stay active longer. Second, cross-talk between the receptors can 
contribute to antagonistic as well as agonistic effects of the two receptors on each other's 
signaling pathways. Third, the amount of receptor expression can contribute to the 
complexity of the cross-talk between receptors. This was shown by Fontaine et al.(Fontaine 
et al., 2002) where receptor expression of TNFR1 and TNFR2 were only detectable in 
neuronal tissue after it was subjected to a stressful environment. 
Cross-talk of the receptors can play a pivotal role in physiological processes of many entirely 
different aspects in the living organism. It has been shown that TNFR1 is required for 
hepatocyte DNA synthesis and liver regeneration (Yamada et al., 2000), however, in an acute 
hepatocyte toxicity model TNFR1 plays a detrimental role in liver destruction (Bradham et 
al., 1998), possibly due to an upregulation of TNFR1. Fascinatingly, transgenic mice 
expressing non-cleavable transmembrane TNF-cx. in endothelial cells were protected against 
Concanavalin A-induced liver failure (Willuweit et al., 2001). This protective effect can be 
attributed to the increased binding affinity of membrane bound TNF-cx. to TNFR2. The same 
effect on tissue destruction and protection was observed in brain tissue (Fontaine et al., 
2002). Furthermore, it has been reported that TNFR1 and TNFR2 in concert are involved in 
cognitive behaviors under normal physiological conditions (Baune et al., 2008). TNF-cx. has a 
diversity of functions which is not solely restricted to either TNFR1 or TNFR2 receptor 
signaling, but is rather dependent on the temporal dynamics of cross-talk between TNFR1 
and TNFR2 according to the physiological conditions in which it occurs. 
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Tumor necrosis factor-C( (fNF-C() and its receptors, TNF receptor 1 (fNFR1) and (fNFR2), 
have been investigated extensively m neurodegeneration, neuroprotection and 
neuroinflammation. TNF-C( plays an important protective function in normal physiological 
circumstances via intricate signaling mechanisms between its receptors. However, anomalies 
in TNFR expression have been found during aging, especially in neurodegenerative diseases 
as Alzheimer's disease (AD) and Parkinson's disease (PD), indicating a shift towards an 
environment with decreased neuroprotection and increased pro-inflammatory state. In the 
present study we investigated the roles of the two TNF-C( receptors, TNFR1 and TNFR2 as 
physiologically functional receptors on cognitive, behavioral and physical performance in 
young and aged mice, which was assessed by behavioral testing for learning and memory, 
anxiety, motor function and coordination skills. Results show significant differences between 
wildtype and TNFR2 / mice in learning and memory tasks as well as in the tasks measuring 
motor and coordination-skills. Our results clearly show that TNFR2 plays a crucial role in 
hippocampus-dependent memory formation and neuromuscular function. 
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Introduction 
Aging is a biological process characterized by time-dependent functional declines, influenced 
by numerous environmental and physiological factors. A dysregulation of the innate and 
adaptive immune system is hypothesized as a prominent key player in the aging process 
which is accompanied by increased inflammatory cytokines, in particular tumor necrosis 
factor alpha (fNF-(X) (Corona et al., 2011). Studies show evidence of an increased low-grade 
inflammatory status in the central nervous system (CNS) associated with the aging process 
(Pizza et al., 2011). This chronic increased neuro-inflammation has also been suggested to be 
involved in decreased neurogenesis in particular in the hippocampus as major affected brain 
region (Schuitemaker et al., 2010; Kohman et al., 2011). 
The innate immune system is well characterized for its protective function against infection 
and cell damage during pathological circumstances. Cytokines also play an essential role in 
immunological signaling mechanisms between the periphery and CNS (Hopkins and 
Rothwell, 1995). However, accumulating data demonstrate that immune proteins are 
heterogeneously expressed in different brain regions and cell types in a manner that is apt to 
non-inflammatory functions (Carpentier and Palmer, 2009). In particular, Tumor necrosis 
factor alpha (fNF-(X) has gained mounting interest not only in association with neurological 
diseases but also regarding its functions in neurogenesis of the developing brain and 
maintenance of neuroplasticity. A study by (Golan et al., 2004) presented that TNF-(X­
deficient mice displayed enhanced hippocampal memory function. Moreover, their results 
suggested that TNF-(X deficiency resulted in accelerated maturation of the dentate gyrus in the 
hippocampus, therefore signifying that TNF-(X influences hippocampal development and 
functioning (Golan et al., 2004). Furthermore, mice overexpressing TNF-(X in the brain, had 
impaired hippocampus-associated memory and learning functions (Fiore et al., 1996; Fiore et 
al., 2000). It is important to consider TNF-(X mediated molecular signaling mechanisms when 
interpreting the above reported findings. TNF-(X exerts a broad range of biological effects in 
not only physiological functions but also the nervous system via two receptors; tumor 
necrosis factor-(X receptor 1 (TNFR1) and tumor necrosis factor-(X receptor 2 (fNFR2) 
(Wajant et al., 2003; Marchetti et al., 2004; Naude et al., 2011). TNFR1-induced signaling 
initiates the production of pro-inflammatory factors and can induce a pro-apoptotic 
environment in neuronal tissue, whereas TNFR2 stimulation promotes neuronal survival 
(Fontaine et al., 2002). The roles of TNFR1 and TNFR2 as functional physiological 
constituents during normal neuronal development and maintenance have gained emerging 
evidence. It has been shown that mice deficient of TNFR1 and TNFR2 had an elevated 
number of mature hippocampal neurons (Iosif et al., 2006) which is in accordance with the 
mentioned study of Golan et al., (2004). Furthermore, activation via TNFR1 is the 
responsible factor of TNF-(X for negative regulation of neurogenesis in the adult 
hippocampus (Iosif et al., 2006). 
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Increased TNF-cx concentrations have been identified with aged-associated chronic brain 
diseases as Parkinson's disease (PD) (Mogi et al., 1994), Alzheimer's Disease (AD) (Paganelli 
et al., 2002) as well as psychiatric disturbances as late-life depression (Penninx et al., 2003). 
Interestingly, increased TNFR1 expression has been found in the vicinity of the 
neuropathology in human brain tissue, associated with PD (Mogi et al., 2000) and in AD 
(Cheng et al., 2010). In addition, decreased TNFR2 expression was reported in human AD 
brain tissue (Cheng et al., 2010). Together, data from these studies show that increased TNF­
cx levels together with an imbalance in TNF-receptor expression are associated with these 
diseases. Therapeutic strategies whereby specific receptors of TNF-cx are targeted in 
neurological diseases, have recently gained interest in research (McCoy et al., 2006; Nijholt et 
al., 2011). Nonetheless, TNF-cx exerts important physiological functions in the CNS. It is 
therefore essential that the outcomes of TNF-cx manipulation on complex functions as 
cognition and behavioral alterations are further investigated. The aging process should 
especially be taken into consideration since the majority of the targeted neurological diseases 
primarily occur in aged individuals. For this reason we investigated the differential effects of 
TNFR1 and TNFR2 on cognitive, behavioral, and neuromuscular functioning processes in 
young and aged mice. In this study overt behavior, memory processes, motor- and 
coordination skills were tested in young adult (3 months) and aged (22 months) wildtype, 
TNFR1 knockout (TNFR1 I )  and TNFR2 knockout (INFR2 I- ) C57BL/6 mice. 
Materials and Methods 
.An imals 
All experiments were conducted on 3 month and 22 month old TNFR1 / , TNFR2 / and wild 
type control mice, all of the C57BL/ 6 strain with ten animals in each group. Animals were 
individually housed under normal laboratory conditions (air-conditioned (21 ±2°C), humidity­
controlled room, 12/12 h light/ dark cycle (light on from 08:00-20:00)). Food and water were 
available ad libitum. All animal experiments were approved by the animal ethical committee of 
the University of Groningen (DEC, application number; 4408C). 
Elevated plus maze test 
The elevated plus maze test was used to measure anxiety-related exploration. Mice were 
placed in the center of a plus-shaped maze that was elevated at 60 cm above the ground. Two 
arms opposite each other were enclosed and the other two served as the open arms without 
walls. Mice were allowed to explore the maze freely for 8 minutes. Transitions were scored as 
the mice moved from one arm to the other. Arm entry was considered to be complete when 
the mouse had placed at least three paws in the arm. Furthermore, the total amount of time 
spent in the center zone, dark arms or open arms were recorded visually by two raters ( one of 
them was blind to the experiment) (Rodgers et al., 1997). 
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Spontaneous alternation test 
Short-term spatial memory performance as an expression of working memory, was 
investigated by recording spontaneous ( since it is not reinforced) alternation behavior in a Y­
maze paradigm. The test was performed in a symmetrical, transparent plastic tubular Y-maze. 
Mice were placed in a Y-maze for 8 min and the entrances chosen were recorded. Arm entry 
was considered to be complete when the mouse had placed at least three paws in the arm. 
The series of arm entries was recorded visually by two independent raters, one of whom was 
blind to the experiment. Percentage alternation is the number of triads containing entries into 
all three arms divided by the maximum possible alternations (the total number of arms 
entered minus 2) X 100 (Robert, 2002). 
Recognition memory and spatial memory test 
Novel object recognition and spatial recognition tests were carried out to investigate memory 
performance for subtle visual cues. The test is based on the assumption that rodents explore 
a novel object more than a familiar one but only if they remember the familiar object. The 
test was conducted in a circular shaped arena for ten minutes on three consecutive days. An 
overhead camera was used to record the animal's behavior for subsequent analysis. Prior to 
the start of testing, animals individually received one habituation session where they were 
allowed to explore the arena individually (day 1). During the sample phase (day 2), the subject 
was allowed to explore two identical copies of the same sample object. On the following day 
( day 3) the mouse was returned to the arena that now contained a novel object and an 
identical copy of the object previously seen during the sample phase. On the last day of the 
test ( day 4) the novel object was moved to another location in the arena that the animal was 
allowed to explore. Each session took 10 minutes. The exploratory preference was expressed 
as the ratio of the time spent exploring the novel object over that spent on the two objects. 
Balance beam test 
The balance beam test was used to assess motor coordination and balance of mice. Mice were 
placed 100 cm from a safety platform on an 11 mm thick square wooden beam that was 50 
cm above surface level. Each animal was given three trials during a single day of testing. 
Measurement was taken during the last trial. The time taken to reach this platform was 
measured and used as an indicator of the mice's motor functioning. 
Wire-hanging test 
The wire-hanging test is based on the animal's prehensile reflex and refers to an animal's 
ability to grasp a horizontal wire with its forepaws and to remain suspended (Dean et al., 
1981; Joseph et al., 1983). The test is used to measure the motor function and deficits of 
rodents. A metal wire 80 cm in length was placed horizontally between two vertical bars at a 
height of 50 cm. The mice were brought close to the wire by the experimenter until they 
could grasp it with their front paws; they were then let go. The time they could hang on and 
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their hanging method was recorded and used as a measure for their motor functioning (Hall, 
1985). 
Fear conditioning 
Fear conditioning is a hippocampus-dependent test, which represents a form of associative 
learning. Freezing response after an unconditioned stimulus, like a mild foot shock, is 
measured. Mice were individually put in a transparent cage with metallic bars at the bottom 
through which mild electric shocks could be applied. Mice were put in the cage and left to 
explore freely. After 3 minutes an electrical shock of 0.7 mA was administered for two 
seconds. Mice remained in the cage for an additional 30 seconds after the shock was given. 
Mice were placed in the same chamber 24 hours later and their freezing behavior was 
observed for 3 minutes, in the absence of a shock. To measure their recollection of the shock, 
freeze response was scored for every 10 seconds. Total amount of freezing is expressed in 
percentage of time (Chen et al., 1996). 
Statistical ana/ysis 
All data were analyzed by one-way analysis of variance (one-way ANOVA), followed by the 
Tukey's post-hoc test to determine the differences between the selected groups using the 
program GraphPad Prism 5 for Windows. Data are presented as a mean value ± the standard 
error of the mean (SEM). 
Results 
Elevated plus m aze 
Elevated plus maze test was performed in order to determine anxiety-like behavior. All mice 
spent more time in the dark than in the light, or the center of the maze. Since the times spent 
in center and light are assumed to be directly correlated with time spent in dark, only the 
graphs for the time spent in the dark are discussed. In the young group, it was observed that 
TNFR2 I mice spent significantly more time in the dark arms and less time in the center, 
compared to control mice (Figure 3.1a). Interestingly, aged TNFR1 I and TNFR2 / mice on 
the other hand, spent significantly less time in the dark arms of the maze and more time in 
the center of the maze (Figure 3.1b). Investigating the aging effect it was found that aged 
wildtype control mice spent significantly less time in the light and center arm and more time 
in the dark arms compared to the young control mice whereas aged TNFR2 I mice spent 
significantly less time in the dark arm and more time in the center compared to their young 
counterparts (Figure 3.1c). Aged wildtype control mice exhibited significantly less activity 
assessed by number of entries into the arms of the maze compared to young wildtype 
controls, whereas aged TNFR2-/- mice had significantly more entries than their younger 
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Figure 3.1. Evaluation of behavior in the elevated plus maze in (a) young and (b) aged mice. (c) Effect 
of ageing on behavior. (d) The number of entries into individual arms of the plus maze of all groups 
tested. Error bars indicate s.e.m (*p < 0.05, ** p < 0.005, *** p<0.0001). 
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Spontan eous alternation 
With the Y-maze spontaneous alternation test short-term memory was measured in young 
and aged mice. No significant differences in both young and aged groups were observed 
(Figures 3.2a, b). However, aged wildtype mice had significantly less entries into the arms of 
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Figure 3.2. Evaluation of short term working memory effects by TNF receptors and aging. The mean 
% spontaneous alternations measured in (a) young and (b) aged mice. (c) Number of entries into 
individual arms over 8 minute time periods. Error bars donate the standard error of mean (s.e.m) (*p < 
0.05) . 
Novel of?ject r ecogn ition and spatial memory 
Equal amount of interactions (::=: 50 %) to both newly introduced objects were observed in all 
of the mice (Figures 3.3a and 3.3b). Wildtype and TNFR1-/- mice explored the novel 
introduced object significantly more than the young animals, whereas no difference was 
observed in TNFR2-/- animals (Figure 3.3a). In the aged animals, only wildtype animals 
showed a significant greater interest to the novel object (Figure 3B). No effect of aging was 
found in the novel object recognition test (Figure 3.3c). Wildtype, TNFR1 / and TNFR2 / 
mice all had significant more interactions with the relocated object (Figure 3.3d). 
Interestingly, none of the aged animals had preferential interest to the spatially relocated 
object (Figure 3.3e). All of the aged mice performed significantly worse in the spatial memory 
test compared to the young animals (Figure 3.3£). Additionally, total mobility over all three 
days was determined for all mice to assess activity. Results showed no significant differences 
between the young and old mice, nor an effect of Aging between the different groups (Figure 
3.3g). 
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Figure 3.3. The effect of aging and TNF receptors on novel object recognition and spatial memory. 
Data is expressed as ratio of interactions with new object compared to object that served as invariable. 
Ratio of interactions spent with newly introduced object in (a) young- and (b) aged- mice and (c) aging 
effect on novel object recognition. Effect of TNF-tx. receptors on spatial memory between groups in 
(d) young mice, (e) aged mice and the effect of (f) aging on spatial memory these mice. Mobility 




Balance b eam 
Young wildtype, TNFR1 I and TNFR2 / mice passed the balance beam at an equal speed 
(Figure 3.4a). No significant differences between aged wildtype, TNFR1-/- and TNFR2 /- mice 
were found for time of crossing (Figure 3 .4b). Aging significantly increased the latency to the 
mice to cross the beam (Figure 3.4c). 
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Figure 3.4. Performance on balance beam. Latency of mice to cross the beam (a) young mice and (b) 
aged mice. (c) Effect of ageing on latency between the groups. Error bars donate s.e.m (*p < 0.05, ** p 
< 0.005). 
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Wire hanging 
Young TNFR2 /- 1n1ce performed significantly worse than young controls and TNFR1-/­
(Figure 3 .Sa) .  Because the aged mice performed poorly, no significant differences between the 
aged groups were observed (Figure 3.Sb) . 
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Fear conditioning 
TNFR2-/ exhibited a significant less freezing response compared to the TNFR1 I and 
wildtype mice in both the young (Figure 3.6a) mice. The same effect was also observed in 
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Figure 3.6. Freeze response by 
fear conditioning. Freeze 
response of mice 24 hours after 
exposure to a light foot shock in 
(a) young mice and (b) aged 
mice. Error bars represent s.e.m 
(*p < 0.05, ** p < 0.005, *** 




The most fundamental findings in this study was that hippocampus associated learning is 
dependent on TNFR2 as observed in the spatial memory test and further validated in the fear 
conditioning test. The functional roles of TNFR1 and TNFR2 on hippocampal neurogenesis 
were previously investigated by Iosif et al., (2006). This study demonstrated that TNFR2 is 
important in neurogenesis and cell proliferation, while TNFR1 has a negative effect on 
neuronal progenitor proliferation during the normal development of the brain and also under 
pathological conditions (Iosif et al., 2006). Interestingly, we found hippocampus-dependent 
memory deficiency in both young and old TNFR2 / animals, which may partly be explained 
by impaired neurogenesis and neuronal plasticity due to the lack of TNFR2. There are several 
highly integrated neuronal networks in the medial temporal lobe, which are involved in 
normal memory function, notably the hippocampus and entorhinal, perirhinal and 
parahippocampal cortex (Witter, 1993). Performance in the novel object recognition test is 
primarily dependent on the perirhinal cortex functioning (McTighe et al., 2010), whereas 
spatial memory predominantly requires hippocampus-dependent memory (Broadbent et al., 
2004). Memory consolidation has been linked with the rate of neurogenesis in the 
hippocampus (Sarkisyan and Hedlund, 2009; Oliveira et al., 2010; Antunes and Biala, 2011). 
Our data from the spatial memory test, namely, that the TNFR2 / animals performed worse 
compared to wildtype and TNFR1 / animals, is consistent with the fact that TNFR2 is 
reportedly involved in hippocampal neurogenesis (Iosif et al., 2006). Our data are in 
accordance with other studies, in which age related hippocampal changes have been 
associated with age-related spatial memory impairment (Begega et al., 2001; Havekes et al., 
2011; K.lencklen et al., 2012). In addition, TNFR2 / animals also performed worse in the fear 
conditioning test which is also primarily hippocampus and amygdala dependent 
(Eichenbaum, 1996; Raineki et al., 2010; Orsini et al., 2011), supporting our findings related 
to spatial memory, observed in the novel object test. 
Normal and pathological aging is associated with learning and memory deficits, and a decline 
in working memory has been shown in several animal and human studies (Lamberty and 
Gower, 1992; Mendelsohn and Larrick, 2011; Wang et al., 2011). Surprisingly, we did not 
observe these age related changes to working memory between any of our groups, measured 
with the spontaneous alternation test. Our finding can be explained by a recent study by Da 
Silva et al., (2011) showing that working memory was not affected in aged mice younger than 
25 months (Da Silva Costa-Aze et al., 2011). An explanation for our results may be that our 
mice were 22 months of age at the time of behavioral analysis. 
Aging is not only associated with learning and memory impairment but also with motor 
dysfunction (Dean et al., 1981; Boger et al., 2011). The motor performance deficit in elderly 
can be the result of nervous system or of neuromuscular dysfunction or both (Seidler et al., 
2010). The prefrontal cortex, basal ganglia and cerebellum are the main control regions for 
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motor function, in particular the frontal cortex and basal ganglia are prone to aging effects 
(Seidler et al., 2010). Coordination skills and motor functions of young and aged animals were 
also tested in our study. We did not find any significant differences between the young 
wildtype and TNFR1-/- or TNFR2-/ animals in the balance beam test. However, in all 3 
groups, aging had a significant effect on coordination skills. 
Muscular strength and neuromuscular function of the animals were tested in the wire-hanging 
test. Young TNFR2-/- mice performed significantly worse in this test compared to control or 
TNFR1 I mice. In accordance with other studies, our findings showed that aging in general 
has an effect on muscular strength and/ or neuromuscular function (Dean et al., 1981; Joseph 
et al., 1983), possibly also due to increased bodyweight in aged animals Both TNFR1 and 
TNFR2 are expressed in skeletal muscle tissue (Uysal et al., 1997; Zhang et al., 2000) but the 
majority of reported data describes TNFR1 mediated functions in muscle tissue. It has been 
suggested that TNFR1 is the TNF-cx receptor responsible for impaired skeletal muscle 
functioning, especially when TNF-cx is increased (Hardin et al., 2008; Wei et al., 2008). Data 
from this study suggests that TNFR2 mediated signaling can play a important role in normal 
muscle functioning. 
We performed the elevated plus maze on mice that had no prior exposure to stress. There is 
strong evidence that midbrain regions such as the raphe nuclei and the periaqueductal grey 
matter play important roles in this experimental protocol (File et al., 2000; Albrechet-Souza 
and Brandao, 2010). Previously, it has been shown that aging has no effect on anxiety 
behavior in rodents based upon observation of defecation and/ or urinations as a sign of 
anxiety (Edstrom and Ulfuake, 2005; Altun et al., 2007; Fahlstrom et al., 2011). However, the 
interpretation of anxiety from the different methodologies of testing anxiety and exploratory 
can be misleading (Fahlstrom et al., 2011). Our findings are in accordance with the elevated 
plus maze data from a previous study done by Fahlstrom et al., (2011) showing that aged 
mice spent less time in the open arms (Fahlstrom et al., 2011). Our results show a clear aging 
effect in the wildtype animals, namely aged mice spending significantly less time in the open 
arms, while the time spent in the dark arms was dramatically increased. Also, the number of 
entries declined in the aged group of wildtype animals. The anxiety-related behavior did not 
change during aging in TNFR1 -/- animals, whereas aging had an opposite effect on the 
anxiety-related behavior in TNFR2 /- animals compared to control wildtype animals. 
In summary, the essential role of TNFR2 on neurogenesis and neuroprotection was shown 
previously in many studies. However, data on how the lack of one of the TNF receptors can 
influence cognitive, physical and behavioral functioning during physiological aging are sparse. 
In this study using a broad spectrum of behavioral tests, we present that TNFR2 plays a key 
role in hippocampus-dependent learning and memory, and also in neuromuscular functions. 
Further molecular investigations are necessary to validate whether this effect of TNFR2 is 
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directly related to hippocampal neurogenesis and/ or if other mechanisms underlie cognitive 
and motor behaviors. 
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Chapter 4 
Abstract 
Alzheimer's Disease (AD) is associated with an altered immune response resulting in chronic 
increased inflammatory cytokine production with a prominent role of Tumor Necrosis Factor 
alpha (TNF-cx). TNF-cx signals are mediated by two receptors: TNF receptor 1 (TNFR1) and 
TNF receptor 2 (TNFR2). Signaling through TNFR2 is associated with neuroprotection, 
while signaling through TNFR1 is generally pro-inflammatory and pro-apoptotic. Here, we 
have identified a TNF-cx induced pro-inflammatory agent, Lipocalin 2 (Lcn2) via gene array in 
murine primary cortical neurons. Further investigation showed that Lcn2 protein production 
and secretion is activated solely upon TNFR1 stimulation when primary murine neurons, 
astrocytes and microglia were treated with TNFR1 and TNFR2 agonistic antibodies. Lcn2 
was found to be significantly decreased in cerebrospinal fluid (CSP) of human patients with 
mild cognitive impairment (MCI) and AD and increased in brain regions associated with AD 
pathology in human post-mortem brain tissue. Mechanistic studies in cultures of primary 
cortical neurons showed that Lcn2 sensitizes nerve cells to amyloid beta (A�) toxicity. 
Moreover, Lcn2 silences a TNFR2-mediated protective neuronal signaling cascade in 
neurons, pivotal for TNF-cx mediated neuroprotection. The present study introduces Lcn2 as 
a molecular actor in neuroinflammation in early clinical stages of AD. 
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Introduction 
The main pathological features in the Alzheimer's Disease (AD) affected brain are 
depositions of �-amyloid (A�) in the extracellular space and neurofibrillary tangles within the 
nerve cells. In particular the neurofibrillary tangles accumulate in a predictable spatial pattern 
and correlate well with disease progression (Nelson et al., 2009a). Neuritic or amyloid plaques 
are rare in persons undergoing normal ageing, but begin to grow in number in the 
hippocampus and neocortex during Mild Cognitive Impairment (MCI) and can subsequently 
develop towards the characteristic pathology of AD. A� plaques become more prevalent and 
spread to the parietal and frontal neocortical areas of the brain with the progression to AD 
(Small et al., 2006). In the search for the biological etiology of AD, numerous studies during 
the last two decades revealed that an activated innate neuroimmune response is an integral 
component of the pathophysiology of this disease (Lee et al., 20106). This activated immune 
response leads to a chronic production of inflammatory cytokines in the vicinity of AD­
associated pathology in brain tissue (Eikelenboom et al., 2006), that can also be detected in 
the cerebrospinal fluid (CSF) and in peripheral blood (Rosenberg, 2005). 
A prominent role in the immune signaling has been assigned to TNF-cx as a key 
proinflammatory cytokine which was found to be highly upregulated in brain tissue associated 
with AD pathology (Zhao et al., 2003; Rao et al., 2011). It is unclear whether TNF-cx 
signaling actively contributes to or limits neuronal injury in AD. However, its importance in 
AD was described whereby a perispinal administration of etanercept (a soluble tumor 
necrosis factor receptor (p75): Fe fusion protein) remarkably improved clinical symptoms of 
AD, thereby signifying the potential role of TNF-cx as a drug target in AD (Griffin, 
2008).TNF-cx exerts balancing or offsetting biological functions in the nervous system via its 
receptors; TNFR1 and TNFR2 (Wajant et al., 2003), especially with respect to cell survival in 
neuronal tissue exposed to traumatic insults. TNFR1-induced signaling initiates production of 
pro-inflammatory factors and can induce a pro-apoptotic environment in neuronal tissue, 
whereas TNFR2 stimulation promotes neuronal survival (Fontaine et al., 2002). More 
recently, in vivo studies using transgenic AD mouse models have shown that TNF-cx functions 
as an important neuroprotective mediator, and likely plays an important role in mitigating the 
pathological changes of AD (Chakrabarty et al., 2011; Montgomery et al., 2011). Due to its 
complex cellular mechanisms, initiated by its two receptors, the ultimate role of TNF 
signaling in neurodegenerative disease may depend on production of different factors in the 
cellular environment, and be different at different stages of the neurodegenerative disease. It 
was shown that the absence of TNFR1 in an AD mouse model caused reduced A� plaque 
formation and prevented learning and memory defects (He et al., 2007). Targeting specific 
TNFR mediated signaling is increasingly viewed as important in considering novel 




Since during an inflammatory response, TNF-cx may trigger the expression and release of 
various inflammatory mediators in the brain, including some not yet specifically associated 
with brain inflammation, we used a gene microarray to identify all transcripts up-regulated in 
rodent cortical neurons exposed to TNF-cx. One such transcript is that encoding the protein 
lipocalin 2 (Lcn2), also known as Neutrophil Gelatinase-Associated Lipocalin (NGAL), 
siderocalin, 24p3, or uterocalin. Lcn2 was discovered nearly two decades ago (Kjeldsen et al., 
1993) and its expression in vivo has previously been associated with the acute phase response 
(Liu and Nilsen-Hamilton, 1995). Interestingly, Lcn2 mRNA is strongly up-regulated in 
cortical tissue from AD modeling mice in which presenelin-1 (PS-1) was overexpressed but 
not in mice overexpressing PS-1 and amyloid precursor protein (APP). This finding suggested 
that Lcn2 might be involved in an early response to inflammatory stimuli in these mice (Wu 
et al., 2006b). However, the functions of Lcn2 in brain, and brain disorders remain largely 
unknown. A recent study has shown that Lcn2 can decrease hippocampus dendritic spine 
numbers in mice subjected to stress (Mucha et al., 2011). So far two receptors have been 
identified for Lcn2: megalin (Hvidberg et al., 2005) and 24p3R (Devireddy et al., 2005). 
In this paper the mechanism of TNP-cx induced Lcn2 expression in primary murine cortical 
neurons, astrocytes and microglial cells was investigated after TNF-cx and its receptors 
TNPR1 and TNPR2 specific stimulation. Moreover, in this study we investigated Lcn2 
protein concentrations in serum and CSP from both MCI and AD patients, and in AD 
human post-mortem brain in comparison to non-demented controls. The mechanistic role of 
Lcn2 in the pathology of AD was further investigated in murine primary cortical neuronal 
cultures. 
Materials and methods 
Materials 
Neurobasal medium, Phosphate Buffered Saline (PBS), Dulbecco's Modification of Eagles 
Medium (DMEM), Hank's balanced salt solution (HBSS), Fetal Bovine Serum (PBS), Fetal 
Calf Serum (PCS), B27 supplement, L-glutamine and penicillin/ streptomycin were purchased 
from Invitrogen (Breda, The Netherlands). Complete mini protease inhibitor cocktail tablets 
from Roche (Mannheim, Germany). Murine Lcn2 was purchased from R&D Systems 
(Minneapolis, MN, USA). VO-OHpic was from Biovision (Mountain View, CA, USA). 
Amyloid-� Peptide1 42 was purchased from EZBiolab (Carmel, IN, USA). Agonistic 
antibodies and murine TNP-R1 agonist were from R&D systems, Minneapolis, MN, USA 
and murine TNP-R2 agonistic antibodies were from Hycult biotechnology, Uden, The 
Netherlands. Primary antibodies for Western Blot were anti-human Lipoc-alin2/NGAL (R&D 
Systems, Minneapolis, MN, USA) 1:1000 dilution, anti-mouse Lcn2 (Abeam, Cambridge, UK) 
1:1000 dilution, antibody for slc22a17 (LifeSpan BioSciences, Seattle, WA, USA) 1:2000 
dilution, megalin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:1000 dilution, antibody 
specific for total PKB/ Akt (Cell Signaling Technology, Beverly, MA, USA) 1:2000 dilution, 
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anti p-Akt (Ser473, Cell Signaling Technology, Beverly, MA, USA) 1:1000 dilution, anti caspase 
3 (Cell Signaling Technology, Beverly, MA, USA) 1:2000 dilution, cleaved caspase 3 (Cell 
Signaling Technology, Beverly, MA, USA) 1:1000 dilution, anti-BIM (Cell Signaling 
Technology, Beverly, MA, USA) 1:500 dilution, anti-p-p65 (Ser536, Cell Signaling Technology, 
Beverly, MA, USA), 1 :2000 dilution and monoclonal mouse antibody specific for actin as 
internal standard (MP Biomedicals, Irvine CA, USA, 1:2000000 dilution). The primary 
antibody for immunohistochemistry was rat monoclonal anti human Lipocalin2/NGAL 
(R&D Systems, Minneapolis, MN, USA). The secondary antibodies used were horseradish 
peroxidase (HPR)-conjugated Donkey-anti-Rabbit (GE healthcare, Buckinghamshire, UK) 
1 :5000 dilution, HRP-conjugated Goat-anti-Mouse (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) 1:5000 dilution, HRP-conjugated Goat-anti-Rat Gackson ImmunoResearch, 
Soham, UK) 1 :5000 dilution and biotinylated donkey-anti-rat and 1 :2000 dilution and 
biotinylated donkey-anti-rat CT ackson ImmunoResearch, Soham, UK) 1 :2000 dilution. All 
other materials were purchased from Sigma-Aldrich, Zwijndrecht, The Netherlands. 
Primary cortical neuron culture 
Primary cortical neurons were prepared from embryonic brains (E14) of C57Bl/6J mice. The 
cortices were carefully dissected, meninges were removed, and the neurons separated by 
trituration. A single cell preparation was obtained by filtration though a gauge mesh filter 
(pore size 40 µm). Cells were plated on poly-D-lysine pre-coated plates at a density of 1 X 105 
cells/well for 96-well plates and 2 X 106 cells/well for 6 -well plates. Neurobasal medium 
supplemented with 2% (v/v) B27-supplement, 0.5 mM glutamine and 1% (v/v) 
penicillin/ streptomycin was used as a culture medium. After 48 hours, neurons were treated 
with 10 µM Cytosine �-D-arabinofuranoside hydrochloride for another 48 h to inhibit non­
neuronal cell growth. Subsequently, the medium was completely exchanged. The neurons 
were used 7 days after preparation for experiments. Animal experimental procedures were 
approved according to the Dutch law by the local ethics committee (DEC 6103). 
Glial cell culture 
Cells were prepared form 1 to 3 day old C57Bl/ 6 nuce cortices. Briefly, cortices were 
removed under sterile conditions and hippocampi were discarded. The corices where cut with 
a scalpel blade into small pieces ( < 1 mm) and incubated in 5 ml HBSS supplemented with 
0.6% (w/v) glucose, 15 mM HEPES and 1% (v/v) Pen/Strep with 0.25% (v/v) trypsin and 
1000 U/ml DNase for 20 minutes at 37 °C. After 20 min incubation, trypsin inhibitor was 
added (0.1 mg/ ml) and the tissue was triturated ten times with a sterile Pasteur pipette. 
Supplemented DMEM (20 ml) containing 10% (v/v) PCS and 1% (v/v) Penstrep was added 
and centrifuged at 200 x g for 10 min. The supernatant was discarded and the pellet 
resuspended with a pipet in supplemented DMEM. The cell suspension was seeded into 75 
cm2 culturing flasks (1,5 brain per flask) and incubated at 37 °C in 5% CO2. The cells were 
grown to confluency ( approximately after a week). After confluency was reached, microglia 
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cells were obtained by shaking the flasks for 2 hours at 37 °C on an orbital shaker at 180 rpm. 
Microglia cells were seeded in 6-well plates (1 X 105 cells/well) and used 24-48 hours 
afterwards for experimentation. The remaining astrocytes were incubated at 37 °C in 5% with 
SmM L-Leucine methyl ester in supplemented DMEM for 1 hour to limit microglia survival. 
The astrocytes where subsequently trypsinized and seeded (1 x 105 cells/well) in a 96-well 
plate. All cells were used for experimentation 24-48 hours after plated. 
Treatment of cells 
Primary cortical neurons were treated with TNF-0( (100 ng/ml) for 24 hours and mRNA 
extracted for gene array. For the assessment of the kinetic of TNF-0( induced Lcn2 protein 
expression, primary cortical neurons, astrocytes and microglia cells were treated with TNF-0( 
(100 ng/ ml) for indicate times. For of TNFR-mediated Lcn2 production, primary cortical 
neurons, astrocytes and microglia cells were treated with either TNF-0( (100 ng/ml), TNFR1 
agonistic antibody (2 µM) or TNFR2 agonistic antibody (20 µM) for 36 hours. For the 
assessment of Lcn2 on TNFR-mediated signaling, primary cortical neurons were treated with 
either TNF-0( (100 ng/ml), TNFR1 agonistic antibody (2 µM), TNFR2 agonistic antibody (20 
µM), Lcn2 (200 ng/ ml) or TNF-0( (100 ng/ ml) TNFR1 agonistic antibody (2 µM), TNFR2 
agonistic antibody (20 µM) together with Lcn2 (200 ng/ ml) for 24 hours. Glutamate induced 
excitotoxicity assay was performed whereby primary cortical neurons were incubated with 
100 ng/ml TNF-0(, TNFR2 agonistic antibody (20 µM) or 200 ng/ml Lcn2 or TNF-0( (100 
ng/ ml) was co-incubated with Lcn2 (200 ng/ ml) or TNFR2 agonistic antibody (20 µM) was 
co-incubated with Lcn2 (200 ng/ ml) for 24 hours. After 24 hours incubation, 50 µM 
( concentration that induced ;::: 50% cell death) glutamate was added to the cells for 1 hour, 
thereafter media was replaced and neuronal cells were allowed to recover for another 24 h 
before determination of cell viability. For A�-induce cellular toxicity, primary cortical neurons 
were incubated with 100 ng/ml TNF-0( or 200 ng/ml Lcn2 or TNF-0( (100 ng/ml) was co­
incubated with Lcn2 (200 ng/ ml) for 24 hours, A�1 42 (25 µM) was added after 24 hours and 
MTT assay was perform 24 hours after A�1 42 treatment. 
Oligo microarrqy, f?ybridization and data ana!Jsis 
Mouse cortical neurons were treated with TNF-0( (100 ng/ml) for 24 hours and RNA was 
extracted using RNeasy extraction kit from Qiagen. Linear amplification of RNA was 
performed (Amino Allyl MessageAmp II aRNA Amplification Kit, Ambion, Austin, Texas) 
prior to labeling with Cy3 and CyS fluorescent dyes (GE Healthcare UK, Chalfont, 
Buckinghamshire, England), and microarray hybridization to oligonucleotide arrays consisting 
of the Qiagen mouse MV3 oligo set with oligonucleotide length generally -70 nucleotides. 
General methods for data extraction, normalization, and filtration for quality and dye bias 
have been summarized in detail previously (Samal et al., 2007). Here data from three 
microarrays were analyzed m the NCI mAdb microarray databasing system 
(http://madb.nci.nih.gov/) after standard Loess correction with allowed quality ratio of 0.3. 
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Significance of transcript up- or down regulation by treatment with TNF-cx was evaluated 
using statistical analysis of microarray (SAM) at a false discovery rate of 0.1. Data were 
filtered for average expression ratios 2:2, and resulting gene list was exported to MS Excel for 
further manipulation. Using Ingenuity Pathway Analysis tool (IP A; 
http://www.ingenuity.com) the transcripts up-regulated 2-fold or more by TNF-cx in mouse 
cortical neurons, were clustered based on their functions. Genes were also clustered based on 
their distribution in significant canonical pathways. Both indirect and direct networks were 
built using the default settings to identify interacting gene products. 
RNA extraction andQ-RT-PCR 
Approximately 2 µg of total RNA was submitted to DNase I (Invitrogen, Carlsbad, CA) 
digestion and reverse transcribed using random hexamers pdN6 and SuperScript II RNase H­
reverse transcriptase (Invitrogen). Splign (http:/ /www. 
ncbi.nlm.nih.gov / sutils/ splign/ splign.cgi) was used to identify the exon and intron 
boundaries. Gene-specific forward and reverse primers were chosen using Primer 3 Input 
(http:// frodo.wi.mit.edu/primer3/), to amplify in each case across an exon-exon junction in 
order to avoid generation of same-sized amplicons from contaminating genomic DNA as 
follows: 5'-TGGAAGAACCAAGGAGCTGT-3' and 5'-G 
GTGGGGACAGAGAAGATGA-3' for Lcn2; 5'-GGCTGTATTCCCCTCCATCG-3' and 
5'-CCAGTTGGTAACAATGCCATGT-3' for actin. Real time PCR (Q-RT-PCR) was 
performed in a premade reaction mix in the presence of the transcribed cDNA and 10 nM of 
each specific primers, using the SYBR green chemistry and an iCycler real-time detection 
system (Bio-Rad, Hercules, CA). Fold changes in mRNA levels were determined by 
normalizing against a non-variable control transcript, actin, using the MCt method (Livak 
and Schmittgen, 2001). 
Preparation of A{J-oligomers for cell culture 
Oligomeric A�1-42 was prepared as described by Granic et al., (2010) (Granic et al., 2010). 
Human Samples 
Serum, CSF and brain tissue were obtained from The Institute Born-Bunge (IBB) Biobank 
(University Antwerp, Belgium). Postmortem examination was performed by a 
neuropathologist. Plasma and CSF samples were from age matched 26 non-demented 
control, 28 mild cognitive impairment and 26 AD patients. Human brain samples were from 
the hippocampus, entorhinal cortex, ventromedial prefrontal cortex (VMPC), occipital lobe 
and cerebellum of 10 age matched non-demented controls and 10 AD diagnosed patients. 
Post mortem interval was comparable between all the samples ranging from 2 to 12 hours. 
See summarized information of patient demographics (Table 4.1). None of the control 
subjects had any neurological diseases that could have led to neuroinflammatory activation. 
Since Lcn2 is being used as a biomarker for kidney disease, subjects with renal failure were 
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excluded. MCI patients used in this study converted to AD. Brain tissue for 
immunohistochemistry was obtained from Semmelweis University and Hungarian Academy 
of Sciences, Budapest, Hungary. Brain tissues from 4 different AD patients and 5 different 
non-demented control patients were stained. Ethics approval for the use of post mortem 
brain tissue for immunohistochemistry was approved by the local ethics committee of 
Semmelweis University ethics committee. The selected AD brain tissue had Braak stage V 
and the selected non-demented control used, Braak stage III. Ethics approval for human 
sample collection of serum and CSP and use of human post mortem brain was granted by the 
local ethics committee from University Antwerp, Belgium (Approval number 2805 and 2806). 
Table 4.1. Patient demographics 
Controls (n=26) I MCI (n=28) I AD (n=26) 
Gender I I I I 
(M/F) 13/13 l 14/14 l 13/13 Serum / CSF I -------------------�-------------�------------I I Age 78.64 ± 5.72 l 78.74 ± 3.78 l 78.30 ± 4.95 
I I 
Gender I i I 5/5 I l 5/5 (M/F) I -Brain tissue I I -------------------�-------------�------------Age 77.99 ± 5.64 I I 81.75 ± 5.62 I -
I ! 
Preparation of brain protein extracts 
Whole brain protein samples and membrane protein fractions were prepared as previously 
described (Cheng ct al., 2010). Phosphatase inhibitor was added to the homogenization 
buffers. 
Lcn2 measurement in serum and CSF f?y EU SA 
Quantification of Lcn2 from serum and CSP samples was measured via a constructed 
sandwich ELISA using human Lipocalin-2/NGAL ELISA capture antibody (R&D Systems, 
Minneapolis, MN, USA), recombinant human Lipocalin-2/NGAL (R&D Systems, 
Minneapolis, MN, USA) for the internal standard and biotinylated human Lipocalin-
2/NGAL detection antibody (R&D Systems, Minneapolis, MN, USA). Serum was diluted 
1:100 and SCP was undiluted. Briefly, plates (96 wells, Maxisorb, Nunc) were coated with the 
capture antibody (100 µl; 2 µg/ml) diluted in PBS (pH 7.4). After overnight incubation at 
room temperature, the coated plates were washed with tris buffered saline (TBS) containing 
0.05% tween 20 (TBS/1) and nonspecific binding sites blocked by incubation with 300 µl of 
PBS containing 1 % BSA (PBS/BSA) for 2 hours at room temperature on a shaker. After 
washing, 100 µl of either the standards (recombinant human lipocalin-2) or samples, diluted 
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in PBS /BSA were added to the plates and incubated for 2 hours at room temperature on a 
shaker. Plates were washed six times and 100 µl of biotinylated human Lipocalin-2/NGAL 
detection antibody (100 ng/ml) diluted in PBS/BSA was added. After 2 hours on shaker at 
room temperature, plates were washed six times and incubated with 100 µl A vidin­
horseradish peroxidase (eBioscience, San Diego, CA, USA) in PBS/BSA (1:1000) for 20 
minutes on shaker at room temperature. Plates were then washed six times and 100 µl of 
substrate solution containing 1 mg/ ml O-phenylenediamine in 0.0SM Citric Acid Sodium 
Phosphate Buffer (pH 5.0) with hydrogen peroxide (0.06%), was added. The reaction was 
stopped by adding 100 µl of a 3N HCl solution. The absorbance was determined at 492 nm 
with background subtraction at 620 nm using an ELISA reader (Asys UVM 340, Biochrom, 
Cambridge, UK). The quantity of Lcn2 was estimated from the calibration curve which 
ranged from 78 to 5000 pg/ ml. 
Immunohistochemistry of non-demented control and AD brain tissue 
The postmortem entorhinal cortex - hippocampus tissues from non-demented control and 
AD patient were fixed with Karnovsky's fixative and sectioned to 30 µm with cryostate 
microtome. The free floating sections were pre-treated with 3% H2O2 followed by 5% 
normal donkey serum. As primary antibody rat anti-Lipocalin 2 (R&D Systems, 1:250), was 
applied and as secondary antibody biotinylated donkey anti-rat (1:500, Jackson Immunolabs, 
West Grove, PA) was used. The staining was completed with avidine-biotine complex (ABC 
elite kit, Vector Laboratories, Burlingame, CA), followed by nickel-enhanced 3,3' -
diaminobenzidine (DAB) and 0.0033 % H2O2. 
Western blot ana/ysis 
Isolation of proteins from cells was performed on crushed ice. Cells were washed twice with 
ice-cold phosphate-buffered saline after treatment and subsequently lysed by the addition of 
100 µl of lysis buffer [SO mMTris-HCl (pH 7.4), 1 % NP-40, 0.25% Na-deoxycholate, 150 
mMNaCl, 1 mM EDTA and complete mini protease inhibitor cocktail tablet (Roche)]. 
Membranous (Egan et al., 1999) and nuclear protein extractions Q oo et al., 2005) were 
prepared as described previously. Protein concentrations obtained from cell lysates and brain 
tissues were quantified by the Bradford assay and adjusted to 1 mg protein/ ml. The samples 
were centrifuged at 8000 x g for 10 min at 4 °C and the supernatants boiled for 5 min in 
Laemmli's sample buffer. Proteins of interest fractionated by SDS-PAGE were transferred to 
olyvinylidenedifluoride membranes (Millipore, Bilerca, USA). Membranes were blocked for 1 
hour with 1 % I-Block (Tropix, Bed- ford, USA) in Trisbuffered saline containing 0.0625% 
Tween-20 and sequentially incubated overnight with primary antibodies at 4 °C. The 
membranes were then washed withTris-buffered saline containing 0.0625% Tween-20 and 
incubated with the appropriate HPR-conjugated secondary antibodies diluted to 1:5000 with 
Tris-buffered saline containing 0.0625% Tween-20 for 1 hour. Immunore- activity was 
detected using enhanced chemiluminescence (Pierce Biotechnology, Rockford, USA). Protein 
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bands were detected by imaged on a Kodak X-Ray film (Eastman Kodak Company, 
Rochester, USA) or by a computer analysis program using Chemi Doc XRS system 
(Chemiluminescence Image Analysis, Bio-Rad). For the detection of secreted Lcn2 protein, 
Western blot analysis of culture medium was performed. Actin served as an internal standard 
protein measurement to eliminate loading variations. 
Assessment of cell viability 
After treatment, MTI (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was 
added (0.5 mg/ ml final concentration) to each well of a flat bottom 96 well culture plate. 
Cells were further incubated for 2 hours at 37 °C in 5% CO2. After incubation, the media was 
removed and cells were lysed in 150 µl DMSO. The absorbance of each well was measured 
with an ELISA reader (Asys UVM 340, Biochrom, Cambridge, UK) at 595 nm with 
background subtraction at 630 nm. 
Statistical ana/ysis 
Data obtained from human CSP and serum Lcn2 analysis and in vitro studies was calculated 
using one-way analysis of variance (AN OVA), followed by Tukey's multiple comparison test. 
Unpaired Student's /-test was used to calculate statistical significance of means of Lcn2 from 
post mortem human brain tissues and 24p3R expression. Results shown represent mean ± 
SEM. Represented in vitro data were from three or more independent experiments. A P-value 
< 0.05 was considered to be statistically significant. 
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Results 
TNF-a-mediated induction of gene expression in primary cortical neurons 
To assess the effect of TNF-a on cortical neuronal gene transcription we analyzed gene 
expression changes in primary cortical neurons after 24 hours of treatment with TNF-a (100 
ng/ml) using in house-printed Qiagen mouse oligonucleotide arrays. Transcripts that were 
significantly up-regulated (.p � 0.05, n = 3 for each group) by TNF-a treatment 2-fold or 
more (fable 4.2) were selected for bioinformatic analysis. The 10 identified transcripts shown 
to be up-regulated 2-fold or more by TNF-a in primary cortical neurons were tiled according 
to their function using IP A, and all fell into one single cluster related to inflammatory 
response. 
Table 4.2. TNF-rl mediated gene induction in primary cortical neurons. 
Gene name Gene Ratio p Value 
symbol n=3 
Chemokine (C-C motif) ligand 2 Ccl2 21.36 0.0004 
Lipocalin 2 Lcn2 5.80 0.0006 
Chemokine (C-X-C motif) ligand 10  Cxcl10 3.48 0.0231 
Chemokine (C-C motif) ligand 7 Ccl7 3.03 0.0179 
CD14 anti.gen (Cd14) Cd14 2.70 0.0017 
Chemokine (C-X-C motif) ligand 2 Cxcl2 2.67 0.0360 
Immunoglobulin superfamily, member 6 Igsf6 2.49 0.0458 
Tissue inhibitor of metalloproteinase 1 Timp1 2.30 0.0025 
Proteasome (prosome, macropain) subunit, beta type 8 Psmb8 2.26 0.0001 
Lysozyme 1 Lyz1 2.18 0.0001 
About a third of these transcripts coded for chemokines such as, Ccl2 and Ccl7, which are 
known to be increased in the CNS in numerous neurodegenerative diseases (Conductier et al., 
2010; Renner et al., 201 1) .  The microarray also showed that Lcn2 mRNA was significantly 
up-regulated 24 hours after the treatment of neurons with TNF-a (100 ng/ml) . We 
confirmed that Lcn2 protein was increased concomitantly with observed mRNA levels by 
western blotting. Interaction networks for gene symbol list of the up-regulated transcripts for 
mouse cortical neurons (10 transcripts) were obtained employing the IP A knowledge base 
and a total of two networks were obtained. One cluster including the transcript encoding 
Igsf6 was filtered out based on a reliance of entire network on a single reference and for its 
low ranking. The highly ranked network included the rest of the 9 transcripts and showed 
after enrichment for regulated transcripts within the network, that TNF-a induces a 













Figure 4.1. Regulatory network for TNF-cx-dependent transcripts in mouse cortical neurons. 
Transcripts with an abundance of two-fold or greater in TNF-cx-treated (24 hours) compared to control 
treated primary cortical neurons by two-color microarray analysis (10 transcripts; see Table 1) were 
used as the input for analysis of potential networks using the signal transduction knowledge 
environment of Ingenuity (http:/ /www.ingenuity.com) . A network involving nine TNF-cx-regulated 
transcripts and four additional components with Ingenuity-confirmed direct or indirect links to them. 
TNF-cx-regulated transcripts are depicted in gray and linked components in white.Circular lines above 
symbols indicate auto-regulation; connecting lines without arrows indicate direct protein 
interaction;dashed and solid arrows indicate indirect (e.g. regulation of mRNA levels) and direct (e.g. 
enzymatic) activation. Additional abbreviations: IL-1 ,  Interleukin-1  beta; INF-ex, Interferon-alpha. 
INF-a induced Lcn2 production in primary neuronal cells 
TNF-oc mediated Lcn2 protein production was further investigated in primary cortical 
neurons, astrocytes and microglia cells in culture. Cells were treated with murine TNF-oc (100 
ng/ml) . In order to determine whether the kinetics of Lcn2 protein production correlated 
with the mRNA expression observed with microarray, primary cortical neurons, astrocytes 
and microglia cells were incubated with TNF-oc at various time points. TNF-oc induced a 
significant increase of intracellular Lcn2 expression 36 hours after onset of treatment in 
neurons (Figure 4.2a), astrocytes (Figure 4.2b) and microglia cells (Figure 4.2c) and 
normalized after 48 hours. Qualitative observation of the secreted protein levels from the cell 
supernatant of all cell types followed the same pattern (Figures 4.2a, 4.2b and 4.2c), but 
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remained increased in the supernatant. To gain further insight in the underlying pathways of 
TNF-oc induced Lcn2 expression, the effect of TNFR1 or TNFR2 mediated signaling was 
further investigated by specific receptor triggering via TNFR1 and TNFR2 agonistic 
antibodies. RNA samples extracted from cortical neurons of mice lacking TNFR1 or TNFR2 
and treated with TNF-oc (100 ng/ ml) during 24 hours, indicated that Lcn2 mRNA up­
regulation by TNF-oc depends on the presence of the type 1 receptor (Figure 4.Sla). 
Expression of Lcn2 protein production in these neurons was further validated (Figure 4.S 1 b) 
by TNFR1 and TNFR2 stimulation using receptor specific agonistic antibodies. Primary 
cortical neurons were treated with 100 ng/ml TNF-oc, 2 µM TNFR1 agonistic antibody or 
20µM TNFR2 agonistic antibody for 36 hours. Treatment time interval of 36 hours for all cell 
types was used based on results obtained in Figures 4.2a, 4.2b and 4.2c. Intracellular Lcn2 
expression was significantly increased by TNF-oc and more specifically by TNFR1 mediated 
stimulation in primary cortical neurons (Figure 4.2d), astrocytes (Figure 4.2e) and microglia 
cells (Figure 4.2f), whereas TNFR2 stimulation had no effect on Lcn2 expression. TNF-oc and 
specifically TNFR1 stimulation also increased secreted Lcn2 levels (Figures 4.2d, 4.2e and 
4.2f). We further found TNF-oc mediated Lcn2 expression requires NF-xB in primary cortical 
neurons as shown in Figure 4.S 1 c. 
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Figure 4.2. TNF-cx mediated Lcn2 production in primary neuronal cells. Expression of intracellular 
and secreted Lcn2 protein levels in primary cortical neurons (a), astrocytes (b) and microglia (c) at 
different time intervals of TNF-cx (100 ng/ml) treatment determined by western blot. The effect of 
TNFR1 - and TNFR2- mediated signaling on Lcn2 expression in primary cortical neurons (d), 
astrocytes (e) and microglia (f) was assessed by western blot, by treating the cells with either TNF-cx 
(100 ng/ ml), TNFR1 agonistic antibody (2 µg/ ml) or TNFR2 agonistic antibody (20 µg/ ml) for 36 
hours. Bars indicate the mean protein expression in % relative to untreated controls ± s.e.m. (*p< 0.05, 
*,t p < 0.005, *** p<0.0001).  
A nafysis of Lcn2 from human tissues 
Lcn2 was not significantly elevated in serum of MCI (1 52 ± 1 7  ng/ ml) or AD patients (1 69 ± 
19  ng/ml) compared to controls (1 32 ± 1 3  ng/ml) (Figure 4.3a) .  However, CSF Lcn2 levels 
were significantly lower in CSP of MCI (1340 ± 1 1 9 pg/ ml; p=0.0027) and AD groups (1494 
± 172 pg/ ml; p=0.036) compared to normal age-matched controls (2079 ± 1 72 pg/ ml) 
(Figure 4.36) .  Lcn2 levels were measured in brain tissue by Western blotting. Lcn2 is 
ubiquitously expressed throughout the human brain (Figure 4.3c) .  It is significantly increased 
in Alzheimer's disease brain tissue specifically in the entorhinal cortex and hippocampus 
(Figure 4.3c) ,  both regions in which AD neuropathology is prominent (Braak and Braak, 
1991 ;  Haroutunian et al. ,  1 998; Haroutunian et al., 1 999; Laakso et al. ,  2000) . Evaluation of 
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Lcn2 in the hippocampus by immunohistochemistry revealed a robust, punctate and diffuse 
staining for Lcn2 in pyramidal neurons in the subiculum-CA1 region in AD brain tissue, also 
observable, albeit at much lower density, in control brain tissue (Figure 4.3d). A punctate 
distribution of Lcn2 was observed only in the pyramidal neurons and their axons and 






. . .. 
E 200 
2 ... .. 
100 � 
































. .. ·=· ... 
. .. ¼ 





Figure 4.3. Expression of Lcn2 in human samples. (a) Serum Lcn2 concentrations among study 
groups. (b) Differences in CSP Lcn2 concentrations between the study groups. Bars indicate the mean 
protein concentrations in the different study groups and are expressed ± s.e.m. (*p< 0.05, ** p < 
0.005). (c) Lcn2 expression in homogenated cerebellum, VMPC, occipital lobe, entorhinal cortex and 
hippocampus brain tissue of control and AD brain tissue determined by Western blot analysis. Bars 
indicate the mean ratio protein expression in non-demented control- and AD- brain tissue ± s.e.m. 
(*p< 0.05, ** p < 0.005). (d) Immunohistochemical staining of Lcn2 of pyramidal neurons in the CA1 
hippocampus region of an AD patient compared to a non-demented control. 
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Effect of Lcn2 on TNF-a signalingpathwqys 
Previous reports clearly indicate that neuroprotective signaling of TNF-cx. is mediated by 
TNFR2 stimulation, which activates the PKB / Akt pathway, leading to the phosphorylation 
of p65 and therefore to the activation of nuclear factor kappaB (NF-xB) which in turn 
initiates upregulation of pro-survival factors (Marchetti et al., 2004). Since it has been shown 
that Lcn2 can reduce TNF-cx. mediated effects (Guo et al., 2010; J in et al., 2011a), we further 
investigated whether Lcn2 had an influence on TNF-cx. mediated signaling, and in particular 
'TNFR2 mediated pro-survival signaling pathways in primary cortical neurons. Cultured 
neurons were treated with either TNF-cx., TNFR1 agonistic antibody or TNFR2 agonistic 
antibody, and also co-incubated with Lcn2 for 24 hours. In these conditions we measured the 
effect of Lcn2 on TNF-cx. induced phosphorylated-AktScr471 and nuclear extract of 
phosphorylated-p655crS36 . Lcn2 significantly impaired TNF-cx. and TNFR2 mediated 
phosphorylation of Akt (Figure 4.4a) and p65 (Figure 4.4b) when Lcn2 was co-incubated with 
T'NF-cx. and TNFR1 or TNFR2 agonistic antibodies. Furthermore, a significant increase in the 
pro-apoptotic factor, cleaved caspase 3, was induced only when cells were co-incubated with 
Lcn2 and TNF-cx. or the TNFR2 agonistic antibody (Figure 4.4c). Even though cleaved 
caspase 3 was increased, no effect on cell viability on primary cortical neurons was found 
(Figure 4.S2a). NF-xB activation via TNF-cx. leads to a down-regulation of the phosphatase 
and tensin homolog deleted on chromosome ten (PTEN) protein, which in turn is a strong 
inhibitor of the PI3K/ Akt pathway (Kim et al., 2004). It has been shown previously that 
Lcn2 can upregulate PTEN activity in cancer cells (Shi et al., 2008). Therefore we further 
explored the inhibitory effect of Lcn2 on TNF-cx.-induced PI3K./ Akt pathway activation by 
determining whether Lcn2 affected PTEN expression in primary cortical neuron cells. 
Primary cortical neurons were treated with Lcn2 (200 ng/ ml) at indicated time intervals 
(Figure 4.4d). Lcn2 caused a significant upregulation of PTEN after 2 hours, which remained 
increased for 24 hours after Lcn2 treatment (Figure 4.4d). Lcn2 also impaired TNF-cx.- and 
specifically TNFR2-mediated downregulation of PTEN (Figure 4.4e). We then verified 
whether Lcn2 causes an upregulation of cleaved caspase 3 observed (Figure 4.4c) as a result 
of an increase of PTEN. To that purpose neurons were pretreated with or without the PTEN 
inhibitor VO-OHpic (300 n11) (Mak et al., 2010) for 30 min and then treated with Lcn2 (200 
ng/ml) co-incubated with TNF-cx. (100 ng/ml) or TNFR2 agonistic antibody (20 µM). VO­
OHpic significantly inhibited the increase of cleaved caspase 3 when Lcn2 was co-incubated 
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Figure 4.4. Influence of Len 2 on TNFR2 mediated signaling pathway in primary cortical neurons. 
Primary cortical neurons were incubated with TNF-cx (100 ng/ml), TNFRl agonistic antibody (2 µM) 
or TNFR2 agonistic antibody (20 µM) and also co-incubated with recombinant murineLcn2 (200 
ng/ml) for 24 hours. Western blot was used to quantify protein expression. (a) Neurons were analyzed 
for PKB/ Akt phosphorylation at the Ser473 site. (b) NF-xB activation was determined via analysis of 
phosphorylation of nuclear p65 at the ser536. (c) Caspase 3 activation was determined by the ratio of 
cleaved caspase 3 levels to caspase 3 levels. Lcn2 mediated PTEN upregulation. (d) Intracellular PTEN 
expression in primary cortical neurons treated with murine Lcn2 (200 ng/ ml) at different time intervals 
was determined via western bolt. (e) The effect of Lcn2 on TNF-cx mediated PTEN regulation. (f) The 
role of PTEN in Lcn2 mediated TNFR2 co-signaling induced caspase 3 activation was assessed by 
pretreating indicated neurons with a PTEN inhibitor; VO-OHpic for 1 hour and subsequent 
incubating with either TNF-cx (100 ng/ml) or TNFR2 agonistic antibody (20 µM), with or without 
Lcn2 (200 ng/ ml) for 24 hours. Bars indicate the mean protein expression in % relative to untreated 
controls ± s.e.m. (*p< 0.05, ** p < 0.005, *** p<0.0001). 
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Lcn2 abrogates TNF-a protection against .AD assotiated .A/3 and glutamate induced n eurotoxitiry 
TNF-cx via a TNF type 2 receptor signaling pathway, can be protective against glutamate 
induced- (Marchetti et al., 2004) and A�-induced neuronal cell death (Patel and Brewer, 
2008b). In view of the effects of Lcn2 on suppressing of the TNFR2-mediated cellular pro­
survival cascade, the effect of Lcn2 on TNF-cx- mediated protection against glutamate- and 
A�-induced toxicity was explored. As previously published (Marchetti et al., 2004) at a 
concentration of 100 ng/ ml soluble TNF-cx was found to protective against A� due to its 
rather low affinity to TNFR2 (Grell et al., 1995; Grell et al., 1998) (Figure 4.S2b). As 
expected, TNF-cx had a significant protective effect on A�- (Figure 4.Sa) and glutamate­
induced toxicity (Figure 4.Sb). Co-incubation of Lcn2 together with either TNF-cx or TNFR2 
agonistic antibody diminished the protective effect exerted by TNF-cx via TNFR2 against A�­
(Figure 4.Sa) and glutamate-induced toxicity (Figure 4.Sb). Lcn2 on its own induced 
significant cell death when co-incubated with A� in a dose-dependent manner (Figure Sc). 
Finally, since the Lcn2 receptor 24p3R exerts pro-apoptotic functions (Devireddy et al., 
2005), the effect of TNF-cx on 24p3R expression was assessed by incubating primary cortical 
neurons with TNF-cx (100 ng/ ml) for 24 hours. TNF-cx significantly increased 24p3R 
expression (Figure 4.Sd). However, postmortem brain tissue from AD patients showed no 
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Figure 4.5. Effect of Lcn2 on TNF-cx. mediated neuronal protection against A� and glutamate induced 
neuron toxicity. (a) Primary cortical neurons were pre-incubated for 24 hours with TNF-cx. (100 ng/ ml), 
TNFR2 agonistic antibody (20 µM) and Lcn2 (200 ng/ml) or TNF-cx. (100 ng/ml) and TNFR2 
agonistic antibody (20 µM) together with Lcn2 (200 ng/ml). After the 24 hour incubation period, A� 1-
42 (25 µM) was added and cell survival was determined 24 hours later with MTT assay. (b) Neurons 
were also pretreated as indicated withTNF-cx. (100 ng/ml), Lcn2 (200 ng/ml) and TNFR2 agonistic 
antibody (20 µM) and or TNF-cx. (100 ng/ ml) and TNFR2 agonistic antibody (20 µM) together with 
Lcn2 (200 ng/ ml) 24 hours and then challenged with 50 µM glutamate ( concentration that induced ;::::: 
50% cell death) for 1 hour. Neuronal viability was determined 24 hours after the glutamate challenge, 
using the MTT assay. (c) Primary cortical neurons were pre-incubated with Lcn2 at different 
concentrations for 24 hours and A�l-42 (25 µM) was then added, where after neuronal survival was 
determined by MTT assay. Bars indicate the mean cell death in % relative to untreated controls ± 
s .e.m. (*p< 0.05, ** p < 0.005, *** p<0.0001) . (d) Expression of Lcn2 receptor; 24p3R in primary 
cortical neurons after 24 hours incubation with TNF-cx.. Bars indicate the mean protein expression in % 




Recent studies have provided convincing evidence for TNF-cx as a mainly neuroprotective 
agent. We therefore performed a gene array on primary cortical neurons treated with TNF-cx 
to investigate whether expression of genes associated with protective cellular mechanisms 
were altered. Interestingly, TNF exposure yielded an upregulated gene expression for some 
chemokines that were highest for Ccl2 and second highest for Lcn2. Lcn2 attracted our 
interest due to recent findings which demonstrate that this protein is involved in activating 
and sensitizing astrocytes and microglia to apoptosis (Lee et al., 2007; Lee et al., 2009), that 
increased Lcn2 gene expression was found in an AD mouse model (Wu et al., 2006b) 
although its underlying mechanisms are largely unknown. Microglia, astrocytes and also 
neurons are known to produce inflammatory cytokines (Chopra et al., 2011). Lcn2 has been 
described as an acute phase protein that is induced via various pro-inflammatory stimuli, 
including TNF-cx (Liu and Nilsen-Hamilton, 1995). It was furthermore shown that TNF-cx is a 
strong stimulating factor of Lcn2 in astrocytes (Lee et al., 2009). Although TNF-cx is known 
not to be the sole inducing factor of Lcn2, a recent study has shown that a monoclonal 
antibody (infliximab), which prevents TNF-cx to bind to its receptors, significantly reduced 
peripheral Lcn2 concentrations in patients with Crohn's disease (Bolignano et al., 20106). It 
was also shown that TNF-cx is upregulated in the vicinity of neuropathological hallmarks in 
the brain of AD patients (Zhao et al., 2003; Rao et al., 2011). These findings therefore 
indicate that TNF-cx may act as a key regulator of Lcn2 production in neurodegenerative 
diseases like AD. The present study shows that TNF-cx induced a significant increased 
expression of intracellular Lcn2 in astrocytes, microglia cells and primary cortical neurons 
upon 36 hour exposure and that secreted Lcn2 levels corresponded well with the intracellular 
levels of this protein. Because TNFR1 and TNFR2 are expressed on neurons (Viel et al., 
2001), astrocytes (Fernandes et al., 2011) and microglia (Veroni et al., 2010), the effect of the 
distinct signaling pathways exerted by individual receptor stimulation was determined by 
treating cells with receptor-specific agonistic antibodies. TNFR1 mediated signaling was 
found to be the sole triggering pathway for Lcn2 production in all three cell types. Given the 
usual signaling events triggered by TNFR1 Lcn2 production is an astoundingly late response. 
In principle, this late response can be dependent on either an unexplored delayed TNFR1 
associated signaling event or due to a cascade of events triggered by TNFR1 induced gene 
transcription which finally leads to increased Lcn2. The very late response to TNFR1 
triggering makes the last hypothesis more likely. In fact, we found TNF-cx mediated 
upregulation of Lcn2 to be dependent on NF-xB signaling (Figure 4.1 c). Whether the Lcn2-
gene, however, is directly activated through NF-kB or by downstream gene products remains 
to be shown. The relevance of TNFR1 signaling in AD was recently substantiated by a study 
of Cheng et al., (2010) who showed increased TNFR1 and decreased TNFR2 expression in 
AD brain, besides a significantly higher binding affinity of TNF-cx to TNFR1 than to TNFR2 
in the AD brain (Cheng et al., 2010). 
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A recent study by Choi et al., (2011) however, showed a significant increase of Lcn2 
concentrations in plasma of MCI compared to control and AD groups (Choi et al., 2011). 
The lack of significant differences in our study might be ascribed to the small patient 
numbers used. The finding of lowered Lcn2 in CSP of both MCI and AD individuals, 
however, was a robust finding in our study and suggests that Lcn2-mediated neuronal 
sensitivity to toxicity in AD progression may be due in part to impaired clearance of this 
molecule from the brain, as has been suggested as well for A�1-42. These results point to the 
potential dynamic regulation of Lcn2 in various cellular compartments through the course of 
the disease. Up-regulation of Lcn2 expression in the choroid plexus, presumably within 
epithelial cells, has been reported previously (Marques et al., 2008). Atrophy of these 
epithelial cells occurs during AD (Serot et al., 2003), and might explain the reduced Lcn2 
production in the CSP. Secondly, megalin is one of the known receptors responsible for the 
transport of Lcn2 across cell membranes (Hvidberg et al., 2005). Patients with AD have 
reduced levels of megalin in the choroid plexus (Alvira-Botero and Carro, 2010). This 
decreased megalin expression might also contribute to lower Lcn2 into the CSP and thereby 
to the lower concentrations found. A large number of studies have indicated that one of the 
most consistent markers in AD is decreased A�1 -42 in CSP of MCI patients that convert to 
AD (Prvulovic and Hampel, 2011). Interestingly, megalin also partakes in A�1 42 clearance 
through the blood-brain barrier and blood-CSP barrier at the choroid plexus (Zlokovic et al., 
1996; Hammad et al., 1997). The fact that Lcn2 is significantly lower in CSP of both MCI and 
AD patients suggests that whatever the mechanism, dysregulation of Lcn2 expression appears 
as an early event in AD. 
Increased Lcn2 expression in the entorhinal cortex and hippocampus brain regions correlates 
strongly with region-specific AD pathology as classically described (Small et al., 2006), and 
also with TNP-cx expression in AD brain tissue (Zhao et al., 2003; Rao et al., 2011). A marked 
increase of intracellular Lcn2 staining in the pyramidal neurons of AD human brain tissue 
was observed compared to control brain tissue. This observation correlates with the finding 
that cyclooxygenase-2, that is upregulated at sites of inflammation, is also primarily 
upregulated in these neurons (Braak and Braak, 1991). Lcn2 mRNA expression was also 
found to be upregulated in area CA1 of the hippocampus in rat after oxidative stress in vivo 
(Wang et al., 2007a), indicating that Lcn2 is upregulated in hippocampus tissue during 
neuronal injury. 
At the cellular level, Lcn2 can act as a pro-apoptotic or pro-survival factor, depending on the 
cell type and cellular environment (Devireddy et al., 2005; Lee et al., 2007; Miharada et al., 
2008; Lee et al., 2009). Although the presence of Lcn2 in brain tissue has been shown (Liu 
and Nilsen-Hamilton, 1995), its main functions in neuronal tissue are largely unknown, 
especially during disease conditions. In this study we found that Lcn2 silenced TNPR2 
mediated PI3K/ Akt activation and NP-xB activation. Lcn2 alone did not have an effect on 
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pro-apoptotic cleavage of caspase 3, but when co-incubated with TNF-C( or TNFR2 agonistic 
antibodies a significant increase in cleaved caspase 3, but no neuronal cell death was 
observed. Silencing TNFR2 mediated PKB/ Akt signaling might have shifted the protective 
signaling cascade to a pro-apoptotic pathway. Our data further indicate that the inhibitory 
effect of Lcn2 on TNFR2 signaling can be via the upregulation of PTEN. Lcn2 exhibits its 
pro-apoptotic properties via the increase of pro-apoptotic BIM (Bcl-2-interacting mediator of 
cell death) expression in certain cancerous cell types (Devireddy et al., 2005) as well as in 
astrocytes (Lee et al., 2009). However, BIM was not involved as a pro-apoptotic factor in 
Lcn2 mediated cell death of microglia cells (Lee et al., 2007). BIM is spliced into the three 
apoptotic isoforms, Bim1-:1 ,, Bim1, and Bims, upon activation (O'Connor et al., 1998). Since we 
did not find any substantial increase of BIMEL expression in primary cortical neurons (Figure 
4.S4), we speculate that Lcn2 might execute pro-apoptotic signaling differently in different 
cell types. Previous in vitro studies have shown that Lcn2 can activate and sensitize astrocytes 
and microglia to apoptosis and increase cell death to toxic substances (Lee et al., 2007; Lee et 
al., 2009). We could show here that sole incubation with Lcn2 had no effect on cell death, but 
significantly increased cell death of primary cortical neurons in a dose dependent manner 
when co-incubated with A�1 42. Moreover, the finding that Lcn2 diminished the neuro­
protective effect of TNF-C( against glutamate- and A�-mediated toxicity in neurons correlates 
with the described mechanistic data (Figure 4.6). 
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Figure 4.6. Lcn2 mediated sensitivity of neurons towards glutamate and A�1-42 toxicity. Lcn2 
expression is induced via TNFRl specific signaling in primary cortical neurons, astrocytes and 
microglia and secreted. Lcn2 can silence TNFR2 mediated phosphorylation of A.kt and 
phosphorylation of p65 via the upregulation of PTEN and therefore inhibit TNFR2 mediated 
neuroprotection against the AD associated excitotoxic factors. 
It is known that Lcn2 can promote apoptosis via its receptor, 24p3R (Devireddy et al., 2005; 
Li et al., 2007). Although no differences of 24p3R expression in human brain between control 
and AD was found, TNF-cx increased 24p3R in primary cortical neurons in vitro. Because 
Lcn2 can act in an autocrine manner (Lee et al., 2007), our in vitro findings leads to the 
speculation that TNF-cx not only increases Lcn2 production and secretion, but also increases 
24p3R expression, thereby enhancing Lcn2 mediated signaling via 24p3R in a pro­
inflammatory environment. In accordance with our findings, Rathore et al., (201 1) recently 
reported that the absence of Lcn2 in Lcn2 knockout mice results in enhanced neuronal and 
tissue survival, and reduced pro-inflammatory cytokines and chemokines after spinal injury 
(Rathore et al., 201 1) .  
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In conclusion, in vitro results suggest that Lcn2 can contribute to the pathophysiology of AD 
by sensitizing neuronal cells against A� through silencing essential immunological 
neuroprotective pathways, therefore making it a rational target for future pharmacological 
intervention. Second, our data suggest Lcn2 as a promising CSF marker that merits further 
investigation as a possible candidate to improve diagnosis for early symptoms of AD. Third, 
Lcn2 appears to be an important determinant of balance-of-effect of TNF-cc via type 1 and 
type 2 receptor signaling in the brain, and a potential target for progressive neurodegeneration 
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Figure 4.S1. (a) Lcn2 mRNA up-regulation by TNF-cx in mouse cortical neurons requires the presence 
of TNF-cx type 1 receptor. Primary cultures of cortical neurons from wild type (WI), TNFR1 knockout 
(TNFR1 KO) or TNFR2 knockout (TNFR2 KO) mice were incubated for 24 hours in control 
conditions or with 100 ng/ml TNF-cx, and Lcn2 mRNA levels were measured by Q-RT-PCR as 
described in Supplemental Materials and Methods. Values are result of one determination for each 
condition. (b) Primary cortical neurons obtained from WT, TNFR1 KO and TNFR2 KO mice were 
further stimulated with TNF-cx (100 ng/ ml) for 36 hours. Lcn2 expression was quantified using 
Western blot. (c) Primary cortical neurons were incubated with 100 ng/ml TNF-cx or with 100 ng/ml 
TNF-cx with NF-xB inhibitor BAY1 1 -7082 (10 µM). Lcn2 levels were quantified using Western blot. 
Lcn2 expression was normalized to actin before the percentage relative to control was calculated. Bars 
indicate the mean protein expression in % relative to untreated controls ± s.e.m. (*p < 0.05, ** p < 
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Figure 4.S2. (a) Effect of TNF ex, specific TNF-cx receptor stimulation and co-treatment with Lcn2 in 
primary cortical neuron survival. Primary cortical neurons were incubated for 24 hours with either 
TNF-cx (100 ng/ml), TNFR2 agonistic antibody (20 µM), Lcn2 (200 ng/ml) or TNF-cx (100 ng/ml), 
TNFR2 agonistic antibody (20 µM) together with Lcn2 (200 ng/ml). A� (25 µM) or 50 µM glutamate 
(concentration that induced ::::: 50% cell death) were used as controls for cell toxicity. (b) Primary 
cortical neurons were incubated with indicated concentrations of TNF-cx to assess the optimal 
protective concentration of TNF ex when co-incubated with A� (25 µM). Neuronal viability was 
determined after 24 hours using the MIT assay. Bars indicate cell viability % relative to untreated 
controls ± s.e.m. (** p < 0.005) . 
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Figure 4.S3. (A) 24p3R expression in different brain regions of non-demented human control and AD 
brain tissues. 24p3R expression was normalized to actin. Bars indicate the mean protein expression ± 
s.e.m. 
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Figure 4.S4. The effect of Lcn2 on BIMEJ, expression. Primary cortical neurons were incubated with 
TNF-cx (100 ng/ml), TNFR2 agonistic antibody (20 µM) and co-incubated with or without 
recombinant Lcn2 (200 ng/m) for 24 hours. BIMEJ, expression was quantified using Western blot. 
BIMm, expression was normalized to actin before the percentage relative to control was calculated. 
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A low-graded inflammatory response is associated with the ageing process, also referred to as 
"inflammaging" and with late-life depression in particular. Preclinical studies have shown that 
peripheral induced inflammation significantly increases cerebral Neutrophil Gelatinase­
Associated Lipocalin (NGAL) expression, whereas increased cerebral NGAL levels lead to a 
pro-apoptotic environment and inhibit hippocampus spine maturation. In this study we 
propose NGAL as a novel inflammatory marker in human late-life depression. Baseline data 
were obtained from a well-characterized prospective cohort study of 510 depressed and non­
depressed older persons (2:: 60 years). Plasma NGAL concentrations were significantly 
associated with the current state of depressive disorder, independent of other determinants 
on plasma NGAL concentrations in humans, like age, sex, lifestyle factors, and anti­
inflammatory drugs. Our data, together with recent molecular findings of the possible 
pathophysiological roles of NGAL in the central nervous system merits NGAL as promising 
new target for late-life depression. 
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Introduction 
A low-graded inflammatory response is associated with the ageing process, also referred to as 
"inflammaging" (Franceschi et al., 2000; Franceschi et al., 2007), which is even more 
pronounced in the presence of chronic somatic diseases during ageing (Singh and Newman, 
2011). Along these lines, immune dysregulation in late-life depression has attracted a great 
deal of attention during the last two decades, since first proposed by Smith (Smith, 1991). 
Recently, two meta-analyses confirmed upregulation of peripheral inflammatory markers in 
depressed patients (Bowren et al. , 2009; Dowlati et al., 2010a), most consistently for 
interleukin-6 (IL-6), tumor necrosis factor alpha (fNF-a:) and C-reactive protein (CRP) 
(Zorrilla et al., 2001; Dowlati et al., 20106). Although data are limited, available studies also 
showed increased expression of pro-inflammatory cytokines in post mortem brain tissue from 
depressed patients (Pandey et al., 2011; Shelton et al., 2011), reflecting the anomalies found in 
the periphery. This process of inflammaging may thus explain the adverse health outcomes of 
late-life depression including increased mortality, morbidity, and impaired recovery from 
illness and disability (Blazer et al., 2001). 
In this respect, we investigated Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a 
novel inflammatory marker in late-life depression. NGAL, also known as Lipocalin 2, 
siderocalin, 24p3, or uterocalin, is a 25 kDa protein (I<.jeldsen et al., 1993) upregulated in 
typical age-associated diseases like cardiovascular disease, kidney diseases (Bolignano et al., 
2010a) and mild cognitive impairment (Choi et al., 2011). Interestingly, peripheral injection of 
the immunostimulant lipopolysaccharide (LPS) increases NGAL production in the CNS of 
mice (Ip et al., 2011), indicating the importance of NGAL as a neuromodulatory 
inflammatory agent. Recently, we showed that increased NGAL levels lead to a pro-apoptotic 
environment in the central nervous system of mice (Naude et al., 2012), whereas others have 
shown inhibitory effects on hippocampus spine maturation (Mucha et al., 2011). As increased 
hippocampal neurogenesis has been proposed as one of the underlying mechanism of 
antidepressants (Duman, 2004) and patients with late-onset depression have smaller 
hippocampal volumes (Lim et al., 2012), NGAL might be an intriguing marker for future 
neurobiological and clinical research in late-life depression. 
Within the present study, we examined NGAL plasma-levels m a large population of 
depressed patients and non-depressed controls aged 60 years and beyond. Our objectives 
were 1) to explore determinants (and thus confounding factors) of plasma NGAL levels in 
humans, 2) to examine NGAL plasma levels as a biomarker for late-life depression adjusted 
for identified confounders, and 3) to examine which characteristics of the depression 





The Netherlands Study of Depression in Older people (NESDO) (Comijs et al., 2011) is an 
on-going cohort study designed to examine the (determinants of the) course and 
consequences of depressive disorders in older persons. Details of NESDO are described 
elsewhere (Comijs et al., 2011), but can be summarized as follows. The NESDO sample 
consists of 378 depressed persons with a current Diagnostic and Statistical .Manual of Mental 
Disorders, Fourth Edition (DSM-IV) diagnosis of major depressive disorder, minor 
depression or dysthymia and 132 non-depressed persons, aged 60 through 93 years. 
Depressed persons were recruited from mental health institutes (both in- and outpatients) 
and from primary care. The non-depressed subjects were recruited from primary care 
practices. All participants underwent a baseline examination at one of the research locations 
or at the homes of the participants. The ethical review boards of the participating institutes 
approved of this study. 
The Composite International Diagnostic Interview (CIDI), version 2.1; 24 month version was 
used in order to determine depression classification according to the criteria of Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and the criteria of the 
International Classification of Diseases-10 (ICD-10) (World Health, 1997). The CIDI has 
high validity for depressive and anxiety disorders (Wittchen et al., 1991; Kessler et al., 2010). 
To determine the research DSM-IV diagnosis of current minor depression, questions were 
added to the CIDI, as in The Netherlands Study of Depression and Anxiety (NESDA) 
(Penninx et al., 2008). Severity of depression was measured by the 30-item self-rating 
Inventory of Depressive Symptomatology (IDS), which has adequate psychometric properties 
(Rush et al., 1986; Rush et al., 1996). For the present analyses, we selected the 132 non­
depressed persons ( comparison group) and those with a past 6 months diagnosis of major 
depressive disorder (MDD, n=359). Of this latter group, 275 persons also met DSM-IV-TR 
criteria for MDD in the past month, while 84 persons were recently remitted, i.e. did not 
meet the criteria for a MDD in the past month. 
NGAL m easurement in plasm a f?y BUSA 
Quantification of NGAL from plasma was performed via a constructed sandwich ELISA 
using human Lipocalin-2/NGAL ELISA capture antibody (R&D Systems), recombinant 
human Lipocalin-2/NGAL (R&D Systems) for the internal standard and biotinylated human 
Lipocalin-2/NGAL detection antibody (R&D Systems). Plasma was diluted 1:100. A blinded 
ELISA analysis was performed on coded samples. Briefly, plates (96 wells, Maxisorb, Nunc) 
were coated with the capture antibody (100 µl; 2 µg/ ml) diluted in phosphate buffered saline 
(PBS, pH 7.4). After overnight incubation at room temperature, the coated plates were 
washed with Tris Buffered Saline (TBS) containing 0.05% Tween 20 (TBS/T) and 
nonspecific binding sites blocked by incubation with 300 µl of PBS containing 1 % Bovine 
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Serum Albumin (BSA) (PBS/BSA) for 2 hours at room temperature on a shaker. After 
washing, 100 µl of either the standards (recombinant human lipocalin-2) or samples, diluted 
in PBS/BSA were added to the plates and incubated for 2 hours at room temperature on a 
shaker. Plates were washed six times and 100 µl of biotinylated human Lipocalin-2/NGAL 
detection antibody (100 ng/ml) diluted in PBS/BSA was added. After 2 hours on a shaker at 
room temperature, plates were washed six times and incubated with 100 µl Avidin-horseradish 
peroxidase (eBioscience) in PBS/ BSA (1:1000) for 20 minutes on shaker at room 
temperature. Plates were then washed six times and 100 µl of substrate solution containing 
l mg/ml of O-phenylenediamine (Sigma) in 0.05M citric acid sodium phosphate Buffer (pH 
5.0) with hydrogen peroxide (0.06%) was added. The reaction was stopped by adding 100 µl 
of a 3N HCl solution. The absorbance was determined at 492 nm with background 
subtraction at 620 nm using an ELISA reader (Asys UVM 340, Biochrom, Cambridge, UK). 
The quantity of NGAL was estimated from the calibration curve which ranged from 78 to 
5000 pg/ ml. Samples were stored at -80 °C. Blood samples were collected in the morning to 
standardize for collection time (Comijs et al., 2011). 
Depression charaderistics 
Next to CIDI depressive disorder diagnosis, depressive disorder characteristics included age 
of onset (determined by a CIDI question about the age of the participant at the time of the 
first depressive episode), recurrency (presence of depressive episode prior to the current 
episode), co-morbid dysthymia (CIDI interview) and depressive symptom severity as 
measured with the IDS. Comorbid anxiety was also taken into account. The CIDI anxiety 
diagnosis was used to determine the presence of an anxiety disorder in the past year i.e. 
generalized anxiety disorders, panic disorder, agoraphobia or social phobia. The Beck Anxiety 
Inventory (BAI) was used to assess the severity of anxiety symptoms (Beck et al., 1988). The 
score on the BAI was used as a continuous variable. 
Antidepressant medication 
Medication use was assessed based on drug container inspection of all drugs used in the past 
month and classified according to the World Health Organization Anatomical Therapeutic 
Chemical classification (ATC) . Medication was only considered when taken on a regular basis 
(at least 50% of the time). Antidepressant medication included selective serotonin reuptake 
inhibitors (SSRls) (N06AB), serotonin-norepinephrine reuptake inhibitors (SNRJ) 
(N06AX16, N06AX21), tricyclic antidepressants (TCAs)(N06AA) and tetracyclic 
antidepressants (TeCA) (N06AX03, N06AX05, and N06AX11). Anti-inflammatory drugs 
included aminosalicylic acid and similar agents (A07EC), anti-allergic agents (A07EB), 
systemically applied corticosteroids (H02A), anti-inflammatory and antirheumatic products 




The following covariates were examined as determinants and thus potentially confounding 
factors in the association between NGAL and depressive disorder. Demographic data were 
collected during the interview (age, gender, partner status and educational level). Somatic 
comorbidity was assessed using a self-report questionnaire regarding the presence of somatic 
diseases, as developed by Statistics Netherlands (Centraal Bureau voor de Statistiek, 
www.CBS.nl) (Kriegsman et al., 1996). Age of onset of the depression was determined by a 
CIDI question about the age of the participant at the time of the first depressive episode. 
Global cognitive functioning was assessed by the Mini Mental State Examination (MMSE) 
(Folstein et al., 1975). The MMSE score ranges from 0-30, with higher scores indicating 
better cognitive functioning. Physical activity was measured with the last-seven-days short­
form (8-items) of the self-administered version of the International physical Activities 
Questionnaire (IPAQ) (Craig et al., 2003). Psychometric properties of the long and short 
version of the IPAQ are acceptable (Craig et al., 2003). 
Statistical ana!Jses 
Potential determinants of plasma NGAL levels were first compared between depressed and non­
depressed persons with Student t-tests for continuous variables and Pearson's chi squared tests f01 
categorical variables. Thereafter, potential determinants were entered as covariates in a linea.1 
regression analysis with plasma NGAL levels as the dependent variable. In order to obtain :: 
normal distribution of the plasma NGAL levels, eight positive outliers were trimmed at the mear 
level plus three SD (60.246 + 3*24.836), resulting in a skewness of 1 .58 and kurtosis of 0.76 (Bus e 
al., 201 1 ;  Bus et al., 2012).  As some covariates had missing data, we imputed the mean value of th<: 
other subjects in case of continuous variables or the most frequent score in case of dichotomous 01 
nominal data. Variables with missing values were: alcohol use (AUDIT sum score, n=9), smokin� 
status (n=3), waist circumference (n=3), physical activity (IPAQ score, n= 15), cognitiv<: 
functioning (MMSE score, n= 1), and finally the number of chronic diseases (n=1). All othe1 
variables had no missing data. Furthermore, as determinants of plasma NGAL might diffe1 
between depressed and non-depressed persons, we also examined potential interactions between a1 
characteristics and the presence/ absence of MDD. 
Finally, we examined the relationship between several characteristics of depressive disorder and 
plasma NGAL levels within the depressed subgroup using separate linear regression analyses pet 
characteristic, adjusted for previously identified determinants (significant at the 15%). All analyses 
were conducted with SPSS version 1 8.0. 
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Restults 
Data on NGAL were missing for 9/359 (2.5%) depressed persons and 3/132 (2.3%) non­
depressed controls ( six persons refused venapunction; blood withdrawal failed in another six 
persons). Depressed persons had significantly higher mean (SD) plasma levels of NGAL 
compared to non-depressed controls (62.4 (23.0) versus 53.5 (21 .1)  ng/ml, t=-3.9, p<.001). 
The depressed persons did not differ from the non-depressed persons with respect to mean 
age and sex, but had an average lower level of education. See table 1 for comparison of other 
baseline characteristics between both groups. 
Table 5.1. Characteristics of depressed patients and non-depressed controls 




Female sex, n (%) 79 (61 .2) 232 (66.3) 
Age (years), mean (SD) 70.1 (7.2) 70.6 (7.4) 
Partner, n (%) 97 (75.2) 183 (52.3) 
Education (years), mean (SD) 12.5 (3.5) 10.4 (3.4) 
Lifasrylc: 
Currently smoking, n (%) 1 1  (8.5) 94 (27.1) 
Alcohol use, mean AUDIT score (SD) 3.7 (2.8) 2.6 (3.6) 
Waist circumference (cm), mean (SD) 98.4 (13.2) 93.6 (13.0) 
Physical activity (IP AQ categories): 
Low, n (%) 22 (17.6) 107 (31 .5) 
Moderate, n (%) 54 (43.2) 131  (38.5) 
High, n (%) 49 (39.2) 102 (30.0) 
Pl!ysical fimctioning: 
Cognitive functioning (MMSE), mean (SD) 28.3 (1 .6) 27.8 (2.0) 
Chronic disease (no), mean (SD) 1 .5 (1 . 1) 2.1 (1 .5) 
Anti-inflammatory drug (AID) use, n (%) 12 (9.3) 44 (12.6) 
Corticosteroid AID use, n (%) 2 (2.3) 1 5  (4.3) 
Non-steroid AID use, n (%) 7 (5.4) 23 (6.6) 
Other AID use, n (%) 2 (1 .6) 9 (2.6) 
Salicylic use, n (%) 25 (19.4) 1 1 1  (31 .7) 
Starin use, n (%) 25 (19.4) 82 (23.4) 
P.rychopathological fimctioning: 
Depressive symptoms (IDS), mean (SD) 7.7 (6.4) 30.5 (13.1) 






















Determinants of plasma NGAL levels in humans 
Linear regression with plasma NGAL concentrations as the dependent variable, showed that 
increased plasma NGAL concentrations were independently associated with male sex, older 
age, having a partner, smoking, a lower severity of alcohol dependency, a higher waist 
circumference, low physical activity, use of anti-inflammatory drugs, and finally the presence 
of a major depressive disorder (see table 2). Testing all interactions with depressive disorder, 
yielded only a significant interaction term with partner status (B=-1.09, SE=0.48, beta=-.15, 
p=.024). This finding indicates that the association between partner status and plasma NGAL 
concentration only holds true among depressed persons (and not in non-depressed subjects). 
Adding this interaction term to the model, neither changed the beta's, nor the significance 
level of the other determinants. 
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Table 5.2. Determinants of plasma NGAL levels (n=479) by linear regression 
Variables of interest B (SE) Beta p-value 
Demographics: 
Female sex -3.42 (2.27) -.07 .131 
Age (years) 0.96 (0.15) .31 <.001 
Partner 5.75 (2.16) .12 .008 
Education (years) -0.1 6  (.30) -0.3 .595 
Ufisryle: 
Currently smoking 4.98 (2.45) .09 .043 
Alcohol use (AUDIT score) -0.46 (0.31) -0.7 .135 
Waist circumference (cm) 0.19 (0.08) .11 .016 
Physical activity (IPAQ categories): 
Moderate (versus low) -3.92 (2.48) -.08 .115 
High (versus moderate) -3.61 (2.62) -.07 .169 
Pf?ysica/ fimctioning: 
Cognitive functioning (MMSE) -0.01 (0.55) -.02 .981 
Chronic disease (no cardiac disease or stroke) -0.44 (1 .02) -.02 .659 
Heart disease 1 . 1 9  (2.79) .02 .670 
Stroke 0.25 (4.20) .00 .953 
Anti-inflammatory drug (AID) 8.54 (3.08) .12 .006 
Salicylic use 1 .86 (2.49) .04 .456 
Starin use -2.08 (2.60) -.04 .425 
P.rychopatho/ogy: 
Depressive disorder (yes) 8.56 (2.41) .17 <.001 
Abbreviations: n, number; SD, standard deviation; AUDIT, Alcohol Use Disorder Identification Test; 
IPAQ, International Physical Activities Questionnaire; MMSE, Mini Mental State Examination; no, 
number; AID, anti-inflammatory drugs; IDS, inventory of Depressive Symptoms; BAI, Beck Anxiety 
Inventory. 
MDV-characteristics as determinants ofNGAL plasma levels in depressed patients 
Multiple linear regression analyses were conducted to examine the association of specific 
characteristics of the depressive disorder within the depressed subgroup. As shown in table 3, 
two characteristics were associated with NGAL levels at a borderline significant level, i.e. 
whether persons suffering from a past 6-month diagnosis of depression did not meet MDD 
criteria in the past month anymore ('early remitted depression') and whether depressed 
persons were suffering from a first versus recurrent episode ('recurrent depression'). 
Including both significant depression characteristics into one final model showed that both 
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effects were independent of each other: recurrent depression (B=4.50, SE=2.32, Beta= . 10, 
p= .054); early remitted depression (B=S.44, SE=2.73, beta= . 10, p= .047). 
Table 5.3. Characteristics of depressive disorder as determinant of plasma NGAL levels in depressed 
older adults (n=350) in separate analyses* 
Variables of interest B (SE) Beta p-value 
Severity of depressive symptoms (IDS sum 0.03 (0.09) .02 .773 
score) 
Anxiety symptoms (BAI sum score) -0.13  (0.1 1) -.06 .227 
Neuroticism (NEO-FFI neuroticism score) -0.22 (0.18) -.07 .214 
Early remission (no symptoms past month) 5 .23 (2.74) . 10  .057 
Age of onset MDD (years) 0.00 (0.06) .00 .979 
Late-onset depression (1 st episode ?: 60 years) 1 .26 (2.68) .03 .638 
Recurrent depression 4.32 (2.33) .09 .065 
Comorbid dysthymia (past-year) -0.67 (2.66) -.01 .801 
Comorbid anxiety disorder (past-year) -2.50 (2.45) -.05 .307 
Use of antidepressant drugs (any) 3.51 (2.60) .07 . 178 
Use of a TCA 2.41 (2.81) .04 .391 
Use of a SSRI -0.86 (2.66) -.02 .747 
Use of other antidepressant drug 2.52 (2.59) .05 .330 
"' All analyses are adjusted for determinants of plasma NGAL levels at the 1 5% level (see table 6.2) 
Abbreviations: n, number; SD, standard deviation; AUDIT, Alcohol Use Disorder Identification Test; 
IP AQ, International Physical Activities Questionnaire; MMSE, Mini Mental State Examination; no, 
number; AID, anti-inflammatory drugs; IDS, inventory of Depressive Symptoms; BAI, Beck Anxiety 
Inventory. 
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Figure 5.1 presents the results comparing plasma NGAL concentrations in non-depressed 
subjects compared with early remitted and currently depressed patients adjusted for 
previously identified determinants (ANCOVA, F=7.22, df=2, p=.001). 
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p = .164 
Figure 5.1. Adjusted marginal mean values of NGAL 
levels in non-depressed controls versus depressed patients 
who did and not met DSM-IV-TR criteria for a MDD in 
the past month (including p-values of the post-hoc 
subgroup tests) . 
Figure 5.2 presents the results comparing plasma NGAL levels adjusted for previously 
identified determinants between non-depressed subjects and depressed patients suffering 
from a first episode versus recurrent episode of depression (ANCOVA, F=7.34, df=2, 
p=.001). 
p <.001 
p = .039 
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Figure 5.2. Adjusted marginal mean values of NGAL 
levels in non-depressed controls versus depressed patients 
suffering from a first episode and a recurrent episode of 
major depressive disorder (including p-values of the post­





With this study we are the first to our knowledge to present NGAL as a novel inflammatory 
marker that is significantly (p<.001) increased among older adults suffering from a major 
depressive disorder according to DSM-IV-TR criteria. Within the depressed group, plasma 
NGAL concentrations were lower in early remitted (1 month) patients compared to patients 
with a present state of depression. Furthermore, patients with a first episode of depression 
had marginally significant lower NGAL concentration compared to those patients suffering 
from recurrent depression. In line with previous studies, we found elevated plasma NGAL 
associated with increased age (Giaginis et al., 2010; Choi et al., 2011). This finding suggests 
that NGAL may in part be in accordance to the notion of "inflammaging" (Franceschi et al., 
2000; Franceschi et al., 2007) whereby an increased low grade inflammatory response is 
associated with the normal ageing process. Higher plasma NGAL levels in humans were 
further associated with male sex, use of anti-inflammatory drugs and life-style factors, i.e. 
smoking, less alcohol use, a higher waist circumference and lower level of physical activity. 
Future studies should definitively take these factors into account for proper interpretation of 
NGAL-levels between patient groups, as was done in the present study. 
Inflammation in late-life depression 
T'he association between inflammation and late-life depression is probably bidirectional. On 
the one hand, specific cytokines like Il-2 and interferon alpha (INF-ex) have been shown to 
induce depressive symptoms when administered to humans (Raison et al., 2006). On the 
other hand, accumulating data suggests that many inflammatory markers are a consequence 
of depression. A recent longitudinal study showed that multiple depressive episodes early in 
life result in increased CRP levels later in life, even when risk factors for inflammation 
(smoking, body mass index and medication) were taken into account, while higher CRP levels 
did not predict the occurrence of depressive symptoms (Copeland et al., 2012). The notion 
that depression precedes inflammation is further validated in a follow-up study wherein 
baseline inflammatory markers; fibrinogen, IL-6, and high-sensitivity C-reactive protein 
(hsCRP) did not predict subsequent depressive symptoms (Duivis et al., 2011). This was also 
shown for CRT, IL-6, 1-antichymotrypsin, intercellular adhesion molecule 1 (ICAM-1), and 
TNF-cx in late-onset depression (Forti et al., 2010). Furthermore, the meta-analyses on the 
association between inflammatory markers and depression also point to the fact that many 
studies in this field did not fully adjust their results for potentially confounding factors like we 
did and that many studies relied on depressive symptom questionnaires instead of formal 
psychiatric diagnoses, thereby being prone to bias due to overlapping symptoms with physical 
diseases. Although we addressed these limitations properly, there are certainly also other 
reasons why NGAL might be a unique component in late-life depression. 
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Molecular pathwqy 
Animal research has shown that NGAL is upregulated in the brain after the induction of a 
peripheral inflammatory response due to injection of an immunostimulant (LPS) (Ip et al., 
2011) as well as after psychological stressors (Mucha et al., 2011). Interestingly, the increase 
of cerebral NGAL expression reduced hippocampal synaptic spine density. Besides 
publishing the first results on NGAL in human brain tissue, we recently proved that NGAL 
expression is selectively triggered by TNF receptor 1 signaling (Naude et al., 2012). In 
addition, we found that NGAL can induce pro-apoptotic signaling cascade by attenuating Akt 
phosphorylation of the protein kinase B (PKB)/ Akt pathway and sensitize neurons to beta­
amyloid induced cell death (Naude et al., 2012). 
Cellular signaling via Akt has been postulated as a key pathway involved in neuroplasticity in 
the hippocampus (Balu et al., 2012). In vitro studies have illustrated the importance of Akt 
phosphorylation for neuronal survival and growth (Diez et al., 2012; Jin et al., 2012). A recent 
study showed that PKB/ Akt activity is decreased in post mortem human brain tissue of 
suicide victims compared to non-depressed controls (I(arege et al., 2011). These data 
collectively suggest that increased CNS NGAL levels can attenuate Akt signaling that 
consequently can lead to reduced neuroplasticity. This hypothesized inhibitory effect of 
NGAL on hippocampal neuronal growth links NGAL to the "neurotrophic hypothesis of 
depression". The neurotrophic hypothesis of depression postulates that a major depressive 
disorder may results from stress-mediated deficits in brain-derived neurotrophic factor and 
homologous factors, within networks critically involved in the pathophysiology and/ or 
treatment of the disorder (Duman and Monteggia, 2006; Schmidt and Duman, 2007; Sen et 
al., 2008). NGAL is hereby an intriguing marker for future neurobiological and clinical 
research in depression. Hippocampal atrophy and/ or reduced neurotrophic support may also 
be an explanation for the fact that NGAL levels were significantly higher in patients suffering 
from a recurrent compared to a first episode of depression. 
NGAL as a biomarker for late-life depression 
The physical properties of NGAL make it suitable for application as a biomarker since it is 
resistant to proteolytic degradation (Kjeldsen et al., 1993), possesses great storage stability and 
can be analyzed from a variety of bodily fluids such as serum, plasma and urine (Pedersen et 
al., 2010). Our data suggests that NGAL might serve as a biomarker for a current state of 
depression, independent of the clinical features of that depression like the severity of 
depressive symptoms, age at onset, chronicity or comorbid anxiety disorders. Furthermore, 
the use of antidepressants (SSRis, TCAs and other antidepressants) was also not associated 
with plasma NGAL levels within the depressed group. This finding further marks NGAL as 
unique marker, since antidepressant drug use has been reported to normalize the levels of 
peripheral inflammatory markers (Kenis and Maes, 2002; De Berardis et al., 201 O; Hannes tad 
et al., 2011) and BDNF levels (Matrisciano et al., 2009; Molendijk et al., 2011). Dissociation 
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of the antidepressant effects and NGAL expression hints at the involvement of biochemical 
pathways different from those reported for other inflammatory markers. 
Optimism for usage as a biomarker, nevertheless, should be tempered as, consistent with 
previously investigated biomarkers for depression, we found large overlap of plasma NGAL 
levels between depressed patients and non-depressed controls. This overlap certainly limits its 
use as a single diagnostic marker. However, we believe that NGAL possesses ideal 
characteristics in order to function as biomarker when combined with other known markers 
associated with the occurrence of depressive symptoms (Papakostas et al., 2011; Schmidt et 
al., 2011). 
Methodological considerations 
The strengths of our study are the large number of older persons suffering depression and 
the comprehensive assessment of depression characteristics and confounding factors. 
However, some limitations should be acknowledged for proper interpretation. Firstly, NGAL 
can be quantified reliably in serum, plasma and urine. In this study we had an option to use 
either serum or plasma for NGAL analysis. Both serum and plasma samples appeared 
suitable to analyze NGAL and to the best of our knowledge no preference for the use of 
either plasma or serum was mentioned in literature. Secondly, NGAL has been shown a 
biomarker for renal dysfunction (Soni et al., 2010) and possibly also cardiovascular disease 
(Bolignano et al., 201 0a). We investigated chronic diseases including cardiovascular and renal 
disease as potential confounders. Although we did not found significant associations between 
NGAL and these diseases, separately or as a collective, it could be that a simple disease state 
of cardiovascular and/ or renal disease might not have been sensitive enough. Finally, the 
cross-sectional study design precludes causal interpretations of the findings. Further 
validation within longitudinal studies whereby blood is collected at various time points 
accompanied by of the clinical symptoms of depression is warranted. 
Final condttsion 
In conclusion, with this study we show that NGAL 1s significantly elevated in plasma 
associated with the state depression and is probably further increased during recurrent 
episodes. These results are independent of other determinants of plasma NGAL 
concentrations in humans, like age, sex, lifestyle factors, and anti-inflammatory drugs. These 
findings evidently show that NGAL possesses ideal characteristics to be used especially in 
combination with other biomarkers to aid with accurate diagnosis of late-life depression. The 
hypothesized involvement of NGAL as pathophysiological element in late-life depression 
merits NGAL as a marker for late-life depression and fulfills the qualities as a promising new 
target for future studies in depression. 
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Abstract 
Systemic low grade inflammation has been associated with late-life depressive symptoms and 
cognitive impairments. Current knowledge on this topic is still very limited, especially with 
respect to the association of particular inflammatory markers with impairment of certain 
cognitive domains and the influence of confounding factors. We examined the relationship of 
plasma NGAL concentrations with cognitive impairment of 369 depressed and 129 non­
depressed older persons (2: 60 years) from The Netherlands study of Depression in Older 
persons (NESDO) cohort. Cognitive functioning was examined for memory ( delayed recall 
10 words test) and executive functioning (STROOP test). Multiple linear regression analyses 
with both measures of cognitive functioning as the dependent variable were conducted to 
examine the association with plasma NGAL levels. Interaction term between NGAL levels, 
depression status and gender were tested and were appropriated, stratified analyses were 
conducted. In our study population we found that increased plasma N eutrophil Gelatinase­
Associated Lipocalin (NGAL) concentrations were negatively associated with memory 
function assessed by delayed word recall test scores in females with depressive symptoms 
(p<.001 ). This effect remained significant (p =.045) after adjustments for demographic, 
physical and life-style characteristics. Additionally, higher plasma NGAL concentrations were 
associated with worse executive functioning in males, but not in females. This association also 
remained significant in the fully adjusted model (p = .010). This study presents NGAL as a 
novel marker associated with memory impairment in depressed elderly females and with 
executive dysfunctioning in elderly males. 
88 
Len 2 and cognition 
Introduction 
Studies have shown that the occurrence of depressive symptoms in the elderly can 
significantly increase the likelihood for the development of mild cognitive impairment and 
Alzheimer's disease (Barnes et al., 2006; Brommelhoff et al., 2009). These and other studies 
have led to the hypothesis that late-life depression is a possible prodromal symptom of 
Alzheimer' s Disease (AD), especially with the presence of impaired cognitive function 
(Potter et al., 2012). In practice, late-life depression is currently not diagnosed efficiently 
(Schwenk, 2002), possibly due to the etiological heterogeneity of this disease (Gottfries, 
2001). Gender has recently been identified as a possible determining factor for the 
susceptibility of late-life depression and cognitive impairment. Females are at increased risk of 
developing late-life depression (Sonnenberg et al., 2000), and also to develop late onset AD 
(Gao et al., 1998; Launer et al., 1999). Studies evaluating the depressed mood as increased risk 
factor for dementia in general population presented conflicting results (Becker et al., 2009; 
Wilson et al., 2010). However, two recently published longitudinal studies in older women 
showed that depression may be a risk factor for cognitive decline (Colenda et al., 201 0; 
Rosenberg et al., 2010). These data provokes the question if depressed women are at greater 
risk for development of cognitive impairment than men. 
A large body of research has linked blood-borne markers of inflammation, in particular pro­
inflammatory cytokines to poorer cognitive performance in older adults (Ticmeier ct al., 2003; 
Dik et al., 2005; Kuo et al., 2005; Milanesch.i et al., 2009; Swardfager et al., 2010; Milaneschi et 
al., 2011). Many of these markers arc also linked to depression in older individuals (Pcnninx 
et al., 2003; Gimeno et al., 2009) as well as AD (Swardfager et al., 2010), emphasizing possible 
interactions among inflammation, mood, cognitive function and underlying pathology. Data 
obtained in recent studies led to the proposal that inflammation precedes the pathology of 
AD and that this chronic neuronal pro-inflammatory environment may in part exacerbate to 
the development of AD (Herrup, 2010; Sastre et al., 2011; Dobos et al., 2012). Recent 
findings have shown that poorer cognitive function in female gender is significantly 
associated with increased peripheral pro-inflammatory markers compared to males (Candore 
et al., 2006; Marsland et al., 2006; Trailor et al., 2010; Canon and Crimmins, 2011) suggesting 
that cognitive function of aged females might also be more susceptible to increased 
inflammatory mechanisms. Understanding biological factors associated with late-life 
depression and their connection with specific risk factors for certain diseases such as AD can 
provide a significant leap toward understanding its etiology and developing preventative 
measures. Neutrophil Gelatinase Associated Lipocalin (NGAL) has recently been identified 
as an inflammatory maker in late-life depression (Naude et al., chapter 5), MCI (Choi et al., 
2011; Naude et al., 2012) and was also shown to be associated with the pathology of AD in 
post mortem human brain tissue and (Naude et al., 2012). 
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For that reason this study aims to investigate the relationship between plasma NGAL and 
cognitive functioning in a large sample of elderly people. The overall hypothesis is that 
increased N GAL plasma levels in humans are associated with impaired cognitive functioning. 
This general hypothesis is specified as follows. Since NGAL is most abundantly expressed in 
the hippocampus (Naude et al. chapter 5) higher NGAL levels might be specifically associated 
with declarative memory impairment ( and not or less pronounced with executive 
functioning). Secondly, based on previous results of increased NGAL plasma levels in 
depression (Naude et al., chapter 5), we expect stronger associations among persons suffering 
from late-life depression. 
Methods 
Sample 
The Netherlands Study of Depression in Older people (NESDO) is a multi-site cohort study 
designed to examine neurobiological and psychosocial determinants of the course and 
consequences of late-life depression. The study is described in full detail elsewhere (Comijs et 
al., 2011), and can be summarised as follows. The total NESDO sample consists of 510 
participants aged 60 through 93 years. There were 378 depressed persons with a current 
diagnosis of major depressive disorder, minor depression or dysthymia (fulfilling research 
diagnostic criteria in the past 6 months), and 132 non-depressed persons included in the 
study. Depressed persons were recruited from mental health care institutes and from primary 
care. The non-depressed subjects were recruited from primary care practices. Persons with a 
primary diagnosis of dementia or under suspicion of dementia by their clinician were 
excluded from participation in NESDO. Furthermore, persons scoring less than 18 points on 
the Mini-Mental State Examination (MMSE, range 0-30; Folstein et al. 1975) were also 
excluded. Hence, all participants had no or mild cognitive impairment, but can be considered 
at risk of developing dementia in the upcoming years by having a diagnosis of late-life 
depression. 
All participants underwent a baseline examination at one of the research locations or at the 
homes of the participants. The baseline examination included amongst others 
neuropsychological testing, the collection of blood samples, a diagnostic interview and 
written questionnaires. Ethical review boards of all participating institutes approved the study 
protocol. 
Main outcome variables: Cognitive peiformance 
Cognitive performance was tested by a short neuropsychological test battery. To assess 
cognitive performance in the memory domain, a modified version of the auditory verbal 
learning test (Rey, 1964) was administered. In this modified version 10 instead of 15 words 
has to be learned, which makes it more feasible for use in an elderly depressed population. 
This test is a modified version of the commonly used 15 words learning test that was 
shortened for use in an elderly population. The participants were instructed to memorize a list 
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of 10 words that were presented in a standardized order. The test consisted of 5 sessions of 
immediate recall and after 15-25 minutes one session of delayed recall. The total score in the 
delayed recall condition (range: 0-10) was used as a measure of memory performance (Rey, 
1964). To assess executive functioning, the abbreviated version of the STROOP colour-word 
test (Stroop, 1935) was administered. The difference score between the interference card 
(incongruent colors and words) and the mean value of the pure text and pure colour card was 
used as a measure of the STROOP interference effect (I<lein et al., 1997). A higher STROOP 
interference score is thus indicative for worse executive functioning. 
A na!Jsis of plasma NGAL 
Blood samples were collected in the morning to standardize for collection time as described 
(Comijs et al., 2011). All samples were processed within one hour and subsequently stored at 
-80 °C. Blood sample handling and analysis was performed as described previously (Naude et 
al. in prep). Briefly, quantification of NGAL from plasma was performed via a constructed 
sandwich ELISA using human Lipocalin-2/NGAL ELISA capture antibody (R&D Systems), 
recombinant human Lipocalin-2/NGAL (R&D Systems) for the internal standard and 
biotinylated human Lipocalin-2/NGAL detection antibody (R&D Systems). Plasma was 
diluted 1:100. A blinded ELISA analysis was performed on coded samples. 
Potential moderators of association NGAL and cognition: depression status and gender 
Depression was considered a potential moderator of the association between NGAL and 
cognitive performance. Diagnosis of depression and dysthymia according to DSM-IV-R 
criteria (AP A, 2000) are assessed with the Composite International Diagnostic Interview 
(CIDI; WHO version 2.1; 24 month version). The CIDI is a structured clinical interview that 
is designed for use in research settings and has high validity for depressive and anxiety 
disorders (Wittchen et al., 1991; Kessler et al., 2010). We added some questions to determine 
the research DSM-IV diagnosis of current minor depression (Comijs et al 2011). Information 
on gender was also available from the CIDI interview. 
Covariates 
In a previous study, demographical, lifestyle and somatic determinants of NGAL 
concentrations were identified as potential cofounders (Naude et al., chapter 5). Given that 
several of these variables might confound the association between NGAL concentrations and 
cognitive performance, the statistical analyses were adjusted accordingly. Demographic data 
on age and education level were collected during the interview. Lifestyle factors were assessed 
by means of self-report. Information about smoking was categorized into current smoker, 
former smoker and never smoked. Alcohol use was measured by the Alcohol Use 
Identification Test (AUDIT; manual WHO 2001) and based on the first two questions on 
frequency of drinking days and number of drinks on an average drinking day, categorized into 
severe alcohol use, moderate alcohol use and no alcohol use. Physical activity was measured 
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with the last-seven-days short-form (8-items) of the self-administered version of the 
International Physical Activities Questionnaire (IPAQ; (Craig et al., 2003). Psychometric 
properties of the long and short version of the IP AQ are satisfactory for research purposes 
(Craig et al., 2003). IPAQ scores were categorized into low, moderate and high physical 
activity. Somatic health was determined by means of self-report, body measurements and 
drug container inspection. A self-report questionnaire provided information on the presence 
of chronic somatic diseases. It was developed by Statistics Netherlands (Centraal Bureau voor 
de Statistiek, www.CBS.nl) (Kriegsman et al., 1996). As cognitive functioning is specifically 
associated with vascular disease, two variables were created. First, the presence of vascular 
disease, defined as either having a heart disease or stroke (yes/ no) and secondly, the total 
number of non-vascular chronic diseases (continuous variable). Abdominal circumference 
was measured in centimetres by an objective, standardized assessment and the measure was 
treated as a continuous variable. Medication use was determined by drug container 
inspection of all drugs used in the past month and classified according to the World Health 
Organization Anatomical Therapeutic Chemical classification (ATC) (see reference, World 
Health Organization). We controlled for all drugs with anti-inflammatory properties which 
were taken on a regular basis (at least 50% of the days). Anti-inflammatory drugs were 
combined into categories of corticosteroid (H02A/H02B), non-steroid (M01A) and other 
drugs (A07EB/ A07EC/M01B). Acetyl salicylic acid (N02B) and statins (C10AA/C10B), 
which also have anti-inflammatory properties, were treated as separate categories. 
S tatisticai ana!Jses 
Distributions of the variables were inspected. In order to obtain a normal distribution of the 
plasma NGAL concentrations, eight positive outliers were trimmed at the mean level plus 
three SD (60.246 + 3*24.836), resulting in an acceptable skewness of 1.58 and kurtosis of 
0.76. The total score of the delayed recall condition in the 10 words test showed a normal 
distribution. The interference score of the STROOP test was positively skewed. As log­
transformation of the interference score was normally distributed (skewness of 0.30, kurtosis 
of 1.16), all analyses were conducted on the log-transformed score. As some covariates had 
missing data, we imputed the mean value of the other subjects in case of continuous variables 
or the modal score in case of dichotomous or nominal data. Variables with missing values 
were: alcohol use (n=9), smoking status (n=3), waist circumference (n=3), physical activity 
(IPAQ score, n=15), cognitive functioning (MMSE score, n=1), and finally the number of 
chronic diseases (n=1). Data were complete for all other variables. 
Multiple linear regression analyses were conducted separately for both cognitive domains, 
with delayed recall score and STROOP interference score as the dependent variables, to 
examine their associations with plasma NGAL concentrations adjusted for confounding 
variables. Moderating effects of depression status (yes/no) and gender (male/female) were 
examined by adding interaction terms to the models. By convention, p-values were 
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considered statistically significant at a value of less than .05 in general or less than .10 for 
interaction terms. All analyses were conducted with SPSS version 18.0. 
Results 
Data on NGAL were missing for 9/359 (2.5%) depressed persons and 3/132 (2.3%) non­
depressed controls. Table 6.1 presents sample characteristics stratified for depression status 
and gender. Plasma NGAL concentrations differ between the four groups (F=5.9, df=3,494, 
p= .001), with non-depressed females having significantly lower NGAL concentrations 
compared to depressed males (p=.001) and depressed females (p=.024) (see figure 6.1). 
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Table 6.1. Sample characteristics stratified for depression status and gender 
Variables of interest 
Demographics: 
1 •emalc sex, 11 (%) 
A�e (years), mean (SD) 
Education (years), mean (SD) 
T jfcstyle: 
Currently smoking, n (%) 
Alcohol use: 
No alcohol use, n (%) 
Moderate use, n (%) 
Problematic/severe use, n (%) 
Waist circumference (cm), mean (SD) 
Physical activity (IPAQ categories): 
I .ow, n (%) 
Moderate, n (%) 
High, 11 (!1/ri) 
Physical and mental functioning: 
Depressive symptoms (IDS), mean (SD) 
Chronic disease (no), mean (SD) 
Vascular disease, n (%) 
Anti-inflammatory drug (AlD) use, n (%) 
Corticosteroid All) use, n (%) 
Non-steroid AID use, n (%) 
Other A] D use, n (0/ii) 
Salicylic use, n (%) 
Statin use, n (%) 
Co1:,rnitive functioning: 
Global cognitive functioning (MMSE), mean 
(SD) 
Delayed recall (10 words test), mean (SD) 
Non-depressed persons 
All Male Female 
(n=129) (n=SO) (n=79) 
79 (61 .2) 
70.1 (7.2) 69.9 
(7.5) 
12.5 (3.5) 1 3.6 
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I �xecutivc functioning (interference score 1 .06 1 .10 1 .04 1 .46 1 .44 1 .47 
STROOP test), mean (SD) (0.44) (0.93) (0.43) (0.99) (0.99) (1.04) 
Abbreviations: n, number; SD, standard deviation; IP AQ, International Physical Activities 
Questionnaire; MMSE, Mini Mental State Examination; no, number; AID, anti-inflammatory drugs; 
IDS, inventory of Depressive Symptoms. 
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Within the whole sample, plasma NGAL concentrations were negatively associated with the 
delayed recall of the 10 words test (Pearson's correlation coefficient: r= -.17, p< .001) and 
positively associated with the interference score of the STROOP test (r=.15, p=.001). 
Multivanate ana/yses ofNGAL concentrations and delqyed recall of the 10-words test 
Regressing plasma NGAL concentrations on the delayed recall of the 10-words test and fully 
adjusting for potential confounders, yielded a significant three-way interaction between 
plasma NGAL level, depression status and gender (p=.074). Therefore, subsequent analyses 
were performed stratified for depression status and gender. As shown in table 6.2, increased 
plasma NGAL concentrations were associated with impaired memory function among 
depressed females, but not in any of the other groups. This association remains significant 
even after correction of demographic, physical and life-style characteristics. 
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Table 6.2. Multiple linear regression analyses stratified for depression status and gender on the 
association between delayed recall 10 words test (dependent variable) and plasma NGAL level with 
different levels of adjustment for confounding variables (model 1 - 4) 
Non-depressed persons (n=129) Depressed persons (369) 
Males (n=50) Females (n=79) Males (n=124) Females (n=245) 
Model B (SE) � p B (SE) � p B (SE) � p B (SE) � p 
-(1.1)1 (0.01) -. 13 .370 -0.02 (0.01) -.20 .085 -0.00 (0.01) -.01 .941 -0.02 (0.01) -.21 .001 
2 -0.00 (0.02) -.03 .853 -0.00 (0.01) -.(Jl .961 0.01 (0.01) .09 .303 -0.02 (0.01) -.15 .018 
1 0.00 (0.02) .00 1 .00 -0.00 (0.01) -.()1 .914 0.01 (0.01) .08 .414 -0.01 (0.01) -.14 .040 
4 -0.02 (0.02) -. 19  .266 (l.00 (0.01) .03 .809 ().()1 (0.01) .10 . 31 5 - -0.01 (0.01) -.14 .045 
1 Unadjusted model 
2 Adjusted for demographics (age and educational level) 
3 Adjusted for demographics & medical status (age, educational level, number of chronic diseases, 
presence of vascular disease, anti-inflammatory drugs, and depressive symptoms) 
4 Adjusted for demographic, medical status and life-style (age, educational level, number of chronic 
diseases, presence of vascular disease, anti-inflammatory drugs, depressive symptoms, smoking, use of 
alcohol, waist-circumference and physical activity) 
Multivariate anafyses efNGA.L concentrations and the intetference score ef the STROOP test 
Regressing plasma NGAL concentrations on the interference score of the STROOP test and 
fully adjusting for potential confounders, did not yield a significant three-way interaction 
between plasma NG.AL level, depression status and gender (p=.54). Excluding this three-way 
interaction yielded a significant interaction between plasma NG.AL level and gender (p=.024), 
but not with depression status (p=.99). Therefore, subsequent analyses will be stratified for 
gender only. As shown in table 6.3, higher plasma NG.AL concentrations were associated 
with worse executive functioning in males, but not in females. This association remams 
significant after controlling for demographic, physical and life-style characteristics. 
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Table 6.3. Multiple linear regression analyses stratified for gender on the association between 
interference score of the STROOP test (dependent variable) and plasma NGAL level with different 
levels of adjustment for confounding variables (model 1 - 4) 
Males (n=174) Females (n=324) 






























3 Adjusted for demographics & medical status (age, educational level, number of chronic diseases, 
presence of vascular disease, anti-inflammatory drugs, and depressive symptoms) 
4 Adjusted for demographic, medical status and life-style (age, educational level, number of chronic 
diseases, presence of vascular disease, anti-inflammatory drugs, depressive symptoms, smoking, use of 
alcohol, waist-circumference and physical activity) 
S ensitiviry anafysis 
In order to examine whether the results are indeed specific for the cognitive domains under 
study, we repeated all analyses additionally adjusted for the MMSE score as a measure for 
global cognitive functioning. These analyses yielded comparable results (data not shown) . 
Discussion 
In accordance with our hypothesis; increased plasma NGAL concentrations are significantly 
associated with impaired cognitive functioning in older people. Furthermore, our results are 
in accordance with previous findings, suggesting that alterations of certain inflammatory 
markers are associated with impaired cognitive function (Candore et al., 2006; Marsland et al., 
2006; Trailor et al., 2010; Canon and Crimmins, 2011) . Stratified analyses for depression 
status and gender, showed that plasma NGAL concentrations were only associated with 
memory function in depressed females. The association between plasma NGAL and 
executive dysfunctioning was independent of depression status and only present among male 
subjects. These associations appeared to be independent of demographic characteristics, 
physical functioning, drug use and life-style. 
Data from our study is in line with a thought-provoking review on the role of gender in 
mediating the inflammatory pathway within the pathophysiology of Alzheimer's disease 
(Candore et al., 2006; Marsland et al., 2006; Trailor et al., 2010; Canon and Crimmins, 2011) . 
Impaired memory assessed by delayed word recall test, has been shown to be effective as 
predictor for possible early AD in people with late-life depression (Lachner and Engel, 1 994; 
Coen et al., 1997; Kiinig et al., 2006) . These findings are further strengthened by a study 
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showing that depressed females had reduced hippocampus volumes associated with poorer 
memory function measured with the delayed word recall test (Sheline et al., 1999) and also 
shown in females from the Nun-study (Mortimer et al., 2004). Furthermore, addition of the 
delayed recall of word test has been shown in more recent studies as an important assessment 
to improve the detection for MCI patients that converted to AD (Tabert et al., 2006; Sano et 
al. , 201 1 ). In summary these findings suggest that affected cognitive domains associated with 
their biological abnormalities may illustrate the heterogeneity of depression in the elderly and 
may also predict possible risk factors for certain disease. In this respect, hippocampus 
associated memory impairment, especially with the presence of depressive symptoms has 
been described as a high risk factor for the development of AD (Laakso et al., 1996; Gauthier 
ct al. , 2006). In patients with non-AD dementia, e.g. vascular dementia, memory impairment 
is generally less pronounced, whereas executive dysfunctioning is often regarded as the 
primary cognitive deficit (Roman and Royall, 1999; Graham et al., 2004). 
Declining executive function is a frequently observed feature of cognitive impairments that 
occur as a result of brain aging (Lewis and Miller, 2007). Reduced executive functioning is 
commonly present in patients with late-life depression (Alexopoulos et al. , 2002; Elderkin­
Thompson et al., 2003), whereas episodic memory impairment is not specifically associated 
with late-life depression (Herrmann et al., 2007; Elderkin-Thompson et al. , 201 1). Studies 
have reported that white matter abnormalities and cerebrovascular disease in late-life 
depression are mainly associated with decreased executive function (Sheline et al., 2006; 
Kohler et al., 2010; Mettenburg et al., 2012). Since we found only an association between 
plasma NGAL concentrations and executive functioning in males, it might be that increased 
concentrations are caused by subclinical vascular disease. Although we corrected for 
depressive symptoms and vascular disease status, results may still be confounded by the 
severity of atherosclerosis. It is known that atherosclerosis is a low-graded inflammatory 
process which precedes vascular events and which is in generally more severe in males 
compared to females. 
Recent data showing increased plasma NGAL associated with MCI (Choi et al. , 201 1)  and 
late-life depression (Naude et al., chapter 5) led to the interest of association of NGAL in a 
high risk group possibly developing AD. Further evidence of increased NGAL protein 
concentrations were shown to be located in the brain regions associated with AD pathology, 
particularly in neurons in the hippocampus measured in post mortem human brain tissue 
(Naude et al., 2012). The effect of increased NGAL in the hippocampus of a mouse model of 
stress further illustrated that it reduced neuronal growth and maturation of hippocampal 
neurons (Mucha et al., 201 1 ). Even though we analyzed circulating peripheral NGAL 
concentrations, a close connection between peripheral inflammation and NGAL expression 
in the CNS was demonstrated whereby immunostimulation via peripheral lipopolysaccharide 
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injection in mice as an inflammatory trigger, resulted in increased neuronal NGAL (Ip et al., 
201 1 ). 
The connection of estrogen concerning its immunomodulatory properties might shed some 
light on the observed effect of female gender on increased NGAL concentrations and lower 
memory function in late-life depressed patients in this study. Estrogens possess anti.­
inflammatory properties which have been presented as a mechanism attributing to its 
neuroprotective roles by down-regulating neuroinflammation especially in the presence of 
pathology of AD (Vegeto et al., 2008; Prat et al., 201 1 ). In relation to NGAL it has been 
shown that estrogen can inhibit epithelial cells to produce NGAL in vitro upon stimulation of 
lipopolysaccharide (Gao et al., 2006). These findings merits the speculation that the loss of 
estrogen in elderly women (Wise, 1999) might consequently contribute to altered NGAL 
regulation. Of note, further evaluation on the effect of hormonal replacement therapy in 
post-menopausal women on plasma NGAL concentrations and its relation to depression and 
cognitive impairment in this study will therefore be of interest in the near future. In essence 
these findings indicates that NGAL might play a vital role in the newly suggested 
"neuroinflammation hypothesis" as etiology of cognitive impairment, particularly associated 
with late-life depression (Craddock and Thomas, 2006; Eikelenboom et al., 2006; Hoozemans 
et al., 2006; Caraci et al., 2010; Haroon et al., 2012). 
Although our study has major strengths including sample size, the use of a comprehensive 
battery of neuropsychological tests and the correction of a variety of confounding factors that 
influences inflammation, some methodological issues warrant attention for proper 
interpretation. First, the NESDO study was primarily set up to study the course and 
consequence of late-life depression. Therefore, the comparison group was relatively small, so 
the absence of effects in non-depressed older females should be confirmed in larger samples. 
Secondly, NESDO included only persons v.rith an MIYISE score of 1 8  or higher. On the one 
hand, this may have attenuated the effects we found. On the other hand, it may also be tl1at 
plasma NGAL concentrations are only an early marker for pathogenic processes. In that case, 
plasma NGAL concentrations may be a promising biomarker for early conversion to AD in 
late-life depression. Thirdly, a larger battery of tests for cognitive functioning including more 
tests for memory function and executive functioning would probably have provided more 
robust results. A final issue might be the cross-sectional nature of the study. However, results 
are promising, and warrant future longitudinal studies. 
In summary, one may speculate that NGAL is an early marker placing depressed older 
women at risk for conversion to Alzheimers's disease, whereas NGAL in males might be 
more closely related to subclinical vascular functioning. We conclude that our findings of 
NGAL can contribute to the growing knowledge of biological markers that may indicate a 
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Dysregulation of immune functioning during ageing can have a substantial influence to 
morbidity and mortality in humans (Bruunsgaard et al., 2001; Krabbe et al., 2004; Franceschi 
et al., 2007). In this respect, a recently published article of an 11 year follow-up study in 1393 
community-dwelling older adults showed that increased Lcn2 was significantly associated 
with mortality (Daniels et al., 2012). Successful ageing in humans on the other hand have 
been associated with optimal functioning of the immune system e.g. reduced pro­
inflammatory environment (Franceschi et al., 1995; Naumova et al., 2011). Evidence of 
increased pro-inflammatory markers associated with neurodegenerative diseases and the link 
with depressive mood have also been documented (Caraci et al., 2010), especially for TNF-cx 
(McCoy and Tansey, 2008; Clark et al., 2010). However, the "neuroinflammation hypothesis" 
in relation to AD pathology and occurrence of depressed mood, particularly in the elderly, 
has only emerged relatively recently. This new concept has also initiated new insights to the 
existing "A� hypothesis" for AD and "monoamine hypothesis" for depression. This notion 
has also led to the understanding of the complexity of neuroinflammation in the ageing brain 
and its relation to diseased states. IL-6, TNF-cx and CRP are the most commonly studied 
inflammatory proteins associated with depressive mood in the elderly and patients with MCI 
and AD (Dowlati et al., 2010a; Swardfager et al., 2010). TNF-cx in particular, possesses 
interesting functions in the CNS; being a potent neuroprotective, pro-inflammatory and pro­
apoptotic agent, depending on the physical environment (chapter 2). These intrinsic 
properties of TNF-cx triggered immense interest in the research community and 
pharmaceutical industry to develop drugs and biologics that modulates specific TNF-cx 
signaling mechanisms as treatments for depression and certain neurodegenerative disorders 
(McCoy and Tansey, 2008; Soczynska et al., 2009). However, ageing leads to complex 
restructuring of the innate and adaptive immune system (Weiskopf et al., 2009). In this 
regard, functions of TNF-cx have also been shown to be affected by ageing (Paolisso et al., 
1998; Bruunsgaard et al., 2000; Kirwan et al., 2001; Patel and Brewer, 2008a; Agius et al., 
2009). The aim of chapter 3 was to elucidate if the normal physiological effects of TNFR1 
and TNFR2 in an aging brain in vivo which according to our best knowledge has not been 
investigated. 
In chapter 3 we examined the effect of aging on TNFR1 and TNFR2 CNS functioning by 
assessing cognitive, behavioral and physical performance. The main finding in this chapter 
was that TNFR2 is pivotal for normal hippocampal-dependent performance, regardless of the 
ageing process. In addition, we found that TNFR2 is important for optimal physical 
performance. Ageing had no adverse effects on either TNFR1 or TNFR2 functioning and vice 
versa. This study together with existing literature (McCoy and Tansey, 2008; Nijholt et al., 
2011) indicates that TNFR1 antagonists or TNFR2 agonists seems like a rational therapeutic 
approach for neurodegenerative diseases in the elderly. However, caution should be taken 
when targeting TNFR2 with an agonist, since literature revealed that long term TNFR2 
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activation can lead to cellular apoptosis (Bigda et al., 1994; Medvedev et al., 1994; Grell et al., 
1999; Chan et al., 2003; Depuydt et al., 2005). Furthermore, upregulated TNFR2 expression 
have also been associated with autoimmune diseases (Faustman and Davis, 2010). Of note, it 
would be of interest to repeat these experiments in mice challenged with an activator of 
neuroinflammation to further validate their functions during neuroinflammatory conditions. 
Genetically modified mouse models provided interesting evidence concerning the protective 
effect of TNF-(X in AD. Increased hippocampal expression of murine TNF-(X showed 
neuroprotective effects and attenuation of A� formation (Chakrabarty et al., 2011). A similar 
effect was observed in an AD mouse model, deficient of TNFR1 (He et al., 2007). 
Interestingly, deletion of both TNFR1 and TNFR2 in an AD mouse model aggravated AD 
pathology (Montgomery et al., 2011). Collectively these findings suggest that attenuation of 
TNFR1 signaling can serve as a promising therapeutic target in treating AD. 
Primary murine cortical neurons were stimulated with TNF-(X the gene expression pattern 
was analyzed by gene array with the aim to identify novel neuroprotective targets induced by 
TNF-(X (Chapter 4). This led to the identification of Lcn2. Knowledge of the functions and 
production of Lcn2 in the CNS was still unknown at the commencement of our investigation. 
Only two studies of the effects of Lcn2 on neuronal cells were published, showing that Lcn2 
sensitizes microglia (Lee et al., 2007) and astrocytes (Lee et al., 2009) to apoptosis in vitro. A 
striking finding with our further investigation was that Lcn2 is increased solely via TNFR1 
mediated stimulation in neurons, astrocytes and microglia cells. The time kinetics leading to 
Lcn2 protein increase (::::: 24-36 hour) found in this study, is exceptional for TNFR1 mediated 
signaling. Interest regarding this issue has led to the following plausible explanation also 
illustrated in Figure 7.1. TNFR1 mediated signaling leads to NF-xB mediated transcription. 
Increased NF-xB activation subsequently leads to increased IkappaB-zeta (IxB-Q protein 
production, a newly identified transcription factor (Yamazaki et al., 2001). Increased IxB-t;; 
accordingly associates with NF-xB, leading to the induction of Lcn2 production (Karlsen et 
al., 2010) (Figure 7.1). Further investigation to clarify the proposed mechanism surely might 
be of interest for specialists in this field. 
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Figure 7 .1. Illustration of proposed mechanism responsible for the delayed TNFRl mediated Lcn2 
production. 
Chapter 4 also provides new insights in the signaling mechanisms of TNP-cx. In brief, we 
found that TNPR1 mediates Lcn2 production, which in turn can act in an autocrine manner 
(Lee et al., 2009), silencing the TNPR2 mediated PI3K/p-AKT neuroprotective pathway. 
This further contributes to the intricate crosstalk between TNPR1 and TNPR2 as discussed 
in chapter 2. Neuronal upregulation of TNPR1 and downregulation of TNPR2 during AD 
(Cheng et al., 2010) together with chronically increased Lcn2 levels, might further exacerbate 
the pro-apoptotic environment. 
The biological functioning of Lcn2 via its two receptors is another important aspect for 
discussion regarding our findings. Megalin (Hvidberg et al., 2005) and 24p3R (Devireddy et 
al., 2005) are the two known receptors that bind to Lcn2. Megalin mainly functions as a 
transporter and binds to a variety of ligands (Nagai et al., 2003). Studies have shown that 
megalin expression is decreased in AD leading to decreased A� transport form the brain to 
the CSP (Pascale et al., 2011). This could also be an explanation for the decreased Lcn2 
concentrations found in the CSP of AD patients. However, the functions of 24p3R are still 
quite unclear. Our in vitro data showed increased 24p3R expression in murine primary cortical 
neuron cells after incubation with TNF-cx. However, western blot analyses showed no 
differences in 24p3R levels between brains of AD compared to control. A recently published 
article showed that 24p3R expression in the brain is specifically located on neurons in mice 
(Ip et al., 2011) . It should be noted that in this study, western blot analyses were performed 
with samples that contained a membranous protein extract from brain tissue, containing 
various cell types. Immunohistochemistry or in situ blotting enabling the detection and 
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quantification of 24p3R protein expressed in localized tissue should preferably be used in 
future studies to provide a clearer result of its regulation during AD. 
We found that Lcn2 sensitized A�-induced toxicity and not glutamate-induced tox1e1ty. 
Lipocalins are a family of proteins that bind to numerous hydrophobic molecules (Breustedt 
et al., 2006). This led to the question whether Lcn2 can possibly also bind to A�42 because of 
its hydrophobic properties. We therefore performed a preliminary in vitro study by incubating 
primary cortical neurons with sub lethal concentrations of A�42, with or without Lcn2. 
Results from this pilot experiment indicated that Lcn2 co-incubated with A�42 resulted in a 
significantly higher intracellular A�42 concentration compared to A�42 incubated withour 
Lcn2 (Figure 7.2). This preliminary result proposes that Lcn2 might bind to A�42, facilitating 
its transport into the cell, possibly via a receptor of Lcn2. This suggestion supports the new 
hypothesis that intracellular A�42 induced cell toxicity to be an important mechanism for cell 
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Figure 7.2. Murine primary cortical neurons were treated with sub lethal A�42 (10 µM), with or 
without Lcn2 (200 ng/ ml) for 24 hours. Intracellular A�42 were determined via western blot. Error bars 
represent sem. * p < 0.05. 
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AD related pathology can occur up to two decades before clinical symptoms of dementia 
appear (Reaume et al., 1996; Holmes et al., 2008; Jack Jr et al., 2011; Sperling et al., 2011). 
Evidence strongly suggests late-life depression as common risk factor, prodrome and 
accompanying symptom of people with AD (Brommelhoff et al., 2009; Panza et al., 2010; 
Enache et al., 2011; Steenland et al., 2012). In respect with the supposed etiology of dementia, 
the inflammatory hypothesis might thus be particularly true in late-life depression (Craddock 
and Thomas, 2006; Eikelenboom et al., 2006; Hoozemans et al., 2006). 
Research in chapter 5 investigated symptoms of late-life depression and its association with 
circulating Lcn2 concentrations was investigated from the NESDO cohort study (Comijs et 
al., 2011). The key finding in this study was that Lcn2 is significantly associated with the 
current state of depressive symptoms even after corrections for confounding factors were 
done. Confounding factors from this well executed study also contributed to the following 
important understandings of Lcn2: 
• Increased circulating Lcn2 is significantly correlated with increased age. 
• Anti-depressant medication does not have an effect on Lcn2. 
• Lcn2 concentrations are lifestyle dependent - increased Lcn2 associated with an 
unhealthy lifestyle e.g. increased waist circumference, smoking and decreased activity. 
The presence of memory impairment with late-life depression greatly increases the risk factor 
for the development of AD (Potter et al., 2012). Tests assessing certain cognitive functioning 
were performed in the NESDO study. We found it of interest to further investigate whether 
circulating Lcn2 concentrations were associated with cognitive impairments together with the 
presence of depressive symptoms (chapter 6). Intriguingly, plasma Lcn2 concentrations are 
significantly increased in depressed aged females with hippocampus dependent memory 
impairments. In this chapter, we speculated that this finding might be connected to the 
decrease of estrogen in post-menopausal women. Estrogen deficiency has been associated 
with increased risk of AD in females (Paganini-Hill and Henderson, 1994). These protective 
effects of estrogen in the brain is mainly due to its anti-inflammatory functioning (V egeto et 
al., 2008). Collective data provided concrete evidence for the use of estrogen as treatment in 
females to prevent AD, but this treatment regime is highly dependent on the timing of 
treatment during the disease development (Petrovska et al., 2012). Our finding seems of 
utmost interest for future studies to investigate Lcn2 as a biomarker to identify a subgroup of 
patients with preclinical AD, who might greatly benefit from treatment with hormonal 
replacement therapy. Furthermore, quantification of Lcn2 concentrations at different 
intervals during treatment might also be useful as indicator for treatment efficacy during e.g. 
hormonal replacement therapy. Of note, NESDO is a 2 year follow-up study. It would be of 
great interest to correlate plasma Lcn2 concentrations with the cognitive performance to 
validate Lcn2 as potential marker for detection of pre-clinical AD. 
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Application of findings and future perspectives 
Lcn2 as biomarker 
Data from this thesis indicate Lcn2 as potential biomarker for late-life depression and 
preclinical/prodromal AD. However, it should be kept in mind that Lcn2 levels are also 
affected with the occurrence of other illnesses as cardiovascular diseases and kidney disease 
(Bolignano et al., 2010a) and possibly cancer (Bolignano et al., 2010c). For this reason, the 
ratio of Lcn2 as key component in combination with multiple markers e.g. A�42, which are 
unique to pre-clinical AD pathology seems to be the most sensible approach for future 
studies. CSF provided the most robust differences in Lcn2 concentrations between non­
demented controls and MCI/ AD patients. Our data show that CSF analysis will provide the 
most differential outcomes between AD and non-AD pathology. This suggestion is further 
supported by the explanation that Lcn2 and A�42 are both transported by megalin from the 
brain to the CSP as mentioned in chapter 4, indicating that Lcn2 concentrations are 
additionally affected by underlying AD pathology. Of note, urine should also be considered 
as source for testing Lcn2 in future studies. The physical properties of NGAL makes it 
suitable for application as a biomarker since it is resistant to proteolytic degradation (Kjeldsen 
et al., 1993), possesses great storage stability and can be analyzed from a variety of bodily 
fluids such as serum, plasma and urine (Pedersen et al., 2010). 
Lcn2 as drug target 
Conclusions from studies investigating new preventative treatment strategies for AD reiterate 
that timing is of utmost importance for positive outcomes. Earliest possible detection of AD 
pathology and subsequent preventative treatment strategies seems to be the most beneficial 
approach for future studies aimed to investigate treatments for AD. Data from this thesis 
strongly indicates Lcn2 as novel therapeutic drug target to prevent neuronal damage caused 
by AD pathology. This concept is further supported by recent animal studies showing that 
increased Lcn2 production can aggravate neuronal damage in a spinal cord injury (Rathore et 
al., 2011) and that Lcn2 can have a negative effect on the hippocampus (Mucha et al., 2011). 
Crossbreeding Lcn2 knockout mice with a transgenic mouse model for AD will create a 
mouse model that will provide fundamental knowledge regarding the functions of Lcn2 in the 
pathology of AD. 
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New therapeutic strategies directed to reduce Lcn2 production 
The aim should be to attenuate Lcn2 production to normal physiological levels and not to 
abrogate Lcn2 protein levels. Mice deficient of Lcn2 showed that diminished Lcn2 can have 
undesirable effects such as increased risk of infections (Flo et al., 2004). 
• Data from this thesis suggests that compounds antagonizing TNFR1 mediated 
signaling seems as a promising solution to decrease Lcn2 production. Data from 
chapter 4 suggests that an agonist for TNFR2 in the presence of high Lcn2 
concentrations can direct a shift towards a proapoptotic signaling mechanism. The 
ability of a drug to cross the blood brain barrier is a major obstacle when designing 
new compounds targeting CNS related diseases. This issue was recently solved by 
engineering an antibody against TNF-cx, that is efficiently transported into the brain via 
the transferrin receptor (Zhou et al., 2011). Newly engineered antagonistic antibody 
for TNFR1 has also recently been described (K.itagaki et al., 2012) and are currently 
being investigated. 
• Targeting IxB� activity is a novel and interesting approach in order to decrease Lcn2 
production during inflammation. Targeting IxB� might also reduce production of other 
inflammatory proteins; Il-6 (Miyake et al., 2010) and Interferon-y (Raices et al., 2009), 
indicating a promising target for not only for AD but also depression. 
• The use of estrogen in females with preclinical forms of dementia also seems 
promising. An In vitro study showed that estrogen reduced Lcn2 expression in vascular 
wall cells treated with LPS (Gao et al., 2006). Estrogen receptor � specific agonists 
have recently been describe to repress neuroinflammation (Gosselin and Rivest, 2011). 
However, timing of treatment with estrogen in AD is of highest importance (Petrovska 
et al., 2012). 
• The use of antibodies neutralizing Lcn2, similarly being used against TNF-cx, might be 
an option. However, this approach has its drawbacks due to the following reasons. 
Normal circulating Lcn2 concentrations (::::60 ng/ ml) are much higher compared to 
that of TNF-cx (�4 pg/ml). Much more antibody should therefore be administered to 
neutralize Lcn2 compared to that for TNF-cx. Production of antibodies is also 
extremely expensive. An alternative therapeutic would be to design small 
molecules/peptides that specifically neutralize Lcn2 mediated effects. In this respect, 
molecules inhibiting Lcn2 to bind to its pro-apoptotic receptor, 24p3R seems to be an 
interesting approach for future investigations. 
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• A healthy lifestyle has been shown as one of the best preventative measures against 
AD. Adequate physical exercise (Liang et al., 2010) and a healthy diet, in particular the 
Mediterranean diet (Solfrizzi et al., 2003; Luchsinger and Mayeux, 2004; Scarmeas et 
al., 2009), have been associated with reduced incidence of AD and lower inflammation 
in patients with late-life depression (Milaneschi et al., 201 1) .  Increased Lcn2 
concentrations found in association with an unhealthy lifestyle ( chapter 5) further 
supports this strategy. 
Concluding remarks 
The ageing process is associated with increased Lcn2. Lcn2 is significantly increased with the 
occurrence of late-life depression, memory complaints and pathology of AD. Lcn2 causes a 
molecular signaling imbalance, shifting cells towards a pro-apoptotic state, thus abating the 
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Figure 7.3. Model of Lcn2 as molecular constituent in the ageing process. Lcn2 increases with the 
normal ageing process. However, Lcn2 is significantly increased during late-life depression, MCI and 
AD. Lcn2 can silence the protective molecular signaling mechanisms of neuroinflammation and also 
sensitize neurons to toxic substances associated with AD. Chronic neuronal exposure to high levels of 




All together these findings provoke the thought that chronically increased Lcn2 causes 
disequilibrium of immune functioning during the ageing process, shifting the balance towards 
its damaging effects and can therefore further contribute to frailty. This thesis presents Lcn2 
as a novel element in the newly introduced model of neuroinflammation hypothesis and 
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Nederlandse samenvatting 
De meeste mensen, zo niet alle mensen die deze samenvatting lezen, hebben persoonlijk 
iemand ontmoet of weten van iemand die gediagnosticeerd is met de ziekte van Alzheimer. 
De ziekte van Alzheimer is een neurodegeneratieve ziekte die voornamelijk voorkomt bij 
oudere mensen. De eerste tekenen van de ziekte van Alzheimer bestaan uit 
geheugenproblemen die geleidelijk ernstiger warden over de tijd, waarna andere functies die 
aangedreven warden door hersenen aangetast raken zoals het taalvermogen en de 
lichaamsfuncties, uiteindelijk leidend tot de dood. De beschrijving van deze ziekte toont aan 
waarom de ziekte van Alzheimer een van de meest gevreesde ziektes is. Bovendien is het op 
dit moment nog niet mogelijk om de ziekte van Alzheimer te genezen, voornamelijk omdat 
we de etiologie van laat beginnende Alzheimer's nog niet ontcijferd hebben. Dit heeft veel 
interesse opgewekt in fundamentele en klinische onderzoeksgebieden om biologische en 
psychiatrische veranderingen in kaart te brengen, met als uiteindelijke doel om oorzakelijke 
factoren te identificeren en om de ziekte van Alzheimer te kunnen diagnosticeren in een 
stadium waarin er nog geen klinische symptomen zijn. 
De diagnose van de ziekte van Alzheimer wordt op dit moment gesteld door middel van 
neuropsychologisch onderzoek. De vroegste klinische diagnose voor potentiele Alzheimer's 
wordt gedefinieerd als een milde cognitieve beperking. Dit wordt gekenmerkt door 
symptomen van achteruitgang in het geheugen <lat afhankelijk is van een belangrijk 
hersengebied, de hippocampus. Neurobiologische studies hebben aangetoond <lat de 
pathologie van de ziekte van Alzheimer al decennia lang aanwezig kan zijn voordat er 
klinische symptomen ontstaan. Het is daarom van groot belang om afwijkingen in een vroeg 
stadium te identificeren, omdat dit onze kennis van de etiologie van de ziekte van Alzheimer 
zal vergroten. Dit zal ons in staat zal stellen om nieuwe therapeutische aangrijpingspunten te 
identificeren en de huidige diagnostische methoden voor deze ziekte te verbeteren. 
Onderzoekers hebben al substantiele vooruitgang geboekt in het identificeren van 
pathofysiologische processen die een rol spelen bij de ziekte van Alzheimer. Er zijn namelijk 
chronische afwijkingen gevonden in de werking van het immuunsysteem in het bloed en de 
hersenen, die een belangrijke rol spelen in het beloop van de ziekte van Alzheimer. Dit uit 
zich door een toegenomen activatie van het immuunsysteem die ook wel inflammatie 
genoemd wordt, in het bijzonder neuro-inflammatie in het zenuwstelsel. 
Het voornaamste doel van het onderzoek <lat uitgevoerd is voor deze these was om verder te 
onderzoeken wat de rol van inflammatie en in het bijzonder neuro-inflammatie is in de ziekte 
van Alzheimer, om nieuwe mechanismen en aangrijpingspunten te identificeren die een nieuw 
stukje kunnen toevoegen aan de grote puzzel van de etiologie van de ziekte van Alzheimer. 
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We zijn daarom ons onderzoek begonnen naar Tumornecrosefactor-alfa (TNF-cx) . TNF-cx is 
een pro-inflammatoir eiwit dat functioneert als een boodschapper en wordt geclassifi.ceerd als 
een cytokine. Onderzoek heeft laten zien dat TNF-cx zowel een belangrijke rol speelt in het 
normaal functioneren van het brein alsook complexe functies vervult bij neurologische 
aandoeningen. TNF-cx vervult zijn functies met behulp van twee receptoren, TNFR1 en 
TNFR2. De communicatie van TNF-cx via TNFR1 en TNFR2 verloopt normaliter via 
complex afgestemde mechanismen, die afwijkingen vertonen bij de ziekte van Parkinson en 
de ziekte van Alzheimer. Hoofdstuk 2 van deze these beschrijft de fysiologische functies van 
TNF-cx gebaseerd op de moleculaire processen die aangestuurd worden door signalen via de 
twee receptoren en de invloed van de factor tijd op deze signalen. Het hoofdstuk vormt een 
literatuuroverzicht dat inzicht geeft in de subtiliteit van de TNF-cx signalen. Verder wordt in 
dit hoofdstuk gesuggereerd dat de afwijkingen in deze signaal mechanismen zoals die in 
bepaalde aandoeningen zoals de ziekte van Alzheimer worden gevonden betekenisvolle 
gevolgen kunnen hebben voor het functioneren en de overleving van cellen. De belangrijkste 
boodschap voor de volgende hoofdstukken is dat TNFR2 voornamelijk werkt als een 
receptor waarvan de signalen neuronen beschermen, terwijl TNFR1 juist pro-inflammatoire 
mechanismen in gang zet. 
In de literatuur is aangetoond dat het natuurlijke verouderingsproces een belangrijke invloed 
kan uitoefenen op het functioneren van het immuunsysteem, waaronder het functioneren van 
TNF-cx. Veroudering kan de productie en de receptorexpressie van TNF-cx bei:nvloeden, wat 
ook waargenomen is in menselijk hersenweefsel dat aangedaan was daar de ziekte van 
Alzheimer. Onderzoekers richten zich nu op het bei:nvloeden van TNF-cx receptoren als 
behandeling voor verschillende aandoeningen. Het doel van hoofdstuk 3 was om de 
fysiologische invloed op cognitieve, gedragsmatige en fysieke prestaties van TNFR1 en 
TNFR2 receptoren te onderzoeken in jonge en oude muizen, wat getoetst werd met 
gedragstesten voor leren en geheugen, angst, motorisch functioneren en coordinatie. De 
testen werden uitgevoerd met jonge en oude muizen die TNFR1 clan wel TNFR2 receptoren 
misten. De belangrijkste bevinding van dit hoofdstuk is dat TNFR2 maar niet TNFR1 een 
cruciale rol speelt in hippocampus-afhankelijke geheugenvorming en motorisch functioneren. 
TNF-cx bezit neuronaal beschermende en celdood bevorderende eigenschappen, zoals 
beschreven in hoofdstuk 2. Dit heeft aanleiding gegeven tot verder onderzoek om de genen 
te ontdekken die, geactiveerd door TNF-cx, betrokken zijn bij de neuro-inflammatoire 
eigenschappen van TNF-cx (hoofdstuk 4). Dit is uitgevoerd door middel van het incuberen 
van primaire corticale neuronen van muizen met TNF-cx. De regulering van verscheidene 
duizenden genen werd geanalyseerd om de specifi.eke genen te identificeren die ge1nduceerd 
werden door TNF-cx. Dit heeft geleid tot het identificeren van Lipocaline 2. Lipocaline 2 is 
een eiwit dat toeneemt tijdens inflammatie. Lipocaline 2 trok op dat moment onze aandacht 
vanwege de voorheen onbekende rol als een functioneel element in het centrale zenuwstelstel 
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en daarnaast vanwege de fysiologische functies die reeds bekend waren op het moment van 
identificatie. We hebben de mechanismen verder onderzocht die betrokken zijn bij TNF-o: 
gemduceerde Lipocaline 2 productie in primair corticale neuronen, astrocyten en microglia 
cellen. Interessant genoeg bleek TNFR1 de enige receptor te zijn die verantwoordelijk was 
voor Lipocaline 2 productie. We hadden het geluk dat wij toegang hadden tot menselijk 
weefsel van niet-demente individuen, mensen bekend met een milde cognitieve beperking en 
Alzheimer patienten waarin we Lipocaline 2 niveaus konden bepalen. De data uit dit 
hoofdstuk laten zien dat Lipocaline 2 niveaus robuust toegenomen zijn in de hersengebieden 
die geassocieerd zijn met de pathologie van de ziekte van Alzheimer. De data van meerdere 
studies laten zien dat inflammatoire eiwitten verhoogd zijn in de cerebrospinale vloeistof van 
patienten met een milde cognitieve beperking en de ziekte van Alzheimer. Wij vonden 
verrassend dat Lipocaline 2 niveaus juist verlaagd zijn in de cerebrospinale vloeistof van de 
patienten met een milde cognitieve beperking en de ziekte van Alzheimer in vergelijking met 
niet-demente individuen. Verdere experimenten die uitgevoerd werden in celculturen met 
primaire corticale neuronen van muizen, geven aan dat Lipocaline 2 functioneert als een 
pathofysiologisch element in de ziekte van Alzheimer. Lipocaline 2 oefent deze rol uit door 
het sensitiseren van primaire corticale neuronen tot celdood wanneer het blootgesteld wordt 
aan pathologische stoffen die geassocieerd zijn met de ziekte van Alzheimer. Het is 
interessant dat verdere mechanistische studies in dit hoofdstuk aantonen dat Lipocaline 2 de 
neuronaal beschermende effecten van TNF-o: tegen toxische factoren die geassocieerd zijn 
met de ziekte van Alzheimer teniet doet door het stilleggen van de TNFR2 signalen. In 
essentie wordt in hoofdstuk 4 Lipocaline 2 gei:ntroduceerd als een nieuw element in de 
pathofysiologie van de ziekte van Alzheimer. 
Wetenschappers hebben vastgesteld dat het optreden van symptomen van depressie in 
oudere mensen een belangrijke risicofactor vormt voor de ziekte van Alzheimer. Op basis van 
onze bevindingen uit hoofdstuk 4 leek het daarom interessant om te bepalen of Lipocaline 2 
niveaus geassocieerd zijn met het optreden van depressie in oudere mensen (hoofdstuk 5). 
Lipocaline 2 concentraties werden geanalyseerd in het bloed van patienten van de 
Nederlandse Studie naar Depressie in Ouderen (NESDO). De NESDO studie was gebaseerd 
op een uitgebreide psychopathologische evaluatie van depressie in ouderen in een relatief 
grate steekproef (n=510), waarbij ook veel potentieel verstorende factoren werden gemeten. 
Dit stelde ons in staat om een goed gecontroleerd onderzoek uit te voeren naar de associatie 
van NGAL met depressie in ouderen. De resultaten uit hoofdstuk 5 laten zien dat 
toegenomen circulerend Lipocaline 2 een betekenisvolle associatie laat zien met symptomen 
van depressie. Het gaat hierbij vooral om de huidige depressieve staat. Daarna ast laten de 
data zien dat verhoogde Lipocaline 2 niveaus samenhangen met een ongezonde levensstijl, 
zoals roken, een grotere middelomtrek en lage fysieke activiteit, en dat de niveaus ook 
toenemen naarmate mensen ouder warden. 
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Populat:iestudies die in ouderen zijn gedaan hebben laten zien dat symptomen van depressie 
in combinat:ie met geheugenproblemen, die vooral te maken hebben met een bijzonder 
herscngebied dat de hippocampus genoemd wordt, de grootste kans gaven op het 
ontwikkelen van de ziekte van Alzheimer. Daarbij hadden vrouwen een grotere 
h..-wetsbaarheid voor het ontwikkelen van Alzheimer's dan mannen. Deze bevindingen, samen 
met onze resultaten uit hoofdstuk 5, lagen ten grondslag aan het idee om te onderzoeken of 
verhoogde Lipocaline 2 ruveaus samenhangen met hippocampus-afhankelijke 
geheugenproblemen en depressieve symptomen in de NESDO studie, welke beschreven is in 
hoofdstuk 6. We hebben gevonden dat Lipocaline 2 concentrat:ies significant verhoogd 
waren specifiek in vrouwen met hippocampus-afhankelijke geheugenproblemen. Daarnaast 
licten de data zien dat Lipocaline 2 toegenomen is in mannen waarbij beperkingen in het 
werkgeheugen in combinat:ie met depressieve symptomen werden gemeten. Deze groep 
mensen heeft ook een verhoogd risico op het ontwikkelen van cardiovasculaire 
aandoeningen. Samenvattend, kan er gespeculeerd worden dat NGAL een vroege indicator 
kan zijn die aangeeft dat depressieve oudere vrouwen een risico lopen om de ziekte van 
Alzheimer te ontwikkelen, terwijl NGAL in mannen sterker samen zou kunnen hangen met 
subklinische vasculaire problemen. 
Eindconclusie 
Deze these begon met explorat:ieve studies naar de mechanismen van neuro-inflammat:ie die 
betrokken zijn bij de ziekte van Alzheimer met de voornaamste focus op TNF-cx. Deze lijn 
heeft geresulteerd in het ident:ificeren van Lipocaline 2. In deze these werd de rol van 
Lipocaline 2 in de ziekte van Alzheimer en depressie belicht vanuit verschillende 
onderzoeksdisciplines. Dit heeft het mogelijk gemaakt om een diepgaande onderzoekslijn te 
ontwikkelen vanuit het ident:ifi.ceren van verhoogde Lipocaline 2 genexpressie in neuronale 
cellen van muizen tot aan studies in mensen. De kern van de bevindingen die uiteengezet 
worden in deze these laat zien dat Lipocaline 2 verhoogd is tijdens het normale 
verouderingsproces, maar dat dit aanmerkelijk sterker het geval is wanneer er depressieve 
symptomen aanwezig zijn. De gegevens van moleculaire studies uit deze these laten zien dat 
deze chronisch verhoogde Lipocaline 2 niveaus mechanismen in gang kunnen zetten die 
leiden tot zwakheid van neuronale cellen. Dit kan vervolgens bijdragen aan de pathofysiologie 
van de ziekte van Alzheimer en depressie bij ouderen. Tot slot tonen de data uit deze these 
aan dat Lipocaline 2 een rationed aangrijpingspunt is voor toekomst:ige pharmacologischc 
intervent:ies voor de ziekte van Alzheimer en depressie bij ouderen, en daarnaast een 
diagnost:ische indicator zou kunnen zijn, in het bijzonder wanneer deze gebruikt zou worden 
in combinat:ie met andere biologische indicatoren voor zowel de ziekte van Alzheimer als 
depressie bij ouderen. 
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Mrikaanse opsomming 
Die meeste mense, indien nie ieder en elk wat hierdie opsomming lees, het persoonlik al met 
iemand te doen gekry of is ten minste bewus van iemand wat met Alzheimer Siekte 
gediagnoseer is. Alzheimer Siekte is 'n neuro degeneratiewe siekte wat oorwegend by 
bejaardes voorkom. V roeere tekens van Alzheimers Siekte word in die algemeen gekenmerk 
deur die inperking van die geheue funksie wat gelydelik vererger met verloop van tyd, die 
inperking van ander brein afhanklike funksies soos spraakvermoe en liggaamsfunksies wat 
uiteindelik tot die dood van die persoon ly. Die bespreking van hierdie siekte regverdig die 
persepsie deur die algemene publiek as een van die mees gevreesde siektes. Hierdie persepsie 
word gerugsteen deur die feit <lat daar huidiglik geen behandeling is vir Alzheimer Siekte nie, 
hoofsaaklik omdat ons nog nie die oorsaak van die laat manifestering van Alzheimer Siekte 
kon ontsluit nie. Die gebrek aan kennis het heelwat belangstelling in die basiese en kliniese 
navorsingsvelde aangewakker ten einde die biologiese en psigiatriese veranderinge by 
Alzheimer pasiente te identifiseer, die faktore wat dit veroorsaak te bepaal asook om die twee 
kliniese stadiums van Alzheimer Siekte te diagnoseer. 
Diagnose van Alzheimer Siekte is huidiglik gebaseer op neurofisiologiese waarnemings 
waarvan waarvan 'n manifestasie van 'n matige kognitiewe inperking as aanduidende faktor 
dien. Hierdie imperking word gekenmerk deur simptome van verminderende geheueverlies 
wat hoofsaaklik gesetel is in 'n spesifieke breinarea, die hippokampus. Neurobiologiese 
studies het aangetoon <lat die patologie van Alzheimer Siekte kan manifesteer dekades 
voordat kliniese simptome aanwesig is. Dit is derhalwe noodsaaklik om vroeere 
abnormaliteite te identifiseer, wat ons kennis sal bevorder van die oorsaak van Alzheimer 
Siekte en ons gevolglik in staat sal stel om nuwe terapeutiese doelwitte te identifiseer en 
derhalwe die diagnose van die siekte te verbeter. Navorsers het wesenlike vooruitgang 
gemaak in die identifikasie van patofisiologiese prosesse wat geassosieer word met Alzheimer 
Siekte. In die verband is kroniese abnormaliteite in die immuunstelsel, in die bloed, asook die 
breinweefsel aangetref, welke abnormaliteite ge:identifiseer word as toonaangewende 
kenmerke in die manifestasie van Alzheimer Siekte. Hierdie word gekenmerk deur die 
verhoogde aktiwiteite in die immuunstelsel, bekend as inflamasie meer spesifiek neuron­
inflamasie in die senuweestelsel. 
Die hoofdoel van die navorsing van hierdie Doktorale studie is om verdere ondersoek in te 
stel na die rol van inflamasie, meer spesifiek neuron-inflamasie in Alzheimer Siekte, en om 
nuwe meganismes te identifiseer wat moontlik 'n verdere stuk in die legkaart van die oorsaak 
van Alzheimer Siekte kan wees. 
Die ondersoek is derhalwe begin met die Tumor Nekrose Fakor-alpha (fNF-cx). TNF-cx is 'n 
pro-inflammatoriese seingewende-proteien wat bekend is as 'n sitokien. Navorsing het 
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aangetoon dat TNF-a. ook 'n belangrike rol verrig in normale breinfunksies asook komplekse 
interaksie tydens neurologiese siektes. TNF-a. funksioneer deur middel van twee reseptore; 
TNFR1 en TNFR2. TNF-a. se seingewing deur middel van TNFR1 en TNFR2 is kompleks 
georganiseerde meganismes wat verander word in siektestoestande soos Parkinson's en 
Alzheimer's. Hoofstuk 2 van hierdie tesis beskryf die fisiologiese funksies van TNF-a. 
gebaseer op die molekulere seingewende-meganismes deur middel van sy twee reseptore en 
veral die kinetika betrokke in seingewing. Hierdie hoofstuk is 'n literere oorsig wat insig 
verskaf in die komplekse eienskappe van TNF-a. seingewing. Hierdie hoofstuk stel verder 
aan die hand dat veranderinge aan die seingewings-meganismes wat gevind word in sekere 
siektes, soos onder andere Alzheimer's 'n betekenisvolle gevolg kan he op sellulere funksies 
en oorlewing. Die belangrikste uitvloeisel van die opvolgende hoofstukke is dat TNFR2 
hoofsaaklik funksioneer as 'n neurobeskermende seingewende reseptor en dat TNFR1 pro­
inflammatoriese meganismes veroorsaak. 
Studies toon aan dat die verouderingsproses op sigself 'n wesenlike invloed kan he op die 
funksionering van die immuunstelsel asook op die funksionering van TNF-a.. Veroudering 
kan TNF-a. produksie beinvloed asook die reseptor voorkoms, wat waargeneem is in die 
brcinweefsel van menslike Alzheimer pasiente. Navorsers poog tans om TNF-a. reseptore aan 
te wend in die behandeling van verskeie siekte toestande. Die doel van Hoofstuk 3 is om die 
funksies van TNFR1 en TNFR2 te ondersoek as fisiologiese funksionerende reseptors op 
kognitiewe gedrags- en fisiese prestasie in jong en ouer muise wat waargeneem was deur 
gedragstoetse ten opsigte van leervermoe, geheue, angstigheid, motoriese funksies en 
koordinasie vermoens. Die toetse is uitgevoer op jong en ouer muise waarin of TNFR1 of 
TNFR2 afwesig was. Die kern bevinding in Hoofstuk 3 is <lat TNFR2 en nie TNFR1 'n 
deerslaggewende funksie verrig in hippokampus-afhanklike geheuevorming en neuro­
spierfunksie. 
TNF-(X besit neurobeskermende en pro-apoptotiese eienskappe soos beskryf in Hoofstuk 
Twee. Hierdie bevindings het verdere navorsing geinisieer om gene te ondersoek, wat 
geaktiveer word deur TNF-a., wat betrokke is in neuro-inflammatoriese meganismes van 
TNF-(X (Hoofstuk 4). Die proses is gevolg deur muis neuronale selle te inkubeer met TNF-cx. 
Die regulering van duisende gene was geanaliseer ten einde die spesifieke gene wat geaktiveer 
word deur TNF-a. te identifiseer. Dit het tot gevolg gehad in die identifikasie van Lipocalin 2. 
Lipocalin 2 is 'n protein wat toeneem gedurende inflammasie. Lipocalin 2 het met verloop 
van tyd ons aandag getrek vanwee die onbekendheid daarvan as 'n funsionele element in die 
sentrale senuweestelsel en ook as gevolg van die erkende fisiologiese funksies tydens 
identifikasie daarvan. Ons het verder die meganisme betrokke by TNF-cx geinduseerde 
Lipocalin 2 produksie in prim.ere kortikale neurone astrosiete and mikroglia selle ondersoek. 
Die interessante bevinding is dat TNFR1 die uitsluitlike reseptor is wat verantwoordelik is vir 
Lipocalin 2 produksie. V erder was ons bevoorreg om toegang tot menslike selweefsel te 
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bekom van individue wat rue aan geheue probleme ly rue, individue wat ly aan matige 
kognitiewe imperking asook van Alzheimer pasiente waarop die Lipocalin 2 vlakke 
geanaliseer is. Data uit hierdie Hoofstuk toon aan dat Lipocalin 2 dramaties verhoog in 
breinareas wat ook geassosieer word met Alzheimer patalogie. Data van verskeie studies toon 
aan dat inflammatoriese proteiene verhoog is in die serebrospinale vloeistof van pasiente met 
matige kognitiewe imperking en Alzheimer. Dit is insiggewend om te vind dat Lipocalin 2 
vlakke verminder in die serebrospinale vloeistof van pasiente met matige kognitiewe 
imperking en Alzheimer pasiene in teenstelling met pasiente wat nie aan geheue probleme ly 
nie. Verdere navorsing op sel-kulture van muis neuronale selle, toon aan dat Lipocalin 2 
funksioneer as 'n patofisiologiese element in Alzheimer Siekte. Lipcolain 2 bewerkstellig die 
sensitering van primere kortikale neurone tot sel vernietiging wanneer dit blootgestel is aan 
die patologiese agente geassosieer met Alzheimer Siekte. Interessant genoeg toon tegniese 
studies in hierdie Hoofstuk aan dat Lipocalin 2 die neuro beskermende uitwerking van TNF­
ct. uitwis teen die toksiese faktore geassoseer met Alzheimer deur die eleminering van die 
TNFR2 seingewing. In wese word Lipocalin 2 in Hoofstuk Vier bekend gestel as 'n 
ongekende element en die patofisiologie van Alzheimer. 
N avorsers het die teenwoordigheid van simptome van depressie by bejaardes ge1dentifiseer as 
'n aspek wat 'n wesenlike risiko inhou vir die ontwikkeling van Alzheimer's. Gebaseer op die 
bevindings in Hoofstuk Vier is dit daarom interessant om te bepaal of die Lipocalin 2 
konsentrasies geassosieer word met die voorkoms van depressie in bejaardes (Hoofstuk 5) . 
Lipocalin 2 konsentrasies in die bloed was geanaliseer in pasiente van die Netherlands Study 
on Depression in Older Persons (NESDO). Die NESDO studie is gebaseer op 'n deeglike 
psigopatologiese evaluasie op depressie by bejaardes in 'n relatiewe groot bevolkingsgroep 
(n=510) met 'n deeglike vasstelling van verwarrende faktore. Hierdie studie het ons in staat 
gestel om 'n sistematiese ondersoek uit te voer na die verwantskap van NGAL met die 
voorkoms van gevorderde-leeftyd depressie. Resultate in Hoofstuk Vyf toon aan dat die 
verhoogde voorkoms van die Lipocalin 2 wesenlik geassosieer word met simptome van 
depressie. Dit toon ook verder dat Lipocalin 2 konsentrasies baie nou geassosieer word met 
'n pasient se huidige simptome van depressie. Daarby toon die data ook verder dat verhoogte 
Lipocalin 2 geassosieer word met 'n ongesonde lewenstyl, byvoorbeeld rook, lae fisiese 
aktiwiteite en verhoogde middelmaat omtrek en dus ook verhoog as gevolg van verhoogde 
ouderdom. 
Bevolkingstudies gedoen op bejaardes toon aan dat simptome van depressie tesame gaan met 
geheueverlies, geassosieer met 'n spesifieke breinarea bekend as die hippokampus, wat tot 'n 
verhoogde kans op die ontwikkeling van Alzheimer's inhou. Daar is ook bevind dat vrouens 
meer vatbaar is vir die ontwikkeling van Alzheimer's as mans. Hierdie bevindings, tesame met 
ons bevindings soos uiteengesit in Hoofstuk Vyf het belangestelling ontketen om verder 
ondersoek in te stel of die verhoogde Lipocalin 2 vlakke geassosieer word met hippokampus-
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afhanklikheid-geheue-imperking asook met simptome van depressie soos verkry van die 
NESDO studie soos beskryf in Hoofstuk 6. Dit is bevind <lat die Lipocalin 2 konsentrasies, 
wesenlik verhoog het slegs in vrouens met hippokampus-afhanklike-geheue-imperking. Die 
data het boonop getoon dat Lipocalin 2 aansienlik verhoog in mans wat 'n inperking van 
korttermyn-geheue en simptome van depressie ervaar. Hierdie groep van mans ervaar ook 'n 
hoe risiko vir die ontwikkeling van kardiovaskulere siektes. In opsomming kan gespekuleer 
word <lat NG.AL 'n vroee aanduiding is dat depressiewe ouer vrouens op risiko is vir die 
oorgang van Alzheimer's terwyl NGAL in mans meer geassosieer word met subkliniese 
vaskulere funksionering. 
Slotsom 
Hicrdie studie het in aanvang geneem met ondersoekende studies na meganismes in neuro­
inflammasie wat betrokke is by Alzheimer's met TNF-cx as die hoof oogmerk daarvan. Dit het 
vcrdcr gely tot die identifikasie van Lipocalin 2. Die rol wat Lipocalin 2 in Alzheimer en 
deprcssie vervul is in hierdie verhandeling uitgevoer deur verskeie navorsing dissiplines. Die 
studie het <lit verder moontlik gemaak om 'n deeglike oordragende navorsing te volg deur 
eers die Lipocalin 2 geen te identifiseer met verhoogde vlakke in muis neuron selle as 
vertrekpunt wat opgevolg is met menslik studies. Die kern van die bevindinge wat in hierdie 
verhandeling uitvloei toon aan dat Lipocalin 2 verhoog word in die verouderingsproses, wat 
aansienlik verhoog in die aanwesigheid van depresiewe simptome. Data verkry van die 
molukulere navorsing soos behandel in hierdie studie toon aan <lat die kroniese verhoging van 
Lipocalin 2 vlakke aanleiding kan gee tot meganismes wat die verswakking van senuweeselle 
kan veroorsaak. Dit kan gevolglik bydra tot die patofisiologie van Alzheimer's en die 
voorkoms van Gevorderde-leeftyd depressie Ten slotte toon data soos vervat in die 
verhandeling <lat Lipocalin 2 as 'n rasionele teiken vir toekomstige pharmakologiese 
intervensie vir Alzheimer's en Gevorderde-leeftyd depressie asook as 'n diagnostiese 
biomerker, veral as <lit gebruik word in kombinasie met ander bekende biomerkers van of 
Alzheimer's of gevorder-leeftyd depressie. 
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